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ABSTRACT 
African horse sickness (AHS) is a debilitating viral disease affecting equines and has 
resulted in many disastrous epizootics. To date, no successful therapeutic treatment 
exists for AHS and the commercially used live-attenuated vaccines (LAVs) have 
various side effects. Insoluble particulates have been shown to increase 
immunogenicity when compared to soluble subunit vaccines and previous studies 
demonstrated protection of BALB/c mice immunised with African horse sickness virus 
(AHSV) VP7 against a lethal challenge of AHSV-7 (Bailey 2016; Rutkowska et al. 
2011; St Clair et al. 1999; Storni et al. 2005; Wade-Evans et al. 1997). This study 
investigates a safer monovalent vaccine alternative based on plant-produced quasi-
crystals of the serogroup-specific AHSV structural protein, VP7. 
AHSV serotype 5 (AHSV-5) VP7 was expressed in Nicotiana benthamiana by means 
of Agrobacterium-mediated infiltration of plant expression vector pRIC3.0 encoding 
VP7 and quasi-crystals purified by means of density gradient ultracentrifugation. The 
presence of AHSV VP7 quasi-crystals was confirmed by western immunoblotting with 
anti-AHSV VLP guinea-pig serum and characterized using transmission electron 
microscopy. After optimizing the purification protocol and achieving satisfactory 
concentrations, AHSV-5 VP7 quasi-crystals were  used in guinea-pig immunogenicity 
studies where the experimental group (n=5)  was inoculated with prime- and boost-
inoculations of between 10 and 50 µg of purified AHSV VP7 quasi-crystals, and the 
control group (n=5) inoculated with a control inoculum prepared in the identical manner 
as the vaccine but using a pRIC3.0 expression vector lacking VP7. Western 
immunoblot analysis of the humoral response showed stimulation of very high titres of 
anti-VP7 antibodies 28 days after the boost-inoculation. In addition, RNA-seq 
transcriptome profiling of guinea-pig spleen derived RNA was used to investigate the 
global immune response to AHSV-5 VP7 quasi-crystals. Thirty genes involved in 
innate and adaptive immunity were found to be significantly differentially expressed 
(q≤0.05) in experimental transcriptome data when compared to the control. Differential 
expression of genes involved in T-helper (Th)1, Th2 and Th17 cell differentiation and 
the T-cell receptor signalling pathway suggest a possible cell-mediated immune 
response to AHSV-5 VP7 quasi-crystals. Upregulation of several important cytokines 
and cytokine receptors were noted in response to VP7 quasi-crystals e.g. TNFSF14, 
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CX3CR1, IFNLR1 and IL17RA. TNFSF14 and CX3CR1 play a role in T-cell 
proliferation and cytotoxic T-cell responses respectively. And IFNLR1 and IL17RA are 
key cytokines in antiviral defences. Upregulation of IL17RA suggests a Th17 response 
which has been reported as a key component in AHSV immunity. 
To the best of our knowledge, this study is the first to report the expression of plant-
produced AHSV VP7 quasi-crystals and the first time that the cell-mediated immune 
response to these particles has been assessed. While further investigation is needed, 
these results suggest that AHSV-5 VP7 quasi-crystals produced in N. benthamiana 
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CHAPTER 1: LITERATURE REVIEW  
1.1 Introduction 
African horse sickness (AHS) is a noncontagious but highly infectious arthropod-borne 
disease affecting equines, and due to many disastrous epizootics it is considered a 
notifiable viral disease by the World Organisation for Animal Health (OIE) (Bekker et 
al. 2014). During infection, AHSV successfully replicates in endothelial cells and 
macrophages, and endothelial cell damage results in the deterioration of the vascular 
system. Circulatory and respiratory impairments manifest in four pathological forms of 
the disease: horse sickness fever, a cardiac form (dikkop), a mixed form and a 
pulmonary form (dunkop) (Bailey 2016; Clift and Penrith 2010). The pulmonary and 
mixed forms are most common amongst horses, ponies and European donkeys, with 
a mortality rate of approximately 95% in susceptible horses (Wade-Evans et al. 1997; 
Zientara et al. 2015; Mellor et al. 1990; Bekker et al. 2014; Maree et al. 2016). Mules 
and African donkeys are commonly affected by milder forms of the disease, horse 
sickness fever and the cardiac form, with a mortality rate of less than 50% (Wade-
Evans et al. 1997; Zientara et al. 2015). Zebras on the other hand are generally 
asymptomatic and are likely to be a natural reservoir for AHSV (Maree and Paweska 
2005).  
The causative agent of AHS is the African horse sickness virus (AHSV), a non-
enveloped Orbivirus from the Reoviridae family, which is predominantly transmitted by 
the biting midge, Culicoides imicola (Bekker et al. 2014; Maree et al. 2016; Wade-
Evans et al. 1997; Zientara et al. 2015). AHSV spreads rapidly and replicates 
efficiently in both mammalian and insect hosts and is therefore a major threat to equids 
(Venter et al. 2009). All nine AHSV serotypes are endemic to sub-Saharan Africa, 
particularly eastern and southern Africa, with many reoccurring outbreaks extending 
to northern parts of Africa and the Mediterranean region (Maree et al. 2016; Wade-
Evans et al. 1997; Zientara et al. 2015). AHS has placed a severe burden on the South 
African equine industry. Horses, donkeys and mules support many people’s 
livelihoods in South Africa and millions of people globally, particularly in poor and 
marginalised communities. These working animals are used in numerous sectors 
including agriculture, construction, tourism, mining, public transport and sport (Bekker 
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et al. 2014; Zientara et al. 2015). The horse racing industry is reported to contribute 
2.71 billion ZAR annually to South Africa’s GDP and, according to a recent audit, 
supports approximately 100 000 employees (Ngalonkulu 2018).  South Africa’s horse 
export industry also attracts substantial financial investment, and stringent quarantine 
restrictions and trade embargoes pose a great threat to this industry (Bekker et al. 
2014).  
The only effective way to control AHS is by widespread vaccination programmes as 
no successful therapeutic treatment exists. However, commercially used live- 
attenuated multivalent vaccines cause viraemia in the host and pose the threat of 
generating novel viruses through re-assortment between field and vaccine strains. 
These biosafety concerns have motivated the search for safer and more affordable 
vaccines that are also effective against multiple AHSV serotypes (Mellor et al. 1990; 
Wade-Evans et al. 1997). 
This study aims to produce AHSV-5 VP7 quasi-crystals in Nicotiana benthamiana with 
the intention of producing a safer and potentially more economical prophylactic 
vaccine. 
1.2 AHSV Geographical Distribution 
AHS was first recognised during the 1719 epizootics in South Africa where 1700 
animal fatalities were documented (Zientara et al. 2015). The causative agent of AHS, 
AHSV, is endemic to sub-Saharan Africa. However, repeated wide-scale epizootics 
have extended to North Africa, the Arabian Peninsula and many Mediterranean 
countries as a result of international horse trade (Maree et al. 2016; Wade-Evans et 
al. 1997; Zientara et al. 2015; Bailey 2016; Martinez-Torrecuadrada et al. 1996). Five 
years of AHS outbreaks occurred from 1987 to 1992 in Spain, Morocco and Portugal 
(Basak et al. 1996; Bailey 2016). And very recently (March/April 2019) outbreaks in 
Chad (http://www.oie.int/wahis_2/public/wahid.php/Reviewreport/Review?page_refer 
=MapFullEventReport&reportid=30236) and Cameroon (http://www.oie.int/wahis_2/ 
public/wahid.php/Reviewreport/Review?page_refer=MapFullEventReport&reportid=3
0190 ) were reported. Only 69 countries are listed by the World Organisation for Animal 
Health (OIE) as AHS-free member countries (Figure 1.1). 
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Figure 1.1: OIE representation of AHS status globally as per November 2018. Green 
indicates AHS free regions, Maroon indicates that the OIE AHS free status has been 
suspended for these countries, and Grey indicates countries which do not have an OIE official 
AHS free status. The above image can be found at: http://www.oie.int/en/animal-health-in-the-
world/official-disease-status/african-horse-sickness/en-ahs-carte/. (World Organisation for 
Animal Health 2018) 
 
The distribution of AHS is seasonal as it depends on the abundance and prevalence 
of its insect vectors. For many years C. imicola was considered to be the main field 
vector for AHS but research by Venter et al. (2000) disputed this and showed that 
C. bolitinos, a common bluetongue virus (BTV) vector, can also efficiently transmit 
AHSV. C. imicola is commonly active during the rainy season in the tropics and during 
summer and autumn in the temperate regions, while C. bolitinos is widely spread 
across southern Africa and commonly found in cooler regions where C. imicola is 
scarce (Venter et al. 2009; Zientara et al. 2015). Climate change has had an 
indisputable impact on the distribution of AHSV insect vectors (Zientara et al. 2015). 
In the last decade, C. imicola has expanded northwards to AHS-free regions and 
devastating outbreaks of the closely related BTV, which is also transmitted by several 
Culicoides species, have been reported in northern Europe. These observations along 
with the spread of serotype 2 and 7 into western and eastern Africa, where typically 
____________________________________________________________________________________________________
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only serotype 9 was present, suggests that AHSV may follow closely behind BTV’s 
expansion (Zientara et al. 2015; Bailey 2016).  
The occasional explosive emergence of AHSV over a short period of time indicates 
that a large number of infected insect vectors are present and that AHSV is 
presumably circulating continuously in a reservoir herd. These reservoir herds may be 
the large populations of wild zebra in the Kruger National Park in South Africa, as 
zebra herds breed throughout the year enabling the continual transmission of AHSV 
to naive foals (Zientara et al. 2015). It is likely that outbreaks amongst these 
populations spread southwards and consequently threaten the surrounding horse 
populations (Thompson et al. 2012). To facilitate the safe exportation of horses to 
Europe, the South African authorities implemented an AHS-free zone, -surveillance 
zone and -protection zone in the Western Cape Province which was accepted by the 
European Union in 1997 (Figure 1.2). In recent years, numerous outbreaks have been 
reported in the surveillance zone, the most notable ones occurring in 1999, 2004, 
2011, 2013, 2014 and 2016. These outbreaks have devastating impacts on the equine 
export industry and concerns have been raised about the spread and elevated 
frequency of AHSV outbreaks in national and international AHS-free zones (Zientara 
et al. 2015; Grewar et al. 2019). 
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Figure 1.2: Depiction of the AHS-controlled area (free zone, surveillance zone and 
protection zone) in South Africa. Pink indicates AHS free zones, Blue indicates the AHS 
surveillance zone, Green indicates the AHS protection zone, and Orange indicates the 
endemic region for AHS/ AHS infected area. The above image can be found at:  
https://www.agriorbit.com/registration-of-zebra-in-ahs-controlled-areas-in-sa/. Image 
courtesy of the State Veterinarian: Boland and Directorate: Animal Health at the Department 
of Agriculture, Forestry and Fisheries (DAFF). Image used with permission from the publisher. 
 
1.3 African Horse Sickness Virus 
 Orbiviruses: AHSV and Bluetongue Virus (BTV) 
AHSV is a non-enveloped Orbivirus from the Reoviridae family, a family which consists 
of 15 genera. The Orbivirus genus is the largest genus comprising 29 species of non-
enveloped viruses characterised by a circular capsid composed of 32 capsomeres. 
These capsomeres enclose the segmented and double-stranded RNA genome 
(Zientara et al. 2015; Bailey 2016; Roy et al. 1994). The bluetongue virus (BTV) is the 
prototype of the Orbivirus genus, and AHSV and BTV are closely related members as 
demonstrated by comparisons of the amino acid sequences of AHSV-4 and BTV-10. 
(Bekker et al. 2014; Wade-Evans et al. 1997). These comparisons suggest a recent 
common ancestor and that strong selective pressures of their specific host’s immune 
system may have caused their divergence (Zientara et al. 2015). As a closely related 
virus, the AHSV virion is modelled around the structure of the Orbivirus prototype, 
BTV, which has been studied more extensively.  
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 AHSV Capsid Structure 
The non-enveloped icosahedral virions of AHSV are approximately 80 nm in diameter 
and the genome consists of ten linear double stranded (ds) RNA segments encoding 
seven structural proteins (VP1 – VP7) and four non-structural proteins (NS1, NS2, 
NS3, NS3a and NS4) which have been observed in AHSV-infected cells (Figure 1.3) 
(Faber et al. 2016; Maree et al. 2016; Zientara et al. 2015; Bailey 2016; Basak et al. 
1996; Dennis 2019; Monastyrskaya et al. 1997). The structural proteins are arranged 
in three clear concentric layers: VP2 and VP5 form the outer capsid shell of mature 
virions and the inner capsid consists of two major core proteins, a VP7 surface layer 
and a VP3 lower layer (Figure 1.3) (Mertens et al. 2004). VP7 and VP3, the inner 
capsid, encloses the core particle which forms the transcriptase complex and consists 
of the (ds) RNA genome arranged in three layers of RNA and three minor enzymatic 
proteins (VP1, VP4 and VP6) (Maree et al. 2016; Zientara et al. 2015; Zwart et al. 
2015; Mertens et al. 2004).  
The VP2 and VP5 outer capsid shell is removed when the virus passes through the 
cell membrane (Basak et al. 1996). The subcore remains, consisting of 120 copies of 
VP3 which are arranged as 12 decamers and this is stabilised by 780 molecules of 
VP7 arranged as 260 trimers forming a highly ordered T=13 lattice (Basak et al. 1996; 
Bekker et al. 2017; Monastyrskaya et al. 1997; Williams et al. 1998). 
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Figure 1.3: A diagrammatic representation of the structure of AHSV, including the outer capsid 
proteins (VP2 and VP5), the major core proteins (VP3 and VP7) and the minor structural 
proteins (VP1, VP4 and VP6). Image adapted from Mertens et al. (2004). 
 AHSV Genome  
The AHSV genome consists of ten linear (ds)RNA segments which can be 
differentiated according to their molecular mass using polyacrylamide gel 
electrophoresis. These (ds)RNA segments have been characterised according to their 
order of migration, three large (L1-L3), three medium (M4-M6) and four small 
segments (S7-S10) (Figure 1.4). The AHSV genome has been sequenced in its 
entirety with the sequences mainly based on serotype 4 (AHSV-4) (Zientara et al. 
2015).  
Each of the (ds)RNA genome segments encode one polypeptide with the exception of 
the two smallest segments (S9 and S10) (Figure 1.4). S9 encodes both the enzymatic 
minor protein VP6 and the non-structural protein NS4. And the S10 gene contains two 
in-frame AUG initiation codons for translation initiation and these are responsible for 
the synthesis of two alternative NS3 gene products, the minor non-structural proteins 
NS3 and NS3A (van Staden et al. 1995; Zwart et al. 2015). The outer capsid proteins, 
VP2 and VP5, are encoded by the L2 and M6 (ds)RNA segments respectively 
(Figure 1.4) (Thompson et al. 2012).  The L2 gene is 3203 nucleotides  in length 
encoding a 1051 amino acid VP2 protein, and the M6 gene is 1564 nucleotides in 
length encoding a 504 amino acid VP5 protein product (Williams et al. 1998). The 
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major core proteins, VP3 and VP7, are encoded by segments L3 and S7 respectively 
and contain serogroup-specific antigenic determinants (Figure 1.4) (Zientara et al. 
2015). The L3 RNA segment is 2715 nucleotides in length and encodes a 905 amino 
acid VP3 protein, while the S7 gene is only 1047 nucleotides and encodes for a 349 
amino acid VP7 protein product (Williams et al. 1998). The enzymatic minor proteins, 
VP1 and VP4 are encoded by L1 and M4 respectively, and the third enzymatic minor 
protein, VP6, is encoded by the S9 gene, 1169 nucleotides in length and translating 
into a 369 amino acid protein (Figure 1.4). The non-structural proteins NS1 and NS2 
are encoded by the RNA segments M5 and S8 respectively and along with NS3 and 
NS3A are involved in virus replication, morphogenesis and the release of viral particles 
from the infected cell (Figure 1.4). The RNA segments, which encode for NS1 and 
NS2, are highly conserved amongst all serotypes. Whereas segments encoding 
NS3/NS3A, VP2 and VP5 are more variable with VP2 holding the dominant serotype-
specific antigenic sites (Kanai et al. 2014). Due to the genetic variability amongst VP2 
serotypes, nine serotypes of AHSV have been determined. In addition, VP2 holds the 
virus receptor-binding site and is commonly used in recombinant vaccine development 
(Bekker et al. 2014; Kanai et al. 2014; Maree et al. 2016; Thompson et al. 2012; 
Zientara et al. 2015). 
 
Figure 1.4: A representation of the (ds)RNA Orbivirus genome. The genome consists of 
three large (L1-L3), three medium (M4-M6) and four small (S7-S10) (ds)RNA segments. 
Image adapted from Viralzone. 
 
____________________________________________________________________________________________________
Shelley Helen Fearon Student No: SMTSHE005 Page 19 
 AHSV Protein Function 
The outer capsid proteins, VP2 and VP5 are the most variable structural proteins of 
AHSV and during infection are responsible for virus attachment and cell entry. After 
entry the loosely bound outer capsid proteins are shed and the core particle is released 
into the cytoplasm to become transcriptionally active (Bekker et al. 2014; Hassan et 
al. 2001; Thompson et al. 2012; Chuma et al. 1992). Both trimeric VP2 and VP5 are 
capable of interacting with the surface of the core in the absence of their fellow outer 
capsid protein (Maree et al. 2016). Hassan et al (1999 and 2001) investigated the 
biological functions of BTV-10 VP2 and VP5. Purified VP2 demonstrated virus 
hemagglutinin activity and was shown to be solely responsible for virus entry into 
mammalian cells. In addition, purified VP2 showed a strong affinity for binding to 
glycophorin A, which is a major intrinsic membrane protein of erythrocytes. This 
suggests that VP2 may play a role in the transmission of BTV by its hematophagous 
insect vector to its mammalian host. Furthermore, AHSV VP2 elicits serotype-specific 
antibodies and contains the main sites for antibody-mediated virus neutralisation as a 
result of being the most exposed outer capsid protein (Martıńez-Torrecuadrada and 
Casal 1995; Zientara et al. 2015). The outer capsid protein VP5 also contains 
neutralising epitopes but does not induce antibody-mediated neutralisation to the 
same degree as VP2, which is likely due to its low surface exposure. Sequence-based 
structure analysis of BTV-10 VP5 showed that VP5 possesses two amino-terminal 
amphipathic helices which are characteristic features for virus-cell penetration. 
Furthermore, purified VP5 was able to modify the permeability of mammalian and 
Culicoide cell membranes and induce cytotoxicity (Hassan et al. 2001; Hassan and 
Roy 1999b). 
VP3 and VP7 are the major core proteins. VP3 dimers form a thin inner scaffolding on 
which the capsomeres are arranged and VP7 is the principal component of these core 
capsomeres (Basak et al. 1996; Kar et al. 2004; Williams et al. 1998; Bailey 2016; 
Mertens 2004). Both VP3 and VP7 are highly conserved amongst the nine AHSV 
serotypes with VP7 having greater than 98% amino acid identity between serotypes. 
VP3 is the most conserved protein between the orbiviruses AHSV and BTV. In 
contrast, AHSV VP7 is serogroup-specific and partially conserved between the 
serogroups AHSV, BTV and epizootic  haemorrhagic disease of deer virus (EHDV) 
with the AHSV and BTV VP7 amino acid sequence sharing only 43% identity (Bailey 
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2016; Bekker et al. 2017; Zientara et al. 2015; Basak et al. 1996; Guthrie et al. 2009; 
Martinez-Torrecuadrada et al. 1996). VP3 controls the size and organisation of the 
capsid structure, and VP7 is the major immunodominant antigen and plays a role in 
cell entry (Bailey 2016; Mertens 2004). The AHSV VP7 protein has 349 amino acid 
residues and consists of 260 trimers forming a T=13 lattice. It is a highly hydrophobic 
protein and forms insoluble crystals ranging between 3-5 µm during natural AHSV 
infection (Basak et al. 1996; Bailey 2016). Orbivirus serogroups are distinguishable by 
serological assays and recognised as distinct species using the serogroup-specific 
antigen VP7 (Maree and Paweska 2005). AHSV VP7 is also highly immunogenic 
which has been concluded from various experiments including one by Martinez-
Torrecuadrada et al. (1996), where the inclusion of purified AHSV VP7 to an AHSV 
VP2 and VP5 inoculate increased antibody titres in horses from 1280 to 20 480 
(enzyme-linked immunosorbent assay (ELISA) titres were determined by the authors 
as the reciprocal of the highest dilution giving three times the blank (pre-immunisation 
sera) A405). Additionally, due to its immunodominance, VP7 is widely utilised in 
serological assays to identify AHSV infections (Maree and Paweska 2005; Martinez-
Torrecuadrada et al. 1996). 
AHSV VP1, VP4 and VP6 are the three core enzymatic minor proteins. VP1 is highly 
conserved and has been identified as the putative viral RNA polymerase, and VP4 the 
capping enzyme with typical guanylyltransferase features (Martinez-Costas et al. 
1998; Vreede and Huismans 1998; Bailey 2016; Mertens 2004). VP6 is suspected to 
be the helicase of AHSV, binding to both single-stranded (ss)RNA and (ds)RNA and 
is likely to play a role in the encapsidation of RNA (de Waal and Huismans 2005; 
Turnbull et al. 1996). 
The non-structural proteins (NS1-NS4) are involved in virus replication, virus assembly 
and the release of viral particles from the infected cell (Kanai et al. 2014; Roy et al. 
1994). NS1 self-assembles into tubules within the cytoplasm of infected cells and 
attaches to intermediate filaments of the cytoskeleton. NS1 may be involved in virus 
transportation and morphogenesis (Zwart et al. 2015). NS2 is responsible for the 
formation of virus inclusion bodies (VIBs); these VIBs are involved in the replication 
and assembly of new viral core particles. NS3 and NS3A are glycosylated membrane 
proteins which mediate the release of mature virus particles from the cell by membrane 
association and permeabilisation. The exact function of NS4 in viral morphogenesis is 
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unclear, however, it seems to play a role in nuclear localisation (Zwart et al. 2015; 
Bailey 2016; Mertens 2004).  
 AHSV VP7 Trimer Structure and Quasi-Crystal Formations 
As mentioned previously, VP7 is one of the major core AHSV structural proteins 
consisting of 349 amino acids (aa) and is approximately 37.8 kDa in size (Williams et 
al. 1998; Zientara et al. 2015; Bailey 2016). AHSV VP7 is highly immunodominant, 
and is therefore commonly used as an AHSV antigen for serogroup-specific diagnostic 
assays (Bekker et al. 2017; Zientara et al. 2015). Furthermore, it is largely insoluble 
and highly hydrophobic, as determined by amino acid sequence analyses and the Kyte 
and Doolittle (1992) algorithm, and consists of a high amount of hydrophobic amino 
acids: alanines (12.9%), prolines (6.6%), valines (10.9%), leucines (7.2%) and 
methionines (3.7%) (aa percentages were calculated using the peptide property online 
tool ProtParam on the ExPASy bioinformatics resource portal (https://web. 
expasy.org/protparam/)) (Basak et al. 1996; Kyte and Doolittle 1982; Roy et al. 1991; 
Gasteiger et al. 2005). During AHSV infection of cells or in isolation in insect cells, VP7 
spontaneously aggregates into large flat hexagonal crystal arrays consisting of six-
membered rings, a feature which is unique to AHSV (Basak et al. 1996; Bekker et al. 
2014; Burroughs et al. 1994). Researchers have observed a wide range of AHSV VP7 
quasi-crystal sizes after recombinant baculovirus infections  i.e. 100 nm to 25 µm 
(Burroughs et al. 1994; Chuma et al. 1992; Maree and Paweska 2005; Wall et al. 2017; 
Bailey 2016). However, during natural AHSV infection of mammalian and insect cells 
or expression by Modified vaccinia virus Ankara (MVA) the sizes of crystals observed 
in the cytoplasm generally range between 3-5 µm (Bailey 2016). The role of VP7 
quasi-crystals during AHSV infection remains unclear (Basak et al. 1996; Bekker et al. 
2014; Burroughs et al. 1994). However, similar insoluble aggregates have been found 
to be beneficial to viruses as sites where viral replication and assembly is promoted. 
It has also been hypothesised that these crystalline-particles may contribute to the 
pathogenesis of the virus as they are likely to be detrimental to normal cellular 
functions and destroy the cell membrane (Bekker et al. 2014).  
The AHSV VP7 crystalline-structure is homotrimeric and the monomers (denoted A, B 
and C) are likely bound by intermolecular disulphide bridges between Cys161 and 
Cys195 residues (Basak et al. 1996; Bekker et al. 2017). Each VP7 monomer has two 
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well defined domains, an upper domain and a lower domain (Figure 1.5) (Roy 2008). 
Due to AHSV VP7’s insolubility, only the more hydrophilic upper domain has been 
resolved by X-ray crystallography, which consists of the central region of the 
polypeptide (aa 121-249) and is folded into an anti-parallel β-sandwich (Figure 1.6) 
(Basak et al. 1996). The lower domain is predicted to be similar to the closely related 
BTV VP7, containing five α-helices from the N-terminal region (aa 1-120) and four 
α-helices from the C-terminal region (aa 250-349) connected by a series of 
hydrophobic loops (Basak et al. 1996; Monastyrskaya et al. 1997). The two domains 
are twisted in an anticlockwise direction around the three-fold axis so that the upper 
domain of one monomer rests on the C-terminal region of its adjacent monomer’s 
lower domain (Figure 1.5) (Basak et al. 1996). The C-terminal helices of the lower 
domain are generally positioned above the N-terminal helices, with one of the latter 
helices forming a flat surface which interacts with the VP3 sub core (Basak et al. 1996; 
Monastyrskaya et al. 1997; Rutkowska et al. 2011).  
 
Figure 1.5: An image of the VP7 trimer atomic structure based on the prototypical 
Orbivirus BTV. VP7 monomer interaction and upper and lower domains are displayed 
(https://link.springer.com/article/10.1007%2Fs12013-008-9009-4). Image courtesy of 
Springer Nature (Roy 2008). Image used with permission from the publisher. (RCSB Protein 
Data Bank DOI: 10.2210/pdb1BVP/pdb). 
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Figure 1.6: An image of the AHSV VP7 upper domain homo-trimer arrangement. The above 
image can be found at: https://www.ebi.ac.uk/pdbe/entry/pdb/1ahs/analysis. Image courtesy 
of the Protein Data Bank in Europe (PDBe) (Basak et al. 1996). Image used with permission 
from the publisher. 
 
The trimerisation of VP7 is not sufficient for the stable formation of virus particles. VP7 
therefore interacts with both outer capsid proteins, VP2 and VP5 and its fellow core 
protein VP3. Helix 2 (aa 26-43) forms part of the flat-bottomed base in the lower 
domain of VP7 and is rich in hydrophobic amino acids. The correct amino acid 
composition and folding of the hydrophobic flat base is essential for stable interactions 
between the VP3 scaffold and VP7 trimers (Maree et al. 2016; Monastyrskaya et al. 
1997). With regard to AHSV VP7 trimer-trimer interactions and crystal formation, 
Bekker et al. (2017) recently highlighted the hydrophobic amino acids Ile228, Pro230 and 
Ala167 as contributors to the inherently strong trimer-trimer interactions and therefore 
to the assembly of AHSV VP7 crystals. 
AHSV VP7 and the closely related BTV VP7 have 29% aa identity and 51% aa 
homology in the upper domains, whilst the N-terminal region of the lower domain has 
65% identity and 82% homology and the C-terminal region has 42% identity and 61% 
homology (Monastyrskaya et al. 1997). Differences between these closely related 
Orbivirus proteins include an AHSV VP7 RGD motif Ala-167, Gly-168, and Gln-169 
located on a flexible loop found deep within the core in comparison to the easily 
accessible BTV VP7 RGD motif Arg-168–Gly-169–Asp-170 (Basak et al. 1996). In 
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contrast to AHSV VP7, BTV VP7 is soluble and does not form crystals during natural 
infection. By inserting BTV derived peptides into specific VP7 hydrophobic regions 
various researchers have attempted to manipulate the solubility of AHSV VP7 (Bekker 
et al. 2017; Monastyrskaya et al. 1997; Rutkowska et al. 2011).  
 Orbivirus Transcription and Replication Cycle 
The AHSV transcription and replication process has not been as well studied as that 
of the closely related prototypic Orbivirus BTV. However, due to their highly similar 
biochemical properties and nearly identical morphology, much of the AHSV 
transcription and replication process has been modelled around that of BTV’s (Manole 
et al. 2012; Roy and Sutton 1998; Dennis et al. 2019). The degree of similarity between 
AHSV and BTV is further demonstrated by the exchange of genome segments during 
simultaneous infection. This re-assortment amongst Orbiviruses has been 
hypothesised as a reason for their rapid evolution (Zientara et al. 2015). 
The initial contact and binding of the Orbivirus to the host cell receptors is mediated 
by the outer capsid protein VP2 leading to receptor-mediated endocytosis. VP7 is 
hypothesised to also play a role in cell entry (Basak et al. 1996; Hassan et al. 2001; 
Hassan and Roy 1999b; Roy et al. 1991; Roy et al. 1994). The clathrin-coated virus 
then moves into the host’s cell and fuses with its endosome (Figure 1.7) (Hassan and 
Roy 1999a; Mertens et al. 2004). The outer capsid proteins VP2 and VP5 separate 
from the virus core after translocating into the low pH environment within the 
endosome. VP5 then penetrates the endosomal membrane which causes the release 
of the virus core into the host cell’s cytoplasm. VP2 and VP5 are subsequently 
degraded and the core-associated transcriptase complex is activated (Figure 1.7) 
(Mertens et al. 2004). The enzymatic minor-proteins, VP1 (RNA polymerase), VP4 
(RNA capping enzyme) and VP6 (RNA helicase) are responsible for transcription of 
the ten dsRNA genome segments. The enzymatic proteins and dsRNA are housed 
safely within the core to protect the virus from the host’s antiviral system. The 
synthesised mRNA is then released from pores in the VP3 core layer into the host 
cell’s cytoplasm and is subsequently translated into viral proteins. Viral proteins are 
transported to virus inclusion bodies (VIBs), the sites where virus assembly and 
replication occurs in the host cell’s cytoplasm. NS2 mediates VIB formation and core 
particle assembly (Bailey 2016; Mertens 2004; Hassan and Roy 1999a; Mertens et al. 
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2004). Further research has shown that BTV VP3 is essential for the recruitment of 
VP7 trimers to VIBs during particle assembly and that VP7 does not form any 
morphological structures unless in the presence of VP3 (Bailey 2016; Bekker et al. 
2014; Kar et al. 2007). The addition of VP7 to the sub-core is important for the core’s 
stability and therefore protection of the transcriptase complex. VP7 is therefore added 
prior to the release of the particles from VIBs (Matsuo and Roy 2013). VP2 and VP5 
are however added subsequent to the release of the assembled core particles from 
VIBs. Fully formed virus particles are then released via budding, a process which is 
likely to be mediated by NS3 (Figure 1.7) (Bailey 2016; van Niekerk et al. 2003; 
Mertens et al. 2004). 
 
Figure 1.7: Orbivirus replication cycle. Transcription and replication cycle based on the 
prototypic Orbivirus BTV. Image courtesy of Veterinaria Italiana (Mertens et al. 2004). Image 
used with permission from the publisher. 
AHSV replication takes place in regional lymph nodes and subsequently spreads 
through the host’s circulatory system by infecting and replicating in hematocytes such 
as peripheral blood mononuclear cells (PBMCs). Secondary viraemia occurs once 
AHSV has further infected and replicated in the lungs, spleen and lymphoid tissues 
(Bailey 2016).  
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1.4 AHSV Vaccines 
 Challenges Surrounding Current AHSV Vaccines  
To date, no successful therapeutic treatment exists for AHS and in South Africa the 
disease is controlled primarily by preventative vaccination programmes, surveillance 
and zoning regulations (Maree et al. 2016; Maree and Paweska 2005). Unfortunately, 
the commercially used multivalent inactivated or live-attenuated vaccines (LAV) are 
associated with several disadvantages: the generation of progeny viruses with novel 
phenotypes can occur due to gene segment re-assortment between different 
serotypes; inoculating animals from new geographical regions with vaccines 
originating from South Africa may introduce foreign topotypes into that region; and lack 
of DIVA (differentiating infected from vaccinated animals) compliance which 
complicates import/export processes (Kushnir et al. 2012; Maree et al. 2016; Mellor et 
al. 1990; Wade-Evans et al. 1997; Dennis et al. 2018; Zientara et al. 2015). A recent 
AHSV serotype 1 outbreak in the Western Cape Province AHS-surveillance zone, 
during April and May 2016, was caused by a reversion to virulence of the presently 
used LAV (Grewar et al. 2019). Due to the above mentioned risks the AHSV live-
attenuated vaccines have not been licenced for use within the European Union (Bailey 
2016). 
The first AHSV vaccines produced in the 1930’s were based on attenuated virus 
strains which had been accomplished by passing the live virus through the brain of a 
juvenile mouse. This resulted in a high level of protection in equids but often caused 
side effects such as encephalitis. Further attenuation was then established by means 
of viral passage in cell culture and surprisingly these attenuated viruses remain as the 
basis of the present day Onderstepoort Biological Product (OBP) vaccines (Zientara 
et al. 2015; Mellor and Hamblin 2004; Mertens 2004). During the 1987-1991 AHSV 
epizootics in Europe an inactive vaccine was administered, however after the epizootic 
was concluded this vaccine was withdrawn as it was reported to be too expensive to 
produce and multiple boosters were needed to induce protection (Kushnir et al. 2012; 
Bailey 2016; Mellor and Hamblin 2004; Mirchamsy and Taslimi 1968). 
Developing more effective prophylactic vaccines is a difficult task as these vaccines 
need to protect susceptible equids against multiple serotypes. In the case of AHSV, 
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immunisation using a single serotype is highly ineffective as it does not generate a 
broad immune response, and in endemic regions like South Africa multiple serotypes 
circulate during outbreaks. Consequently, combinatorial vaccines are currently 
administered in South Africa in the form of two polyvalent vaccines from OBP which 
must be administered 28 days apart. The first vaccine includes the AHSV serotypes 
1,3 and 4 and the second includes serotypes 2, 6, 7 and 8. These vaccines do not 
contain serotype 9 as serotype 6 and 9 generally cross-react. In addition, AHSV-9 is 
considered to have low virulence and its prevalence in South Africa is seldom reported. 
Furthermore, serotype 5 has been excluded from the OBP vaccine as its inclusion has 
resulted in severe side effects and fatalities (Maree et al. 2016; Wade-Evans et al. 
1997; Zientara et al. 2015; Maree and Paweska 2005).  
The Terrestrial Animal Health Code of the OIE recommends that strict regulations are 
adhered to during equid exportation to prevent movement of infected equines into 
AHSV-free countries. One of these unfortunate but necessary recommendations is 
that these horses should not have been vaccinated against AHS within the last 
40 days due to the difficulty in distinguishing between vaccinated and infected animals 
(DIVA compliance) (Zientara et al. 2015). 
 Current AHSV Prophylactic Vaccine Research  
Vaccination is central to the control of AHSV and many potential vaccines have been 
investigated with little success in producing a more effective, safe and affordable 
vaccine than the conventional prophylactics (Maree et al. 2016). These have included 
DNA vaccines (Romito et al. 1999), inactivated vaccines (House et al. 1994; Lelli et al. 
2013a; Mellor and Hamblin 2004; Mirchamsy and Taslimi 1968), various recombinant 
subunit vaccines (SUVs) using baculovirus expression vectors (Martı́nez-
Torrecuadrada and Casal 1995; Scanlen et al. 2002; Roy and Sutton 1998; Kanai et 
al. 2014; Martinez-Torrecuadrada et al. 1996) and those based on attenuated poxvirus 
vectors (Castillo-Olivares et al. 2011; Chiam et al. 2009; Guthrie et al. 2009; Calvo-
Pinilla et al. 2014; Alberca et al. 2014; Manning et al. 2017; Calvo-Pinilla et al. 2018), 
core-like particle (CLP) vaccines (Maree et al. 1998), virus-like particle (VLP) vaccines 
(Dennis 2019; Maree et al. 2016), ‘synthetically derived’ reassortments of AHSV using 
reverse genetics (Lulla et al. 2017; Lulla et al. 2016; van de Water et al. 2015; van Rijn 
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et al. 2018) and VP7 trimer based vaccines (Bailey 2016; Rutkowska et al. 2011; 
Wade-Evans et al. 1997). 
During the AHSV outbreaks in Europe from 1987 to 1992 an inactivated monovalent 
AHSV-4 vaccine called Equipest was available. The vaccine was based on purified 
AHSV-4 inactivated using formalin. This vaccine resulted in immunity and protection 
in horses against AHSV-4 for a period of 6 months post-vaccination. However, this 
vaccine had various disadvantages in that it was serotype specific, multiple inoculation 
boosters were needed and the vaccine was reported to be expensive to produce. It 
was therefore removed off the market after AHSV was eradicated in Europe after 1992 
(Bailey 2016; Mellor and Hamblin 2004; Mirchamsy and Taslimi 1968). 
Recombinant SUVs are usually based on the surface components of a virus such as 
the outer capsid or major core proteins and are safer than live attenuated or inactivated 
vaccines as they do not contain any replicative properties. Unfortunately, SUVs often 
elicit a low immune response therefore requiring higher doses and boosters and the 
co-administration of adjuvants. One such recombinant SUV was investigated by 
Martinez-Torrecuadrada (1996) and colleagues: this study showed that a recombinant 
baculovirus vector co-expressing VP2, VP5 and VP7 induced neutralising antibodies 
and protection. A few years later, another study focusing on the baculovirus vector, 
demonstrated that soluble AHSV-5 VP2, triggers neutralising antibodies in guinea pigs 
and induces full protection in horses when combined with saponin adjuvants (Scanlen 
et al. 2002).  
Many SUV studies have focused on live attenuated poxvirus vectors such as 
recombinant modified vaccinia Ankara (MVA) and the recombinant canarypox virus 
vector (Alberca et al. 2014; Chiam et al. 2009; Guthrie et al. 2009; Calvo-Pinilla et al. 
2014; Manning et al. 2017; Calvo-Pinilla et al. 2018; Castillo-Olivares et al. 2011). One 
such pilot study demonstrated that MVA vaccines expressing AHSV VP2 and VP7 
stimulated immunogenicity in ponies and another showed that MVA-VP2 vaccination 
provided successful protection against the disease and against viraemia (Alberca et 
al. 2014; Chiam et al. 2009; Calvo-Pinilla et al. 2014). In addition, Guthrie et al. (2009) 
developed a recombinant canarypox virus vectored (ALVAC®) vaccine co-expressing 
AHSV-4 VP2 and VP5 and this was shown to be successful in protective immunisation 
against a live virus challenge.  
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In 1998, a study by Wade-Evans et al. assessed insoluble AHSV VP7 crystals as a 
subunit vaccine using an established mouse model. After exposure to a lethal dose of 
AHSV-7, 80-100% of immunised mice survived in comparison to a 0-20% survival rate 
observed in non-immunised mice. Immunisation using denatured VP7 crystals or 
bacterial GST-VP7 fusion proteins as opposed to intact VP7 crystals resulted in lower 
levels of protection, suggesting that the conformation of VP7 crystals is important for 
protection. In addition, the duration of viraemia was highly reduced in immunised mice 
in comparison to non-immunised mice post-infection. However, the circulating 
antibody titres against AHSV VP7 were low (log10 titres less than 1.0) suggesting that 
protection was therefore unlikely to be as a result of an antibody-mediated immune 
response. The authors suggested that in the absence of neutralising antibodies cell-
mediated immunity may enable cross-reactive protection (Wade-Evans et al. 1997). A 
more recent study by Bailey (2016) also demonstrated that VP7 crystals did not yield 
a favourable humoral response.  
Virus-like particles (VLPs) have been considered as one of the most favourable 
alternatives to conventional vaccines and a major advancement in SUV development. 
There are presently four recombinant VLP based vaccines on the market: 
GlaxoSmithKline’s Cervarix® and Merck and Co., Inc.’s Gardasil® for the human 
papillomavirus, and GlaxoSmithKline Engerix® and Merck and Co., Inc.’s Recombivax 
HB® for the hepatitis B virus (Kushnir et al. 2012; Zientara et al. 2015). VLPs usually 
include the structural viral proteins which have an innate ability to self-assemble. 
Furthermore, these VLPs mimic the native virus but do not contain the replicative 
transcription complex and are therefore non-pathogenic, lacking infectious material. 
They do however induce a strong humoral and cellular immune response as a result 
of the display of native conformations of diverse epitopes (Kushnir et al. 2012). In 1998 
Maree et al. produced AHSV core-like particles (CLPs) in insect cells. However, this 
was a complex system involving the co-infection of two baculoviruses which expressed 
VP3 and VP7 separately, and only produced partial CLPs. In 2016 a further study was 
conducted by the same authors which involved assembling the major viral core and 
outer capsid proteins (VP2 and VP5) using a single recombinant baculovirus for co-
synthesis of VP3 and VP7 to produce more affordable alternatives (Maree et al. 2016). 
While VLPs induce a stronger protective immune response than recombinant single-
protein subunit vaccines, VLP vaccines may not be as cost-effective as they are more 
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complicated to produce involving the co-expression and assembly of viral structural 
proteins (VP2, VP3, VP5 and VP7) into virus-like structures, which often leads to 
problems in terms of reproducibility. This may cause further difficulties when upscaling, 
particularly as a result of the necessity for polyvalent vaccines which cover all nine 
serotypes (Maree et al. 2016). A more recent alternative which seems very promising 
is the generation of plant-produced AHSV VLPs which are likely to be more cost-
effective to produce and scalable (Dennis 2019).  
Another vaccine strategy is to create chimeric CLPs by displaying foreign epitopes on 
the surface of viral or multimeric particles. A prerequisite for this strategy is that 
chimeric particles need to assemble into stable CLPs. Both BTV and AHSV have been 
explored as foreign antigen presenting VLPs (Burroughs et al. 1994; Rutkowska et al. 
2011).  Rutkowska et al. originally investigated the possibility of using insoluble AHSV 
VP7 chimeric particles as a vaccine delivery system and then extended their study to 
incorporate soluble chimeric VP7 trimers. They reasoned that one could take 
advantage of the preferential formation of VP7 trimers during CLP assembly, and that 
these VP7 trimers may invoke a better humoral immune response than a single CLP. 
Their study determined that soluble chimeric VP7 proteins were able to form stable 
trimers and induce a strong humoral immune response, and that the neutralisation 
antibody titres resulting from the soluble fraction of VP7 was approximately ten times 
higher than that of the insoluble VP7 crystalline-particles (Rutkowska et al. 2011). 
Furthermore, a reverse genetics approach has been utilised by some researchers 
generating ‘synthetic’ reassortments of AHSV serotypes. The Disabled Infectious 
Single Animal (DISA) vaccine which lacks NS3/NS3A (van de Water et al. 2015; van 
Rijn et al. 2018) and the Entry Competent Replication-Abortive (ECRA) vaccine using 
a VP6-defective AHSV strain in combination with in trans complementation of VP6 
(Lulla et al. 2017; Lulla et al. 2016).  
For an effective AHSV vaccine both a humoral and cellular immune response is 
needed. This has been shown to be essential in protective immunity against BTV 
(Andrew et al. 1995; Calvo-Pinilla et al. 2014; Jeggo et al. 1984). Many researchers 
have focused on the humoral immune response to AHSV (Alberca et al. 2014; Calvo-
Pinilla et al. 2014; Castillo-Olivares et al. 2011; Chiam et al. 2009; Kanai et al. 2014; 
Manning et al. 2017; Calvo-Pinilla et al. 2018; Martinez-Torrecuadrada et al. 1996; 
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Bailey 2016). However, few have focused on the role of cellular immunity in protection 
against AHSV. Those that have shown both humoral and cellular immune responses, 
are based on pox viral vectors MVA expressing AHSV-4 VP2 and NS1 and canarypox 
virus expressing AHSV-4 VP2 and VP5 (ALVAC®). These candidate vaccines were 
shown to induce CD8 T-cell proliferation (Guthrie et al. 2009; Pretorius et al. 2016). In 
addition, a DNA vaccine encoding AHSV VP2 demonstrated a cytotoxic T-cell 
response (Romito et al. 1999). 
 Host Immune Responses and Vaccine Design 
After pathogen infection, endogenous (heat shock proteins and nucleic acid damage) 
and exogenous (pathogen or adjuvant) cues alert the innate immune system to destroy 
the foreign antigen. These non-specific innate immune responses function within a few 
hours after infection and include the pattern recognition receptors (PRR) described in 
Chapter 3 (Cui et al. 2014; Storni et al. 2005; Takeuchi and Akira 2010). PRRs 
recognise pathogen-associated molecular patterns (PAMPs) and trigger their 
associated signalling cascades leading to the production of various cytokines 
(Chapter 3) (Cui et al. 2014; Takeuchi and Akira 2009, 2010). If the pathogen is not 
destroyed by the quick acting innate responses, adaptive responses are triggered by 
PRR pathways (Storni et al. 2005). These adaptive responses include humoral 
immune responses i.e. B-cell receptor pathway activation and cell-mediated immune 
responses i.e. T-cell receptor pathway activation (Refer to Chapter 3 for more detail) 
(Janeway et al. 2001; Savignac et al. 2010; Dorner and Radbruch 2007).  
Viruses often have mechanisms which can evade or supress the immune system. For 
this reason, it is important that both humoral and cell-mediated immune responses are 
required for an effective AHSV vaccine. Furthermore the survival of vaccinated 
animals which demonstrate low antibody titres after a lethal challenge suggest that 
cell-mediated responses are important in AHSV immunity (Guthrie et al. 2009; 
Martinez-Torrecuadrada et al. 1996; Wade-Evans et al. 1997; Scanlen et al. 2002). 
Live vaccines generally induce strong T-cell responses. Whilst subunit vaccines, 
particularly soluble proteins, can often induce a humoral response and neutralising 
antibodies but rarely stimulate favourable T-cell responses (Storni et al. 2005). 
Furthermore, effective vaccines need to target antigen presenting cells (APCs) such 
as dendritic cells as these are well known T-cell activators. Soluble proteins do not 
____________________________________________________________________________________________________
Shelley Helen Fearon Student No: SMTSHE005 Page 32 
activate APCs and their immunogenicity is therefore low unless adjuvants are added 
(Storni et al. 2005).  
 Particulates and Quasi-Crystals as Vaccines 
There is little research available on the use of protein crystals as vaccines, however 
there are numerous reasons why particulates may be favourable vaccine candidates. 
Firstly, due to the highly ordered and repetitive nature of protein crystals, 
immunologically important epitopes are likely to be more efficiently presented to the 
immune system as evidenced by comparative studies (Fehr et al. 1998; St Clair et al. 
1999) and this is hypothesised to enhance B-cell and T-cell responses (Chapter 3) 
(St Clair et al. 1999; Bailey 2016; Storni et al. 2005; Rutkowska et al. 2011). Several 
studies have demonstrated that particulate antigen delivery systems induce Th1 and 
CTL responses similar to that of attenuated and inactivated viruses (Friede and 
Aguado 2005; Sharp et al. 2009; Storni et al. 2005).   
Secondly, particulates are more effectively phagocytosed by APCs than soluble 
antigens and are therefore more efficient in presenting these to the adaptive immune 
system (Bachmann and Jennings 2010; Manolova et al. 2008; Snapper 2018; Vidard 
et al. 1996). Many particulate vaccine adjuvants have been shown to increase the 
dendritic cell uptake of antigens, increase IL-1 secretion and enhance cell-mediated 
immune responses (Sharp et al. 2009). APC presentation of particulates is covered in 
more detail in Chapter 3. 
Other advantages include quasi-crystal stability and biodegradability (Bailey 2016). 
Furthermore, natural pathogens are particulate in nature and it therefore stands to 
reason that an effective vaccine would do well to mimic this characteristic (Storni et al. 
2005). 
 AHSV VP7 Quasi-Crystals as a Potential Candidate Vaccine  
AHSV VP7 is a highly immunodominant protein which has been demonstrated by high 
titres of anti-VP7 antibodies during natural AHSV infection (Bailey 2016). It is therefore 
widely used to identify AHSV infections using rapid diagnostic serological assays, 
enzyme-linked immunosorbent assays (ELISAs) and quantitative reverse-transcription 
polymerase chain reaction (RT-qPCR) assays (Maree and Paweska 2005; Martinez-
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Torrecuadrada et al. 1996; Bailey 2016; Zientara et al. 2015). It is also serogroup-
specific, with at least 98% amino acid similarity between serotypes, a trait which is 
very beneficial in vaccine design as it negates the need for a multivalent vaccine  
(Chuma et al. 1992; Williams et al. 1998; Bailey 2016).  
An AHSV VP7 quasi-crystal vaccine would be simple to produce as it only relies on 
one structural protein for assembly and has the benefit of a highly ordered and 
repetitive quasi-crystal conformation. This repetitive display of epitopes is likely to 
enhance B-cell and T-cell immune responses (Bailey 2016; Friede and Aguado 2005; 
Rutkowska et al. 2011; St Clair et al. 1999; Storni et al. 2005). The closely related BTV 
VP7 has been shown to possess serotype-cross-reactive T-cell epitopes (Mertens 
2004). Since AHSV VP7 is similar to BTV it may contain similar epitopes and 
comparably enhance the immune response to the virus (Martinez-Torrecuadrada et 
al. 1996).  
Wade-Evans et al. (1997) speculated that the crystalline conformation of AHSV VP7 
is important for inducing protection as VP7 crystals were more efficient at protecting 
mice against a live challenge when compared to soluble VP7. In contrast, other studies 
suggest that AHSV VP7 is more immunogenic when solubilised, however these 
studies are focused on the humoral response and did not investigate the cell-mediated 
response (Bailey 2016; Martinez-Torrecuadrada et al. 1996). AHSV challenge studies 
have demonstrated protection in animals with low antibody titres and no neutralising 
antibodies therefore suggesting other immune mechanisms such as cell-mediated 
immunity (Martinez-Torrecuadrada et al. 1996; Wade-Evans et al. 1997). For many 
years the main criteria for efficacious vaccines has been a humoral response and 
neutralising antibodies. However, the cell-mediated immune response may be as 
important in vaccine design. 
Furthermore, AHSV VP7’s intrinsic ability to aggregate and self-form crystalline 
structures can be exploited to produce large quantities of quasi-crystals to meet the 
high demands for vaccine production (Maree and Paweska 2005; St Clair et al. 1999).  
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1.5 Plant Expression Systems 
In recent years, plant expression systems have received increasingly more attention 
as an alternative to the more traditional prokaryotic and eukaryotic cell culture 
platforms for vaccine production. Plant expression systems are advantageous as they 
are safer to produce, have a low risk of pathogen contamination and the literature 
suggests upstream processes are easily scalable and more cost-effective (Chen et al. 
2013; Rybicki 2009; Mir-Artigues et al. 2019; Schillberg et al. 2019). In terms of 
upstream processes, the infrastructure and raw materials needed for plant expression 
systems are less expensive when compared to cell-based platforms, as plants can be 
grown in greenhouses and only require light, water and soil/ hydroponic medium, while 
cell-based systems require fermenters installed in dedicated facilities, sterile 
equipment, complex media and bioreactors. Furthermore, in terms of scalability, cell-
based systems are restricted by the fermenter’s capacity and production speed, while 
plant expression platforms can be increased by simply growing more plants (Mir-
Artigues et al. 2019). However, downstream processes for protein purification can still 
be complicated and costly as plant-specific compounds such as phenols and toxic 
alkaloids (particularly in the case of Nicotiana plants) need to be removed before plant-
produced recombinant proteins can be used as pharmaceuticals (Chen et al. 2013). 
N. benthamiana is commonly used for the transient expression of recombinant 
proteins as it is a resilient species which easily withstands Agrobacterium-mediated-
infiltration (agroinfiltration) and produces high yields of biomass (Chen et al. 2013). 
Agroinfiltration is an efficient gene-delivery technique where Agrobacterium 
tumefaciens is introduced into plants by syringe- or vacuum-infiltration (Chen et al. 
2013; Maclean et al. 2007). In this technique, the natural plant pathogen 
A. tumefaciens has been manipulated to deliver genes of interest into plant host cells 
and induce transient expression of the required recombinant protein (Kapila et al. 
1997; Maclean et al. 2007; Chen et al. 2013). Various expression vectors are used for 
agroinfiltration, including non-viral and plant-virus based vectors which have been 
integrated into modified A. tumefaciens plasmids (Chen et al. 2013; Regnard et al. 
2010; Rybicki 2009). Agrobacterium-mediated-infiltration and plant expression vectors 
are covered further in Chapter 2. 
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The current technology surrounding plant-produced pharmaceuticals is well 
developed and many examples of successfully produced plant-derived antibodies and 
proteins exist (Paul and Ma 2011; Lomonossoff and D’Aoust 2016). Plant-produced 
VLP candidate vaccines for porcine circovirus (Gunter et al. 2019), AHSV (Dennis et 
al. 2018) and influenza (Pillet et al. 2019) have been shown to elicit strong immune 
responses in mice, horses and humans respectively. And the aforementioned VLP 
influenza vaccine candidate produced by Medicago is presently in phase III clinical 
trials (https://clinicaltrials.gov/ct2/show/NCT03739112). Furthermore, a plant-
produced swine fever virus (SWV) E2 subunit vaccine demonstrated complete 
protection in SWV challenged pigs (Laughlin et al. 2019). A plant-derived therapeutic 
enzyme for the lysosomal storage disorder (LSD), Gaucher’s Disease, has been 
developed (Chen et al. 2013). And the lysosomal enzyme, beta-galactosidase, has 
been produced in moss as a therapeutic for LSDs such as Fabry disease (Shen et al. 
2016). Many plant-produced therapeutics are in clinical trials such as the HIV 
neutralising human monoclonal antibody (P2G12) which is in phase I clinical trials (Ma 
et al. 2015) and a conjugated vaccine for treatment of B-cell follicular lymphoma (Tuse 
et al. 2015). Furthermore a plant-produced combination of monoclonal antibodies, 
ZMapp, was shown to reverse severe Ebola virus symptoms (Qiu et al. 2014). 
1.6 Conclusions 
Repeated AHSV outbreaks in national and international AHS-free zones are reported 
to have devastating economic consequences. The presently used prophylactic 
vaccines have detrimental side-effects and a new inexpensive, safer, DIVA compliant 
alternative is therefore required.  
The cell-mediated immune response to vaccines has generally been overlooked but 
increasing evidence has shown that it is essential for a successful AHSV candidate 
vaccine. AHSV VP7 is highly immunogenic and its quasi-crystal formation is likely to 
generate strong cell-mediated responses. Furthermore plant-produced AHSV VP7 
quasi-crystals have the added benefits of plant production platforms in that they are 
safer, easily scalable and upstream cultivation is more cost-effective. 
To the best of our knowledge this is the first attempt to express and purify AHSV VP7 
quasi-crystals from N. benthamiana plants. And furthermore, the first time that the 
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humoral and cell-mediated immune responses to VP7 quasi-crystals have been 
investigated. 
1.7 Project Aims and Objectives 
This study aims to develop recombinant plant-produced AHSV-5 VP7 quasi-crystals 
for use as a potential candidate vaccine. 
The first objective was to optimise the expression conditions of AHSV-5 VP7 in N. 
benthamiana. An AHSV-5 VP7-encoding gene cloned into two plant expression 
vectors (pEAQ-HT and pRIC3.0) was used for small-scale (<10 g) agroinfiltration of 
N. benthamiana plants. Time trials and comparison studies were carried out by 
AHSV-5 VP7 detection using SDS PAGE, western blotting and Coomassie staining. 
To this end the optimal parameters: expression vector, culture density (OD600) and 
harvest day post-infiltration, were selected. 
The second objective involved optimising the purification protocol and characterising 
VP7 quasi-crystals. Discontinuous gradient ultra-centrifugation was performed, and 
levels of plant produced VP7 protein detected by western blotting and Coomassie 
stained gels. Formation of VP7 quasi-crystals was confirmed by transmission electron 
microscopy (TEM) and concentrations quantified by gel densitometry.  
The third objective was to investigate the intra-cellular formation of quasi-crystals by 
embedding AHSV-5 VP7 agroinfiltrated leaves and performing in situ TEM.  
The final objective was to test the vaccine potential of plant-produced AHSV-5 VP7 
quasi-crystals. This included assessing the stability of AHSV VP7 quasi-crystals at 
4C, -20C and -80C over a 28-week period and analysing their ability to induce an 
AHSV VP7-specific immune response (humoral and cell-mediated) in guinea pigs. 
Immunogenicity studies were carried out at the Research Animal Facility (RAF) at the 
University of Cape Town (UCT). Guinea-pig sera were analysed for anti-VP7 
antibodies by western blotting to investigate the humoral immune response, and the 
cell-mediated immune response was considered by analysing the differential 
expression of immune related genes. This was accomplished by extracting spleen-
derived RNA, RNA-sequencing, bioinformatics using the Illumina Basespace platform 
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and R (R Core Team 2018) was used to analyse the global immune response from 
DESeq2 results.  
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CHAPTER 2: EXPRESSION & PURIFICATION OPTIMISATION OF AHSV-5 VP7 QUASI-
CRYSTALS 
2.1 Introduction 
VP7 is one of the major core structural proteins of the African horse sickness virus 
(AHSV), which forms 260 stable trimers and assembles into a highly-ordered lattice 
surrounding a thin scaffold of 120 copies of VP3. AHSV VP7 is essential for viral 
replication and holds the major serogroup-specific antigenic sites (Bekker et al. 2017). 
It is also a highly immunogenic protein and for this reason has been widely utilised in 
serological assays to identify infections and distinguish between Orbivirus serogroups 
(Maree and Paweska 2005; Martinez-Torrecuadrada et al. 1996). The trimeric 
particles of AHSV VP7 have been shown to be stable at room temperature in the 
presence of 10% (w/v) sodium dodecyl sulphate (SDS), revealing strong monomer-
monomer interactions (Monastyrskaya et al. 1997; Rutkowska et al. 2011). These 
intermolecular contacts are likely due to disulphide bridges formed between Cys195 
residues of interacting VP7 monomers, as recently discovered by Bekker et al. (2017). 
Additionally, the polar residues Arg255 and Lys123 have been highlighted as potential 
contributors to polymerisation (Bekker et al. 2017). 
AHSV VP7 is a largely insoluble and hydrophobic protein consisting of a high amount 
of alanines (12.9%), prolines (6.6%), valines (10.9%), leucines (7.2%) and 
methionines (3.7%) as concluded by Basak et al.  (1996) and Roy et al. (1991) and 
validated by the peptide property online tool ProtParam on the ExPASy bioinformatics 
resource portal (https://web.expasy.org/protparam/)) (Gasteiger et al. 2005). 
Rutkowska et. al. (2011) found less than 10% of AHSV WT VP7 in the soluble fractions 
following density gradient purification. And whilst the top domain has been resolved 
using x-ray crystallography, its insolubility has resulted in difficulties in resolving the 
bottom domain. Basak et al. (1996) and Rutkowska et al. (2011) have suggested that 
the residues Ala167 (top domain) and Leu345 (bottom domain) respectively play a role 
in AHSV VP7 insolubility. And Monastyrskaya et al. (1997) suggested that residues of 
the top domain are critical in the insolubility of AHSV VP7 when compared to the 
solubility of the closely related bluetongue virus (BTV) VP7. 
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During AHSV particle assembly, VP7 trimers inherently aggregate into large flat 
hexagonal quasi-crystals both during AHSV infection and in vitro (Maree et al. 2016; 
Rutkowska et al. 2011). Reported crystal sizes range from 100 nm to 25 µm 
(Burroughs et al. 1994; Chuma et al. 1992; Maree and Paweska 2005; Wall et al. 2017; 
Bailey 2016). A length of 250 µm has been reported by Chuma et al. (1992). Bailey et 
al. (2016) observed that crystal sizes generally range between 3-5 µm during natural 
AHSV infection or when AHSV VP7 is expressed by Modified vaccinia virus Ankara 
(MVA). Whilst expression using baculovirus seems to result in a wider distribution of 
sizes up to 25 µm. They speculated that this may be due to the regulatory mechanisms 
driving expression and that abnormally high expression levels could result in irregular 
crystal sizes (Bailey 2016). 
Little is known about AHSV VP7 aggregation, crystal formation and its role in the virus 
life cycle (Rutkowska et al. 2011; Wall et al. 2017). It is possible that these crystals are 
just a by-product rather than a crucial component of the viral replication process 
(Burroughs et al. 1994). Some studies have suggested that the majority of VP7 may 
preferentially aggregate to form crystals as opposed to virions (Bekker et al. 2014; 
Maree et al. 1998) and that this may be a way for the virus to evade the host’s immune 
system (Bailey 2016). However, this seems unlikely since the repetition of 
immunologically important epitopes in crystal formations is more likely to enhance 
immune responses (Friede and Aguado 2005; Rutkowska et al. 2011; St Clair et al. 
1999). Bekker et al. (2017) recently highlighted the hydrophobic amino acids Ile228, 
Pro230 and Ala167 as potential contributors to the crystal formation of AHSV VP7; in 
earlier research by the same authors it was shown that intracellular aggregation is due 
to inherent properties of AHSV VP7 rather than influences by other AHSV proteins, 
cellular trafficking or degradation pathways (Bekker et al. 2014).  
During AHSV infection, VP7 is a highly immunodominant antigen and for this reason 
it is broadly used in ELISAs as an AHSV diagnostic tool (Bailey 2016; Maree and 
Paweska 2005; Martinez-Torrecuadrada et al. 1996). Furthermore, cross-linking of 
immunogenic epitopes in AHSV VP7 crystalline particles is considered to induce B-cell 
and T-cell immune responses (Friede and Aguado 2005; Rutkowska et al. 2011; St 
Clair et al. 1999). Due to its immunogenicity, various researchers have sought to 
further characterise AHSV VP7 and examine its potential use in prophylactics and 
therapeutics. To this end it has been successfully expressed and purified using 
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recombinant baculovirus-infected Sf9 insect cells (Basak et al. 1996; Bekker et al. 
2014; Chuma et al. 1992; Maree and Paweska 2005; Martinez-Torrecuadrada et al. 
1996; Rutkowska et al. 2011; Wall et al. 2017) and BHK cells infected with bacterial 
GST-VP7 fusion protein (Wade-Evans et al. 1997). In recent years plant expression 
systems have received an increasing amount of attention as an alternative to 
mammalian, insect and bacterial cell culture systems. Largely because plants offer a 
more scalable and safer option when compared to these conventional systems (Chen 
et al. 2013). As mentioned previously, the most commonly used plant species for 
transient expression of recombinant proteins is N. benthamiana as it is resilient and 
grows rapidly thereby producing high yields of biomass (Chen et al. 2013).  
Agrobacterium tumefaciens is a natural plant pathogen which induces tumour 
formation by stimulating cell division; this relationship has been manipulated to deliver 
genes of interest into selected plant hosts. A. tumefaciens’ tumour-inducing (Ti) 
plasmid includes the transfer DNA (T-DNA) and virulence (vir) gene region. The vir 
gene products aid in processing and transporting T-DNA into the plant host cell’s 
nucleus. Here the T-DNA is transcribed and translated using host cell enzymes. On 
the left and right boundaries of the T-DNA are two 25 bp direct repeats. The DNA 
positioned between these flanking repeats is tranferred into the plant nucleus and 
incorporated into the host’s genomic DNA (Maclean et al. 2007; Zupan et al. 2000). 
However, many of these T-DNA copies are not integrated into the genome but rather 
re-circularise or remain as linear copies in the nucleus and are transiently expressed. 
Therefore, by modifying the Ti plasmid to replace tumour inducing genes in the T-DNA 
region with a gene of interest, transient expression of selected proteins can easily be 
produced by agroinfiltration (Chen et al. 2013). Transient expression, as opposed to 
stable transformation, is preferable as it is less time-consuming and can therefore 
produce recombinant proteins rapidly as opposed to the labour-intensive stable 
transformation technology (Lomonossoff and D’Aoust 2016). 
As mentioned in Chapter 1, a variety of non-viral or plant-virus based expression 
vectors can be used for Agrobacterium-mediated-infiltration (Chen et al. 2013; 
Regnard et al. 2010; Rybicki 2009). Previous studies have demonstrated that AHSV-5 
VP7 is effectively expressed in N. benthamiana using the pEAQ-HT and pRIC3.0 
expression vectors (Dennis 2019). Having shown this, this study aimed to compare 
AHSV-5 VP7 quasi-crystal yields resulting from these two virus-based vectors. Both 
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the pEAQ-HT and pRIC3.0 vectors include origins of replication for E. coli (ColE1 ori) 
and A. tumefaciens (RK2 ori), and the transgene is inserted within the T-DNA borders 
and controlled by the Cauliflower mosaic virus (CaMV) 35S promoter (Regnard et al. 
2010; Sainsbury et al. 2009).  
More specifically, pEAQ-HT is a cowpea mosaic virus (CPMV)-based hyper-trans 
expression system which targets expression to the cytoplasm (Thuenemann et al. 
2013). It includes the nptII gene for kanamycin resistance and TrfA, an essential 
replication locus for A. tumefaciens. In addition, P19, a suppressor of gene silencing, 
is included in the T-DNA region. P19 originates from the Tomato bushy stunt virus 
(TBSV) and has been shown to enhance recombinant protein yield (Sainsbury and 
Lomonossoff 2014; Sainsbury et al. 2009).   
pRIC3.0 is a self-replicating plant expression vector based on a mild strain of the bean 
yellow dwarf virus (BeYDV), a ssDNA circular geminivirus which has been shown to 
result in high levels of cytoplasmic expression of recombinant proteins (Regnard et al. 
2010). Regnard et al. (2010) reported that expression via the pRIC vector resulted in 
50% more human papillomavirus subtype 16 major CP L1 (HPV-16 L1) and three- to 
seven-fold more enhanced green fluorescent protein (EGFP) and human 
immunodeficiency virus subtype C p24 (HIV-1 p24) antigen, when compared to 
expression by the non-replicating A. tumefaciens vector pTRAc. pRIC3.0 includes the 
bla gene for ampicillin/carbenicillin resistance. Within the borders of the A. tumefaciens 
T-DNA are the: BeYDV long intergenic region (LIR) which contains transcriptional 
promoters and the viral origin of replication, the BeYDV short intergenic region (SIR) 
which holds transcription termination signals, and the BeYDV rep gene which encodes 
the replication-associated genetic elements. After infiltration and entry into the host’s 
nucleus, the T-DNA is released and re-circularises to form a dsDNA pRIC3.0 replicon. 
The viral genome replicates by means of rolling circle replication, using Rep and host 
cell replication proteins, thereby increasing expression of the gene of interest 
(Regnard et al. 2010).  
Whilst plant expression systems have various advantages over the aforementioned 
conventional platforms, downstream purification processes can be complicated and 
costly (Chen et al. 2013). This chapter focuses on optimising the expression and 
purification process of AHSV-5 VP7 quasi-crystals from N. benthamiana in order to 
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produce favourable antigen yields and purity for immunogenicity studies (Chapter 3). 
The most commonly used method for purifying both soluble and insoluble AHSV VP7 
from insect and mammalian cells, is sucrose density gradient ultracentrifugation 
(Basak et al. 1996; Chuma et al. 1992; Maree and Paweska 2005; Martinez-
Torrecuadrada et al. 1996; Wall et al. 2017) and some researchers have reported 
using an additional caesium chloride (CsCl) density gradient (Burroughs et al. 1994; 
Wade-Evans et al. 1997). In density gradient purification, particles are separated by 
moving through a density gradient by means of centrifugal force until they reach the 
equivalent density in the surrounding medium (isopycnic point). Alternative methods 
used to purify AHSV capsid proteins include affinity chromatography and ammonium 
sulphate precipitation, however both methods seem to result in conformational 
alterations possibly due to included chaotropic agents (Martinez-Torrecuadrada et al. 
1996; Monastyrskaya et al. 1997). In addition, Bailey et al. (2016) applied freeze-thaw 
cycles and filtration techniques to isolate and extract AHSV VP7 quasi-crystals. In this 
study density gradient ultracentrifugation was selected for purification as it is a well-
known successful method for isolating virus particles. It is also more likely to preserve 
the conformation of AHSV VP7 quasi-crystals, a critical component in providing 
protection against a viral challenge, as suggested by Wade-Evans et al. (1997). 
Iodixanol was selected as the preferred density gradient medium as it is non-ionic, 
non-toxic to cells and metabolically inert and therefore unlikely to affect the 
conformational integrity of particles. Iodixanol also has the added advantage of low 
viscosity, low osmolarity and most importantly it is sterile and therefore safer than 
sucrose for vaccine preparations (Ford et al. 1994).  
2.2 Materials & Methods 
 Constructs 
The constructs pRIC3.0-AHSV5-VP2, -VP3, -VP5, -VP7 and pEAQ-AHSV5-
VP2, -VP3, -VP5 and -VP7 were kindly provided by S. Dennis, a member of the 
Biopharming Research Unit (BRU) at the Department of Molecular and Cell Biology 
(MCB), University of Cape Town (UCT). Consensus gene sequences (GenBank 
accession numbers shown in Addendum A) were codon optimised (OptimumGene 
codon optimization algorithm) for expression in N. benthamiana by S. Dennis and 
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synthesized by GenScript (Nanjing, China). The pEAQ-HT expression vector was 
provided by G. Lomonossoff (John Innes Centre, UK) and the pRIC3.0 expression 
vector by G. Regnard (BRU, MCB Department, UCT). S. Dennis electroporated the 
pRIC3.0-AHSV5-VP7 and pEAQ-AHSV5-VP7 plasmid constructs into Agrobacterium 
tumefaciens strains, GV3101 (containing the helper plasmid pMp90RK) and AGL1 (A. 
radiobacter AGL1-ATCC BAA-101) respectively as described by Maclean et al. (2007). 
These transformed Agrobacterium were acquired from the culture collection of the 
BRU, MCB Department, UCT and streaked onto lysogeny broth (LB) agar plates [1.0% 
tryptone, 0.5% yeast extract, 0.5% NaCl, 1.5% agar, pH 7.0] which had been 
supplemented with the appropriate antibiotics (AGL1: kanamycin 50 µg/ml, 
carbenicillin 25 µg/ml and GV3101::pMp90RK: kanamycin 30 µg/ml, carbenicillin 50 
µg/ml, rifampicin 50 µg/ml). Liquid cultures were then grown in LB [1.0% tryptone, 
0.5% yeast extract, 0.5% NaCl, pH 7.0] with gentle agitation at 220 rpm O/N at 28C 
and glycerol stocks stored at -80C.  
Gene inserts from AGL1/ pEAQ-AHSV5 constructs were confirmed via colony PCR 
and inserts from GV3101::pMp90RK/ pRIC3.0-AHSV5 were confirmed after DNA 
extraction and PCR using KAPA Taq DNA polymerase (KAPA Biosystems). The 
primer sequences used were as follows:  
pEAQ-HT forward: 5'-TTCTTCTTCTTGCTGATTGG-3' 
pEAQ-HT reverse: 5'-CACAGAAAACCGCTCACC-3' 
pRIC3.0 forward: 5'-CATTTCATTTGGAGAGGACACG-3' 
pRIC3.0 reverse: 5'-GAACTACTCACACATTATTCTGG-3'  
The pEAQ-AHSV5 constructs’ PCR profile consisted of an initial denaturation step at 
95C for 5 min, 30 cycles of denaturation at 95C for 30 sec, annealing at 51C for 
30 sec, extension at 72C for 3.5 min and a final extension step at 72C for 7 min. The 
PCR profile used for pRIC-AHSV5 constructs included one cycle of initial denaturation 
at 95C for 3 min, 30 cycles of denaturation at 95C for 30 sec, annealing at 59C for 
30 sec, extension at 72C for 3.5 min and a final extension at 72C for 4 min.  
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 Agrobacterium Inoculum Preparation for Infiltration of Recombinant 
AHSV-5 VP7 in N. benthamiana Leaves 
2.2.2.1 Agrobacterium inoculum preparation for small-scale (<10 g) 
syringe-infiltration 
Cultures of recombinant pEAQ-AHSV5-VP2, -VP3, -VP5 & -VP7 and pRIC3.0-
AHSV5-VP2, -VP3, -VP5 & -VP7 A. tumefaciens cells (AGL1 and GV3101 
respectively) were grown to exponential phase as described by Maclean et al. (2007) 
for small-scale (<10 g) syringe-infiltration. Pre-cultures were grown by placing 1 ml 
glycerol stock into 10 ml LB which had been supplemented with the appropriate 
antibiotics for each Agrobacterium strain, as per 2.2.1. In addition, 2 mM magnesium 
sulphate (MgSO4) was added to prevent clumping and the pre-cultures were then 
incubated O/N at 28C with gentle agitation (220 rpm). 
Cultures were then upscaled.  Pre-cultures were used to inoculate 50 ml Luria-Bertani 
broth (LBB) [0.25% tryptone, 1.25% yeast extract, 0.50% NaCl, 10 mM 2-
morpholinoethanesulfonic acid (MES), pH 5.6] which had been supplemented with the 
antibiotics specified in 2.2.1 and 2 mM MgSO4. Once again, these cultures were 
incubated O/N at 28C with gentle agitation (220 rpm).  
The inoculum was prepared by diluting cultures to the required optical density (OD600) 
in resuspension solution [10 mM MES, 10 mM MgCl2.6H2O, pH 5.6]. 200 µM 
acetosyringone was added to the diluted cultures which were incubated for 1 hour at 
room temperature to allow for expression of the vir-genes prior to infiltration. Phenolics 
such as acetosyringone, which are naturally secreted by wounded dicotyledonous 
plants, assist in inducing the expression of vir genes (Chen et al. 2013; Maclean et al. 
2007) 
2.2.2.2 Agrobacterium inoculum preparation for medium to large-scale 
(10 g <) vacuum-infiltration 
Pre-cultures containing recombinant pRIC3.0-AHSV5-VP2, -VP3, -VP5 and -VP7 
constructs were prepared as per 2.2.2.1, however cultures were upscaled to a greater 
volume. 50 ml pre-cultures were used to inoculate 500 ml LBB which had been 
supplemented with the appropriate antibiotics (as noted in 2.2.1) and 2 mM MgSO4. 
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In addition, these cultures were induced O/N with 20 µM acetosyringone at 28C with 
gentle agitation (220 rpm). 
Subsequently, the inoculum for AHSV-5 capsid protein co-expression via vacuum-
infiltration was prepared as per 2.2.2.1 at an OD600 of 0.5. 
 Agroinfiltration and Optimisation of AHSV-5 VP7 Transient Expression in 
N. benthamiana 
2.2.3.1 Determination of optimal expression conditions: Expression 
vector comparison, and co- vs single-infiltration 
Four- to five-week-old N. benthamiana plants were syringe-infiltrated, using a blunt-
ended syringe, on the abaxial side of the leaf with the inoculum prepared in 2.2.2.1. 
An inoculum optical density of 0.5 at 600 nm was selected for this experiment, as 
previous research by S. Dennis (BRU, MCB Department, UCT) had shown this to be 
the optimal OD600 for AHSV-5 VLP expression and assembly in N. benthamiana. Two 
plants per vector (pEAQ-AHSV5 and pRIC3.0-AHSV5) were co-infiltrated with 
recombinants VP2: VP3: VP5: VP7 at a ratio of 1: 1: 1: 1. In addition, a further two 
plants per construct were infiltrated with AHSV-5 VP7 recombinants alone. Plants 
were grown at 22-25C under 16-h/ 8-h light/dark cycles until day of harvest. Four 
leaves (two from each plant) per parameter were harvested 3 days post-infiltration 
(dpi). pEAQ-HT and pRIC3.0 empty vectors were used as negative controls and were 
infiltrated at an OD600 of 0.5. 
Crude extracts were prepared by combining the harvested leaves with phosphate-
buffered saline (PBS) [10 mM Na2HPO42H2O, 137 mM NaCl, 2.7 mM KCl, 2 mM 
KH2PO4, pH 7.4] at a 1:3 (w/v) ratio and homogenised using a pestle and mortar. The 
extracts were then filtered through one layer of MiraclothTM (Merck, Darmstadt, 
Germany) and filtrate clarified by centrifugation at 15 900 x g/RCF (max) for 15 min 
using a benchtop Eppendorf microcentrifuge 5424 (Merck, Darmstadt, Germany). 
The supernatant was then prepared for SDS-PAGE analysis by adding 5x sample 
application buffer [2%SDS, 100 mM Tris-Cl (pH 7.5), 2 mM EDTA, 52% glycerol, 4.3% 
2-mercaptoethanol, 0.1% bromophenol blue] and heat denatured at 95C for 5 min. 
The total soluble protein (TSP) concentrations were quantified using a NanoDrop 1000 
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Spectrophotometer (Thermo Fisher Scientific, Massachusetts, USA) at 280 nm and 
equal amounts of total protein were loaded into each lane. This was selected as the 
best method for quantification as Maree and Paweska (2005) found that the Bradford 
assay yielded values of approximately one-tenth of the actual concentration when 
compared to OD measurements (A280) and values estimated from SDS-PAGE gels 
using the LumiAnalystTM software. The authors speculated that this may result from 
reduced binding of the dye to the surface of AHSV VP7 trimers (Maree and Paweska 
2005).  
2.2.3.2 Determination of optimal expression conditions: Optical density 
selection and time trials 
Four- to five-week-old N. benthamiana plants were syringe-infiltrated as per 2.2.3.1 
with the inoculum prepared in 2.2.2.1 at an OD600 of 0.3, 0.5 and 0.8 to ascertain the 
optimal optical density for AHSV-5 VP7 protein expression. Six plants were co-
infiltrated with pEAQ-AHSV5 recombinants VP2: VP3: VP5: VP7 at a ratio of 1: 1: 1: 
1, of which two plants were used per OD600 (0.3, 0.5 and 0.8). These co-infiltration 
ratios and optical density replicates were repeated for the pRIC3.0-AHSV5 
recombinants. In addition, a time trial was performed to determine the optimal harvest 
day for the maximum protein yield. This was done by harvesting three leaves per 
parameter on 3, 5 and 7 dpi. Negative controls and crude extracts were prepared as 
per 2.2.3.1. 
 Agroinfiltration and Optimisation of AHSV-5 VP7 Quasi-Crystal Purification 
by Density Gradient Ultracentrifugation 
2.2.4.1 Standard density gradient purification using the established 
optimal parameters 
Four- to five-week-old N. benthamiana plants, grown at 22-25C under 16-h/8-h 
light/dark cycle, were vacuum-infiltrated using a vacuum of 100 kPa with the inoculum 
prepared in 2.2.2.2 at the selected optical density of 0.5 at 600 nm. Since it was shown 
that the pRIC3.0-AHSV5 vector seemed to yield greater protein expression, plants 
were co-infiltrated with pRIC3.0-AHSV5 recombinants VP2: VP3: VP5: VP7 at a ratio 
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of 1: 1: 1: 1. The pRIC3.0 empty vector was used as a negative control and infiltrated 
at an OD600 of 0.5. 
Infiltrated leaves were harvested at 3 dpi, weighed (±13.5 g per gradient) and either 
used immediately or frozen at -80C. N. benthamiana leaves were combined with PBS, 
pH 7.4, at a 1:2 (w/v) ratio and 1x Complete protease inhibitor cocktail (Roche, Basel, 
Switzerland) was added per 50 ml volume of PBS. The extract was then thoroughly 
homogenised using the T25 digital Ultra-Turrax blender (IKA, Staufen, Germany) 
and incubated for 1 h at 4C with gentle agitation. The homogenate was filtered 
through one layer of MiraclothTM (Merck, Darmstadt, Germany) and subsequently 
clarified by centrifugation at 23 300 x g/RCF (max) for 15 min at 4C using the 
Beckman Avanti J-25 High Speed Centrifuge (Beckman Coulter, Brea, CA). Twenty-
seven ml of the clarified supernatant was then removed and placed onto a 
discontinuous iodixanol (OptiprepTM; Sigma-Aldrich, St Louis, Missouri) gradient. 
The iodixanol solutions were diluted in PBS to produce the desired concentrations and 
underlaid to create a 12 ml discontinuous step gradient (2 ml-20%, 2 ml-30%, 
3 m-40%, 3 ml-50%, 2 ml-60%). The gradient was subsequently ultracentrifuged at 
174 900 x g/RCF (max) for 2 h at 4C in a SW 32 Ti rotor (Beckman Coulter, Brea, 
CA). Twelve x 1 ml fractions were then collected from the bottom of the tube and 28 µl 
of each were loaded onto a 10% SDS-polyacrylamide gel. Following this, Coomassie 
blue staining and western immunoblot analyses were performed. 
2.2.4.2 Concentrating AHSV-5 VP7 quasi-crystals using an iodixanol 
cushion and low-speed centrifugation during clarification  
Agroinfiltration and purification methods in 2.2.4.1 were repeated with the following 
adjustments:  
Infiltrated N. benthamiana leaves were harvested at 5 dpi to increase maturation time. 
Fresh leaves were weighed (± 6.5 g per cushion) and combined with PBS at a 1:5 
(w/v) ratio. Protease inhibitor cocktail was included as per 2.2.4.1. Centrifugation 
speed during crude extract clarification was reduced to 1200 x g/RCF (max) for 10 min 
to decrease the potential loss of AHSV-5 VP7 quasi-crystals in the pellet. 
Subsequently, 32.5 ml of the clarified supernatant was then removed and placed onto 
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a 5 ml-25% and 1 ml-60% iodixanol cushion (Figure 2.1(1)). The cushion was 
ultracentrifuged at 174 900 x g/RCF (max) for 3 h at 4C in a SW 32 Ti rotor (Beckman 
Coulter, Brea, CA). Previous research has shown the density of AHSV-5 VP7 quasi-
crystals to be 1.31 g/ml (Burroughs et al. 1994), whilst the density of 60% iodixanol is 
±1.32 g/ml and 25% iodixanol is 1.13 g/ml (https://www.axis-shield-density-gradient-
media.com/V01.pdf). Applying a 25% and 60% iodixanol solution should theoretically 
concentrate AHSV-5 VP7 quasi-crystals at the 25% and 60% interface. After 
ultracentrifugation, six 400 µl fractions were collected (Figure 2.1(2)) and pooled with 
their respective replicates from a second cushion (Figure 2.1(3)). The resultant 800 µl 
fractions were diluted to a concentration of <25% iodixanol (Figure 2.1(4)) before 
placing onto six separate 30-60% iodixanol step gradients (750 µl volumes at 10% 
increments) (Figure 2.1(5)). The gradient was then centrifuged at 235 300 x g/RCF 
(max) for 3.5 h at 4C in a SW 55 Ti rotor (Beckman Coulter, Brea, CA). Four 750 µl 
fractions were then collected, visible gradient bands aspirated, remaining pellets 
resuspended and remaining sample above the 30% iodixanol layer collected from 
each gradient. Twenty-eight µl samples of each of these were loaded onto a 10% 
SDS-polyacrylamide gel for analysis. Fractions from gradients originating from 
cushion fractions three and four were selected for Coomassie blue staining, western 
immunoblotting (2.2.5) and TEM analysis (2.2.6) as these are situated at the 25/60% 
cushion interface.  
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Figure 2.1: Iodixanol cushion and density gradient purification process to concentrate 
AHSV-5 VP7 quasi-crystals. The iodixanol percentages are indicated on each layer in the 
images and in brackets in step (4). Crude: Clarified supernatant, PBS: Phosphate-buffered 
saline, Fr: Fraction. 
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2.2.4.3 Increasing AHSV-5 VP7 trimer-trimer interactions via buffer pH 
adjustments 
Agroinfiltration and purification methods in 2.2.4.1 were repeated with the following 
adjustments:  
Plants were infiltrated with recombinant pRIC3.0-AHSV5-VP7 constructs alone. 
Infiltrated leaves were harvested at 7 dpi, fresh leaves weighed (±11 g per cushion) 
and combined with PBS, pH 7.4, or 0.2 M Tris-HCl, pH 8, at a 1:3 (w/v) ratio. To clarify 
the filtrate, it was centrifuged at 1200 x g/RCF(max) for 15 min at 4C (Figure 2.2(1)) 
and the subsequent supernatant centrifuged at 23 300 xg/RCF(max) for 30 min 
(Figure 2.2(2)) using the Beckman Avanti J-25 High Speed Centrifuge (Beckman 
Coulter, Brea, CA). Supernatant (33 ml), originating from ±11 g biomass, was 
transferred to a 6 ml-50% iodixanol cushion (39 ml centrifuge tube) (Figure 2.2(3)); 
and 3 ml of the resuspended pellet, originating from 14 g biomass, was transferred to 
a 2 ml-50% iodixanol cushion (5 ml centrifuge tube) (Figure 2.2(4)). A 50% iodixanol 
layer was selected as its density was considered to be sufficient to exclude a greater 
amount of lower density particles while concentrating AHSV-5 VP7 quasi-crystals 
(1.31 g/ml density) into this layer or into concentrated pellets. The density of 50% 
iodixanol was calculated to be ±1.27 g/ml when using both diluent alternatives: PBS 
and 0.2 M Tris-HCl. The 39 ml centrifuge tubes were placed into the SW 32 Ti rotor 
and 5 ml tubes into the SW 55 Ti rotor (Beckman Coulter, Brea, CA). These were 
centrifuged at 174 900 x g/RCF (max) and 124 400 x g/RCF (max) respectively for 4 h 
at 4C. Six x 1 ml (39 ml centrifuge tubes) and 4 x 500 µl (5 ml centrifuge tubes) 
fractions were then collected. Samples of the crude pre- and post- 1200 x g/RCF (max) 
spin were collected and the resuspended pellets from both cushions sampled. Twenty-
two µl of each sample was loaded onto a 10% SDS-polyacrylamide gel. Following this 
Coomassie blue staining and western immunoblot analyses were performed.  
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Figure 2.2: Purification process for PBS, pH 7.4, and 0.2 M Tris-HCl, pH 8, comparison. 
Original biomass from which each sample was derived is indicated on the sample layer. 50%: 
Iodixanol percentage used. 
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2.2.4.4 Increasing AHSV-5 VP7 quasi-crystal yield using low-speed 
differential and density gradient centrifugation 
Agroinfiltration and purification methods in 2.2.4.1 were repeated with the following 
adjustments:  
Plants were infiltrated with recombinant pRIC3.0-AHSV5-VP7 constructs alone. 
Infiltrated leaves were harvested at 6 dpi and combined with 0.2 M Tris-0.15 M NaCl, 
pH 8 (including protease inhibitor), at a 1:3 (w/v) ratio. The filtrate was initially clarified 
by centrifugation at 1200 x g/RCF (max) for 10 min and a subsequent second spin at 
3000 x g/RCF (max) for 35 min at 4C using the Beckman Avanti J-25 High Speed 
Centrifuge (Beckman Coulter, Brea, CA). The pellet, originating from ±20 g biomass, 
was then resuspended in 1.5 ml, placed onto a discontinuous sucrose gradient 
(1.4 ml-40%, 1.4 ml-50% and 0.8 ml-68%) and spun at a low speed of 
17 500 x g/RCF (max) for 1 h at 4C in the SW 55 Ti rotor (Beckman Coulter, Brea, 
CA). Sucrose solutions, prepared in 0.2 M Tris-0.15 M NaCl, were used during this 
experiment in order to reduce costs during optimisation. After ultracentrifugation, 5 x 
800 µl fractions were collected and dialysed against 0.2 M Tris-0.15 M NaCl and 
further samples collected and analysed as per 2.2.4.3. 
2.2.4.5 Sucrose- and iodixanol density gradient conversion 
Agroinfiltration and purification methods in 2.2.4.1 were repeated with the adjustments 
made in 2.2.4.4, and the sucrose gradient was replicated as per 2.2.4.4. In contrast, 
the iodixanol step gradient was converted to 1.4 ml-30% (1.18 g/ml), 1.4 ml-40% 
(1.22 g/ml) and 800 µl-60% (1.32 g/ml) to produce the equivalent sucrose densities 
using the equation: D=
Vd+𝑉1 𝑑1
V+𝑉1
 , where D= density of mixture; V= volume of iodixanol 
stock solution; d= density of iodixanol stock solution; V1= volume of diluent; d1= density 
of diluent (https://www.axis-shield-density-gradient-media.com/V01.pdf). The rotor 
and ultracentrifugation protocols were used and performed as per 2.2.4.4. 
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2.2.4.6 Increasing AHSV-5 VP7 quasi-crystal yields for immunogenicity 
studies 
Agroinfiltration and purification methods in 2.2.4.1 were repeated with the adjustments 
made in 2.2.4.5. Additional alterations to the protocol were made to produce a more 
stable gradient resulting in a purer product and to increase the yield of AHSV-5 VP7 
quasi-crystals. The biomass was doubled, producing a pellet originating from ±40 g 
biomass. This pellet was resuspended in 2.5 ml of 0.2 M Tris-0.15 M NaCl and placed 
onto an iodixanol gradient adjusted to: 500 µl-30%, 1 ml-36%, 800 µl-40% and 
400 µl-50%. A 1 ml 36% iodixanol layer was included to avoid contamination of the 
40% iodixanol layer by plant proteins; and the 60% iodixanol layer was adjusted to a 
50% layer as few AHSV-5 VP7 quasi-crystals were observed in the 60% layer. The 
ultracentrifugation protocol remained as per 2.2.4.4, however the centrifugation time 
was adjusted to 3.5 h to increase the probability of AHSV-5 VP7 quasi-crystals 
reaching their isopycnic point. After ultracentrifugation, 3 x 500 µl fractions were 
collected and analysed as per 2.2.4.3. 
 SDS-PAGE, Coomassie Staining and Western Immunoblot Analysis 
Crude extracts and purified samples were combined with 5x SDS sample application 
buffer [2%SDS, 100 mM Tris-Cl (pH 7.5), 2 mM EDTA, 52% glycerol, 4.3% 
2-mercaptoethanol, 0.1% bromophenol blue] and heat-denatured for 5 min at 95C. 
Eight µl of the Colour Prestained Protein Standard, Broad Range (11–245 kDa) (New 
England Biolabs, Ipswich, MA), was used as a molecular weight marker and sample 
volumes of between 25 µl and 35 µl were loaded onto 10% SDS-PAGE-gels and 
electrophoresed in a Bio-Rad Mini-Protean Tetra Cell System (Bio-Rad, Irvine, CA) 
at 120 volts for approximately 2 h.  
In order to analyse the purity qualitatively and to quantify the concentration of AHSV-5 
VP7 protein, gels were stained with Coomassie Brilliant Blue G-250 staining solution 
(Merck, Darmstadt, Germany) O/N, destained O/N with a destaining solution [45% 
methanol, 10% glacial acetic acid and 45% dH2O] and rinsed in distilled water.  
For protein quantification, purified AHSV-5 VP7 protein and bovine serum albumin 
(BSA) (Sigma-Aldrich, St Louis, Missouri) standards (0.250, 0.125, 0.060, 0.030, 
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0.015 mg/ml) were run on the same 10% Coomassie stained SDS-PAGE gel and 
AHSV-5 VP7 concentrations estimated using a BSA standard curve. The SynGene 
Genius bio-imaging system was used to visualise and document gels and GeneTools 
(Synoptics, Cambridge, UK) or Image Studio Lite (Li-Cor, Nebraska, USA) 
software was used to quantify gel bands. The fresh weight (FW) yield was calculated 
using the equation: 𝐹𝑊 𝑦𝑖𝑒𝑙𝑑 =
𝐶  𝑉
𝐵
, where C= final concentration quantified using 
a BSA standard curve as explained above; V= volume of the fraction being analysed; 
B= total biomass used. 
For western immunoblot analysis, transfers of SDS PAGE-gels were carried out onto 
HyBondTM C Extra nitrocellulose membranes (AEC-Amersham, Gauteng, South 
Africa) using a Trans-blot_Semi-dry transfer cell (Bio-Rad, Irvine, CA) at 15 volts for 
1.25 h. Membranes were then blocked with blocking buffer (5% non-fat dairy milk 
(NFDM) and PBS-T (1 x PBS and 0.1% Tween-20 (Sigma Aldrich, St Louis, MO)) 
for 30 min, after which they were probed O/N at 4C with polyclonal anti-AHSV5-VLP 
guinea-pig serum primary antibody (BRU, MCB Department, UCT) which was 
prepared in blocking buffer at a 1:5000 dilution. After four 15 min washes with blocking 
buffer, membranes were then probed for 1 h at 35C with the goat anti-guinea-pig IgG 
alkaline phosphatase-conjugated secondary antibody (Sigma-Aldrich, St Louis, 
Missouri) which was diluted in blocking buffer to a 1:5000 dilution. After four 15 min 
washes in PBS-T, proteins were detected with 5-bromo-4-chloro-3-indoxyl-phosphate 
(BCIP) and nitroblue tetrazolium (NBT) (BCIP/NBT 1-component, KPL, SeraCare, 
Milford, MA), substrates for alkaline phosphatase.  
 Transmission Electron Microscopy  
Carbon-coated copper grids with a mesh size of 200 were made hydrophilic by glow 
discharging at 25 mA for 30 sec using an EMS Glow Discharge Unit. Within 24 hours 
after glow discharging, 20 µl sample droplets of crude plant extract or purified fractions 
were placed on top of the carbon-coated grids for 10 min (Maree and Paweska 2005). 
Thereafter, grids were washed carefully by placing them beneath three 20 µl droplets 
of sterile water and carefully blotted onto filter paper. These were then negatively 
stained by placing grids below a 20 µl droplet of 2% uranyl acetate for 30 sec and set 
down onto filter paper to slowly absorb the excess stain. Careful consideration was 
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taken not to dehydrate the grids before staining, as rapid dehydration has been shown 
to result in a decrease in AHSV-5 VP7 quasi-crystal detection (Maree and Paweska 
2005). Samples were observed using a Tecnai 20 transmission electron microscope 
(TEM). 
 Fixing, Dehydration and Embedding of Agroinfiltrated Leaf Sections for In 
Situ TEM 
N. benthamiana leaves were agroinfiltrated with recombinant pRIC-AHSV5-VP7 
cultures by vacuum-infiltration as per 2.2.2.2. Leaves were harvested on 5 dpi and a 
leaf cutting of approximately 3 cm x 3 cm was removed by scalpel blade in a petri dish 
in the presence of 2.5% glutaraldehyde diluted in 0.1M phosphate buffer [20 mM 
NaH2PO4, 80 mM Na2HPO4, pH 7.4]. The leaf cutting was then soaked in 2.5% 
glutaraldehyde for 72 h at 4C. After this, the sample was divided into 1 mm x 3 mm 
fragments in the presence of 2.5% glutaraldehyde and incubated in this solution over 
a 48-h period at 4C. The leaf fragments were then washed three times for 5 min each 
in 0.1 M phosphate buffer (pH 7.4) and following this fixed in one part 2% osmium 
tetroxide and one part 0.2 M phosphate buffer [40 mM NaH2PO4, 160 mM Na2HPO4, 
pH 7.4] for 1 h. After this, fragments were washed twice for 5 min each with 
0.1 M phosphate buffer (pH 7.4) and a further two washes were carried out for 5 min 
each using sterile water.  
After fixation, an ethanol dehydration series was performed, leaf fragments were 
incubated in 30%, 50%, 70%, 80%, 90%, 95% ethanol for 5 min each and finally placed 
in 100% ethanol for 10 min. The final 100% ethanol incubation step was repeated 
twice. Subsequently, leaf fragments were dehydrated in 100% acetone for 10 min and 
this was also repeated twice. 
Following dehydration, leaf fragments were mixed at room temperature for 24 h in 
1:1 acteone: Spurr’s resin (Agar Scientific, Essex, UK) mixture. After this the 
fragments were mixed at room temperature in a 75%, 87.5% and 100% Spurr’s resin 
(diluted with 100% acetone where necessary) for 4 h, 24 h and 4 h respectively. This 
was then replaced once again by 100% Spurr’s resin and incubated for 72 h at room 
temperature. Finally, the fragments were embedded in 100% Spurr’s resin and 
incubated for 24 h at 60C. The embedded leaf samples were then cut into ultrathin 
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leaf sections with a diamond knife and placed onto copper grids with a mesh size of 
200. These grids were stained with 2% uranyl acetate for 10 min and subsequently 
washed with 20 µl sterile water droplets five times for 15 sec each. Grids were blotted 
dry and placed onto lead citrate in a CO2 free environment for 10 min. These were 
then washed thoroughly with sterile water and blotted dry on filter paper. Samples 
were observed using a Technai G2 TEM. 
2.3 Results 
 Transient Expression of AHSV-5 VP7 in N. benthamiana  
2.3.1.1 Determination of optimal expression conditions: Expression 
vector comparison and co- vs single-infiltration 
To optimise the expression conditions for AHSV-5 VP7 in N. benthamiana, yields 
produced by expression vectors pRIC-3.0 and pEAQ-HT were compared. Additionally, 
a co-expression (AHSV-5 VP2, VP3, VP5 and VP7) tactic was explored to ascertain 
whether other AHSV capsid proteins influence the expression levels of AHSV VP7 
and/or trimer formation. Previous research involving the closely related BTV, found 
that VP3 has an effect on BTV VP7 trimer lattice formation and intracellular 
distribution, in that BTV VP7 only associates with virus inclusion bodies in the 
presence of VP3 and forms no morphological structures in its absence (Bekker et al. 
2014; Kar et al. 2007; Loudon and Roy 1991). Furthermore, the successful production 
of AHSV VP7 quasi-crystals via co-expression (AHSV-5 VP2, VP3, VP5 and VP7) was 
previously demonstrated by a member of the BRU (data not shown). 
N. benthamiana leaves were syringe-infiltrated as per 2.2.3.1, and 3 days post-
infiltration (dpi) crude extracts were prepared as per 2.2.3.1. Three dpi was chosen as 
the initial harvest day as AHSV-5 VP7 expression in N. benthamiana was previously 
demonstrated as early as 3 dpi by Dennis et al. (2018). Equal amounts of TSP were 
loaded into each well of the SDS PAGE gel (2.2.5) and the expression levels of 
AHSV-5 VP7 using the pRIC-3.0 and pEAQ-HT vectors were compared. VP7 forms 
very stable trimers and even after the addition of SDS sample application buffer and 
heat denaturation at 95C for 5 min both monomers and trimers are observed after 
SDS PAGE and western immunoblotting (2.2.5). After western blot analysis 
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(Figure 2.3), AHSV-5 VP7 monomer bands (37 kDa) were found to be similar in terms 
of intensity when comparing the pRIC3.0 and pEAQ-HT vectors. However, in 
comparison to all other combinations, stronger AHSV-5 VP7 trimer bands (135 kDa) 
were detected in the crude extract after co-infiltration with pRIC-AHSV5-VP2, -VP3, -
VP5 and -VP7 recombinants (pRIC3.0 - Co). 
 
Figure 2.3: Comparison of expression vectors, pRIC3.0 and pEAQ-HT, and co-
infiltration (AHSV-5 VP2, VP3, VP5 and VP7) vs single-infiltration (AHSV-5 VP7). Western 
immunoblot analysis of AHSV-5 VP7 expression and monomer (37 kDa) and trimer (135 kDa) 
protein accumulation on 3 dpi. An inoculum culture OD600 of 0.5 was used during syringe-
infiltration. For analysis equal amounts of protein were added to each lane. Mw: NEB 
molecular weight marker (sizes displayed in kDa), VP7: Crude leaf extract from plants 
expressing AHSV-5 VP7, Co: Crude leaf extract from plants co-expressing AHSV-5 VP2, VP3, 
VP5 and VP7, (-): Negative control- pRIC3.0 and pEAQ-HT empty vector crude leaf extract. 
Arrows indicate the positions of AHSV-5 VP2 (123 kDa), VP5 (57 kDa), VP7 monomer 
(37 kDa) and VP7 trimer (135 kDa). 
2.3.1.2 Determination of optimal expression conditions: Selection of 
optical density and harvest day post-infiltration 
To further optimise the expression conditions for AHSV-5 VP7 in N. benthamiana, the 
expression vectors pRIC-3.0 and pEAQ-HT were compared once again, along with a 
comparison of optical densities and harvest day post-infiltration. Since it was shown in 
2.3.1.1 that co-infiltrated plants (AHSV5-VP2, -VP3, -VP5 and -VP7) accumulated a 
higher yield of AHSV VP7 protein, evident by strong VP7 trimer bands (135 kDa) 
(Figure 2.3), plants were co-infiltrated in the experiments to follow. 
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N. benthamiana leaves were syringe-infiltrated with inoculum prepared in 2.2.2.1.  
Optical densities of 0.3, 0.5 and 0.8 at 600 nm were compared (2.2.3.2) and leaves 
were subsequently harvested on 3, 5 and 7 dpi as per 2.2.3.2 to determine the optimal 
harvest day for the maximum protein yield. As shown in Figure 2.4, all N. benthamiana 
plants showed signs of necrosis and chlorosis by 5 dpi after syringe-infiltration. 
However, plants co-infiltrated with pEAQ-HT recombinants demonstrated higher levels 
of necrosis by 5 dpi when compared to those co-infiltrated with pRIC3.0 recombinants. 
 
pRIC3.0-AHSV5 
(VP2, VP3, VP5 & 
VP7) 
pEAQ-AHSV5 






Figure 2.4: Physiological conditions at 5 dpi and 7 dpi after syringe infiltration. N. 
benthamiana leaves were co-infiltrated (AHSV-5 VP2, VP3, VP5 and VP7) with pRIC3.0 or 
pEAQ-HT recombinants at an OD600 of 0.5 (OD600 0.3 and 0.8 not shown).   
When comparing the co-infiltration inoculum optical densities 0.3, 0.5 and 0.8 and their 
effects on AHSV-5 VP7 expression levels: The western immunoblots in Figure 2.5.a 
and b show qualitatively similar levels of AHSV-5 VP7 monomer expression and trimer 
formation across the varying optical densities, with the exception of expression levels 
shown at 3 dpi using the pRIC3.0 expression vector (Figure 2.5.b). At 3 dpi higher 
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levels of pRIC-AHSV-5 VP7 protein expression were shown when using a 0.5 OD600 
as opposed to an OD600 of 0.3 or 0.8, evident in the intensity of the trimer band 
(135 kDa). When qualitatively assessing the expression vector and harvest day effects 
on AHSV-5 VP7 expression by visual comparison: AHSV-5 VP7 monomer and trimer 
band intensity seemed relatively similar across all harvest days when using both the 
pEAQ (Figure 2.5.a) and pRIC (Figure 2.5.b) expression vectors with a marginal 
increase in trimer band intensity on 5 dpi using the pRIC3.0 vector. In contrast, the 
lowest level of AHSV-5 VP7 expression and trimer formation was observed on 3 dpi 
using the recombinant pRIC3.0 vector (Figure 2.5.b). Unfortunately, in this 
experiment, the optimal harvest day was a very qualitative assessment, as the 3 dpi, 
5 dpi and 7 dpi samples were not on the exact same western immunoblot. However, 
every attempt was made to follow the protocol (2.2.5) for each immunoblot in the exact 
same manner and to avoid inconsistencies. 
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Figure 2.5: Comparison of expression vectors, optical density at 600 nm and harvest 
day. (a) and (b) Western immunoblot analysis of pEAQ-AHSV5 (a) and pRIC-AHSV5 (b) VP7 
expression and monomer (37 kDa) and trimer (135 kDa) protein accumulation on 3 dpi, 5 dpi 
and 7 dpi. N. benthamiana leaves were co-infiltrated (AHSV-5 VP2, VP3, VP5 and VP7) by 
syringe using an OD600 of 0.3, 0.5 or 0.8. For analysis equal amounts of protein were added 
to each lane. Mw: NEB molecular weight marker (sizes displayed in kDa), dpi 3-7: Days post 
infiltration, 0.3-0.8: Inoculum culture OD600 used, (-): Negative control - pRIC3.0 and pEAQ-
HT empty vector crude leaf extract. Arrows indicate the positions of AHSV-5 VP2 (123 kDa), 
VP5 (57 kDa), VP7 monomer (37 kDa) and VP7 trimer (135 kDa). 
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 Purification of AHSV-5 VP7 Quasi-Crystals by Density Gradient 
Ultracentrifugation  
2.3.2.1 Standard density gradient purification using the established 
optimal parameters 
Having established the optimal parameters for AHSV-5 VP7 protein expression in 
N. benthamiana to be: (1) the expression vector pRIC3.0-AHSV5, (2) co-infiltration 
using AHSV5-VP2, -VP3, -VP5 and -VP7, (3) 0.5 OD600 and (4) day 3 as the optimal 
harvest day post-infiltration, these conditions were used to scale-up production and 
develop a purification protocol for AHSV-5 VP7 quasi-crystals. A co-infiltration tactic 
was pursued at this stage as results from Figure 2.3 suggested that higher yields of 
AHSV VP7 protein may accumulate in co-infiltrated plants. And the optimal harvest 
day of 3 dpi was selected as high levels of necrosis and chlorosis were observed after 
3 dpi in previous experiments (Figure 2.4). 
The initial density gradient purification performed was a relatively standard procedure 
used by members of the BRU for purifying AHS virus-like-particles (AHSV VLPs). 
Agroinfiltration, density gradient purification and ultracentrifugation were carried out as 
per 2.2.4.1.  
As seen in Figure 2.6.a, the iodixanol gradient layers stratified well after 
ultracentrifugation and the 20% and 30% iodixanol layers in combination were 
sufficient to trap the majority of contaminating plant proteins (fractions 10-12). Western 
immunoblot analysis of the fractions (Figure 2.6.b) revealed AHSV-5 VP7 monomer 
and trimer bands in the crude extract (Cr) and fractions 5-12, with band intensity 
increasing in higher fractions. No AHSV-5 VP7 quasi-crystals were observed in any of 
the 12 fractions during TEM analysis. However, CLPs were observed in fraction 6 
(40% iodixanol) (Figure 2.6.c). Additionally, a band of approximately 50 kDa was 
noted but this was also present in the negative control and therefore likely to be a plant 
protein. 
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Figure 2.6: Initial iodixanol density gradient and ultracentrifugation method to optimise 
AHSV-5 VP7 quasi-crystal purification. (a) Image displaying the 20-60% iodixanol step 
gradient after ultracentrifugation. N. benthamiana plants were co-infiltrated with AHSV-5 VP2, 
VP3, VP5 and VP7 and the inoculum culture OD600 0.5 used for vacuum-infiltration. Crude leaf 
extracts were prepared from leaves harvested on 3 dpi. Black lines denote the change in 
iodixanol percentage. Iodixanol layers and corresponding fractions displayed.  (b) Western 
immunoblot analysis of AHSV-5 VP7 expression and monomer (37 kDa) and trimer (135 kDa) 
protein accumulation. For analysis equal sample volumes of 28 µl were added to each lane. 
Mw: NEB molecular weight marker (sizes displayed in kDa), (-): Negative control - pRIC3.0 
empty vector crude leaf extract, Cr: Crude leaf extract before density gradient purification from 
plants co-expressing AHSV-5 VP2, VP3, VP5 and VP7, 1-12: Fractions from iodixanol step 
gradient with corresponding iodixanol layers (20-60%) indicated above. Arrows indicate the 
positions of AHSV-5 VP7 monomer and VP7 trimer. (c) TEM image of CLPs observed in 
iodixanol gradient fraction 6 (40% iodixanol). Scale bar: 0.2 µm.   
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2.3.2.2 Concentrating AHSV-5 VP7 quasi-crystals using an iodixanol 
cushion and low-speed centrifugation during extract clarification  
Results from 2.3.2.1 indicated that after ultracentrifugation the majority of available 
AHSV-5 VP7 was in soluble form. It was therefore suspected that due to its highly 
insoluble nature, the insoluble VP7 quasi-crystals were being lost in the pellet in high-
speed differential spins during crude extract clarification and only soluble VP7 
remained after purification. 
In order to concentrate AHSV-5 VP7 protein and potentially increase crystal formation 
a 25/60% iodixanol cushion was used prior to the discontinuous step gradient (30-
60%) as per 2.2.4.2. Furthermore, a lower initial spin (1200 xg/RCF (max)) was used 
to remove contaminants from the filtrate as crystal loss was suspected in the pellet 
when using high speed spins (23 300 xg/RCF (max)). Once again a co-infiltration tactic 
was used (AHSV-5 VP2, VP3, VP5 and VP7), as results from Figure 2.3 suggested 
that co-infiltrated plants may accumulate a higher yield of AHSV-5 VP7 protein. 
N. benthamiana plants co-expressing AHSV-5 VP2, VP3, VP5 and VP7 showed no 
signs of necrosis three days after vacuum-infiltration and were therefore harvested on 
5 dpi to increase the maturation time (Figure 2.7).  
3 dpi 5 dpi 
  
Figure 2.7: N. benthamiana leaf physiology at 3 dpi and 5 dpi after vacuum-infiltration. 
Plants co-infiltrated with recombinant pRIC3.0-AHSV5-VP2, -VP3, -VP5 and -VP7 at an OD600 
of 0.5. 
As shown in Figure 2.8, the iodixanol cushion and gradient layers separated well, and 
the 25% iodixanol cushion layer (Figure 2.8.a) and 30% iodixanol gradient layer 
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(Figure 2.8.b and c) seemed sufficient to trap the majority of plant crude extract. Clear 
white bands were observed in the 40% layers of both iodixanol gradients (Figure 2.8.b 
and c) resulting from the cushion fractions 3 and 4 i.e. the 25/60% iodixanol interface 
(Figure 2.8.a). 






Figure 2.8: Iodixanol cushion and density gradient ultracentrifugation to optimise 
AHSV-5 VP7 quasi-crystal purification. (a) Image displaying the 25% and 60% iodixanol 
cushion after ultracentrifugation. Crude extract was prepared from N. benthamiana plants co-
expressing AHSV-5 VP2, VP3, VP5 and VP7. The inoculum culture OD600 for vacuum-
infiltration was 0.5 and leaves were harvested on 5 dpi. Red lines represent the boundaries of 
fractions 3 and 4. (b) Fraction 3, 30%-60% iodixanol density gradient after ultracentrifugation. 
(c) Fraction 4, 30%-60% iodixanol density gradient after ultracentrifugation. Black lines denote 
the change in iodixanol percentage and red arrows the observed bands which were 
subsequently aspirated. Iodixanol concentrations, volumes and corresponding fractions 
displayed. Fr: Fractions. 
Western immunoblot analysis of the iodixanol cushion and gradient shown in 
Figure 2.8, revealed strong AHSV-5 VP7 monomer and trimer bands in the iodixanol 
cushion fractions 3 (C-Fr3) and 4 (C-Fr4) (Figure 2.9.a and b). In the subsequent 
iodixanol gradients, light AHSV-5 VP7 monomer and trimer bands were present in the 
aspirated bands (B) where AHSV-5 VP7 was expected to concentrate, whilst stronger 
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bands were observed in the 30% and 40% iodixanol gradient layers. Little to no bands 
were observed in the 50% and 60% layers or the resuspended gradient pellet (P). 
Coomassie staining in Figure 2.9.c and d revealed higher levels in the 30% and 40% 
layers of cushion fraction 3 (Figure 2.9.c). While AHSV-5 VP7 trimer bands were 
observed in western immunoblots (Figure 2.9.a and b), no trimer bands were 
observed in Coomassie stained gels (Figure 2.9.c and d). 
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Figure 2.9: Analysis of AHSV-5 VP7 expression after co-infiltration, and purification by 
means of an iodixanol cushion and density gradient purification. (a) and (b) Western 
immunoblot analysis of iodixanol cushion fraction 3 (a) and fraction 4 (b), and resultant 30%-
60% density gradient fractions. (c) and (d) Coomassie stained SDS-PAGE gels of iodixanol 
cushion fraction 3 (c) and fraction 4 (d) after density gradient ultracentrifugation. Equal sample 
volumes of 28 µl were added to each lane. Arrows indicate the positions of AHSV-5 VP7 
monomer (37 kDa) and VP7 trimer (135 kDa). Mw: NEB molecular weight marker (sizes 
displayed in kDa), CP: Iodixanol cushion pellet, C-Fr3: Fraction 3 of iodixanol cushion, C-Fr4: 
Fraction 4 of iodixanol cushion, EV: Negative control - pRIC3.0 empty vector crude leaf extract, 
B: Aspirated band from 30-60% iodixanol density gradient, P: Resuspended pellet from 30-
60% iodixanol density gradient, 30-60%: Iodixanol concentrations. 
Figure 2.10 shows AHSV-5 VP7 quasi-crystals observed during TEM analysis in the 
aspirated band from the 40% iodixanol gradient layer originating from 
cushion-fraction 3 (Lane 3 (labelled B) in Figure 2.9.a). Few crystals were observed, 
one of approximately 300 nm in size shown on the left of Figure 2.10 and one unclear 
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crystal formation of ±650 nm on the right of Figure 2.10. Despite the presence of 
strong AHSV-5 VP7 monomer and trimer bands in the 30-40% iodixanol layers after 
western immunoblot analysis (Figure 2.9) no AHSV-5 VP7 quasi-crystal formations 
were observed in these gradient layers, only CLPs (data not shown). 
  
Figure 2.10: TEM images of AHSV-5 VP7 quasi-crystals in the aspirated gradient band (40% 
iodixanol layer) using fraction 3 from the iodixanol cushion. N. benthamiana plants were 
co-infiltrated with AHSV-5 VP2, VP3, VP5 and VP7. Scale bar: 100 nm.   
2.3.2.3 Increasing AHSV-5 VP7 trimer-trimer interactions via buffer pH 
adjustments 
Results from 2.3.2.2 suggested that most of the purified AHSV-5 VP7 was once again 
in soluble form as it was observed in the higher gradient fractions (Figure 2.9). 
Samples were therefore assessed at every step during the protocol to detect the 
relative loss of AHSV-5 VP7 protein during low-speed spins and in the resultant pellet 
as only the supernatant had been used in previous experiments during gradient 
purification. In addition, a single-infiltration using the recombinant pRIC3.0-
AHSV5-VP7 construct alone was pursued and this strategy’s impact on quasi-crystal 
yields investigated. 
Furthermore, it was suspected that PBS (pH 7.4) was not a favourable buffer for 
enhancing VP7 trimer-trimer interactions. Previous research has suggested that the 
forces involved in AHSV VP7 trimer-trimer interactions are likely hydrophobic and 
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electrostatic (Bekker et al. 2017). The buffer pH range of Tris-HCl (pH 7.2-9.0) is higher 
than that of PBS (pH 5.8-8.0) and was therefore used as a comparison to investigate 
whether an increase in pH may increase trimer-trimer interactions and promote crystal 
formation. A higher pH as opposed to lower pH was investigated as previous 
researchers have reported successful AHSV VP7 crystal formation at pH 8 (Maree 
and Paweska 2005)  Agroinfiltration and density gradient purification was carried out 
as per 2.2.4.3.  
Figure 2.11 shows the 50% iodixanol cushions using PBS, pH 7.4 (Figure 2.11.a and 
b) and 0.2 M Tris-HCl, pH 8 (Figure 2.11.c and d) as the buffers. The 50% iodixanol 
layer remained clear after centrifugation when using the resuspended crude pellet 
(Figure 2.11.a and c) and supernatant (Figure 2.11.b and d) and the majority of plant 
crude extract was trapped above this layer.  
____________________________________________________________________________________________________






      
d) 
         
Figure 2.11: Iodixanol cushion and density gradient ultracentrifugation: Comparison of 
buffers PBS, pH 7.4 (a and b) and 0.2 M Tris-HCl, pH 8 (c and d) for AHSV-5 VP7 quasi-
crystal purification. Images display the 50% iodixanol cushions after ultracentrifugation, 
using the resuspended crude pellet (a and c) and supernatant (b and d). Crude extract was 
prepared from N. benthamiana plants expressing AHSV-5 VP7 alone. The inoculum culture 
OD600 for vacuum-infiltration was 0.5 and leaves were harvested on 5 dpi. Dotted lines denote 
the 50% iodixanol boundary (b and d). Iodixanol volumes and fractions are displayed next to 
the figure. Fr: Fractions.  
Figure 2.12.a and b display western immunoblot analysis of samples prepared from 
cushions shown in Figure 2.11a and b using PBS, pH 7.4, and Figure 2.12.c and d 
demonstrate western immunoblots of samples from cushions Figure 2.11.c and d 
using 0.2 M Tris-HCl buffer, pH 8. In Figure 2.12.a, western immunoblot analysis 
revealed strong AHSV-5 VP7 monomer and trimer bands in the crude before (Cr1) 
and after the initial low-speed spin of 1200 x g/RCF (max) (Cr2) when using PBS, 
pH 7.4 as the buffer of choice. In addition, strong bands were observed in the 
supernatant (S) after the 23 300 x g/RCF (max) spin and little was observed in the 
resuspended pellet (Crude-P) (Figure 2.12.a). In Figure 2.12.a and b, AHSV-5 VP7 
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monomer and trimer bands were only apparent in the higher fractions of the cushion 
when using both the pellet (Pellet Cushion – 3/4 and R) and supernatant (Supernatant 
Cushion – 5, 6 and R). In Figure 2.12.c, western immunoblot analysis revealed strong 
AHSV-5 VP7 monomer and trimer bands in the crude before (Cr1) and after the initial 
low speed spin of 1200 x g/RCF (max) (Cr2). Little was observed in the 
supernatant (S) and resuspended pellet (Crude-P) after the 23 300 x g/RCF (max) 
spin (Figure 2.12.c). In addition, in Figure 2.12.c, strong AHSV-5 VP7 monomer and 
trimer bands were apparent in the resuspended pellet of the cushion when using the 
crude pellet for purification (Pellet Cushion – P), while little was observed in the 
remaining sample (Pellet Cushion – R). In contrast, in Figure 2.12.d, monomer and 
trimer bands were only apparent in fraction 6 and the remaining sample of the cushion 
when using the supernatant (Supernatant Cushion – 6 and R).  
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Figure 2.12: Western immunoblot analysis and comparison of buffers: PBS, pH 7.4 
(a and b) and 0.2M Tris-HCl, pH 8 (c and d), for AHSV-5 VP7 purification. (a) and (c) 
Western immunoblot analysis of the crude plant extract and 500 µl fractions 1-4 from the 50% 
iodixanol cushion using the resuspended crude pellet. (b) and (d) Western immunoblot 
analysis of 1 ml fractions 1-6 from the 50% iodixanol cushion using the crude supernatant. 
Equal sample volumes of 22 µl were added to each lane. Arrows indicate the positions of 
AHSV-5 VP7 monomer (37 kDa) and VP7 trimer (135 kDa). Mw: NEB molecular weight 
marker (sizes displayed in kDa), (-): Negative control - pRIC3.0 empty vector crude leaf 
extract, Cr1: Crude plant extract before 1200 x g/RCF(max) centrifugation, Cr2: Crude plant 
extract after 1200 x g/RCF(max) centrifugation, S: Supernatant, P: Resuspended pellet, 1/2: 
Fractions 1 and 2 combined, 3/4: Fractions 3 and 4 combined, R: Remaining sample above 
the cushion after ultracentrifugation, 1-6 (supernatant cushion): Fractions 1-6.  
Coomassie staining analysis of samples prepared from cushions shown in Figure 2.11 
are shown in Figure 2.13. This revealed marginally stronger bands in the crude 
supernatant after the 1200 x g/RCF (max) (Cr2) spin and crude pellet (Crude-P) when 
using the 0.2 M Tris-HCl buffer, pH 8 (Figure 2.13.b), as opposed to PBS, pH 7.4 
(Figure 2.13.a). In addition, when using PBS, pH 7.4, as a buffer (Figure 2.13.a), an 
AHSV-5 VP7 monomer band was observed in the pooled third and fourth fraction of 
the cushion when using the crude pellet for purification (Pellet Cushion – 3/4).  In 
contrast to this, when using 0.2 M Tris-HCl, pH 8 (Figure 2.13.b), an AHSV-5 VP7 
monomer band was observed in the resuspended pellet of the cushion when using the 
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crude pellet for purification (Pellet Cushion – P). Very little evidence of AHSV-5 VP7 
bands were observed in the cushion originating from the supernatant when 





Figure 2.13: Comparison of buffers (a) PBS, pH 7.4, and (b) 0.2 M Tris-HCl, pH 8, for 
AHSV-5 VP7 expression using iodixanol density gradient purification. N. benthamiana 
plants were infiltrated with AHSV-5 VP7 alone (a) and (b) Coomassie stained SDS-PAGE gels 
of the crude plant extract, 500 µl fractions 1-4 from the 50% iodixanol cushion using 
resuspended crude pellet, and 1 ml fractions 1-6 from the 50% iodixanol cushion using crude 
supernatant. Equal sample volumes of 22 µl were added to each lane. The arrow indicates 
the position of AHSV-5 VP7 monomer (37 kDa). Mw: NEB molecular weight marker (sizes 
displayed in kDa), (-): Negative control - pRIC3.0 empty vector crude leaf extract, Cr1: Crude 
plant extract before 1 200 x g/RCF(max) centrifugation, Cr2: Crude plant extract after 
1 200 x g/RCF(max) centrifugation, S: Supernatant, P: Resuspended pellet, 1/2: Fractions 1 
and 2 combined, 3/4: Fractions 3 and 4 combined, R: Remaining sample above the cushion 
after ultracentrifugation, 1-6 (supernatant cushion): Fractions 1-6. 
Figure 2.14 demonstrates the presence of AHSV-5 VP7 quasi-crystal formations 
during TEM observation in the crude extract after the 1200 x g/RCF (max) spin (Cr2) 
(Figure 2.14.a) and in the pellet after the 23 300 x g/RCF (max) spin (Crude-P) 
(Figure 2.14.b) when using PBS buffer. Figure 2.14.b, suggests degradation of 
quasi-crystal structure. Interestingly, no crystals were observed in the crude extract 
(Cr2) when using 0.2 M Tris-HCl, however the observation of crystal formations may 
have been impeded by the presence of large quantities of crude plant debris. No other 
crystal formations were noted in any other cushions and their fractions.  
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Figure 2.14: TEM images indicating crystal formations in the crude extract after 
1200 x g/RCF (max) spin (a) and after the 23 300 x g/RCF (max) spin (b) using PBS buffer. 
N. benthamiana plants were infiltrated with AHSV-5 VP7 alone. Scale bar: 100 nm (a) and 
50 nm (b) 
2.3.2.4 Increasing AHSV-5 VP7 quasi-crystal yield using low-speed 
differential and density gradient centrifugation 
The presence of AHSV-5 VP7 quasi-crystals in the crude but lack thereof after high-
speed spins suggested possible disassembly of these crystalline-particles. It was 
therefore decided to investigate whether low-speed spins of crude filtrate and during 
density gradient purification may prevent degradation and promote the assembly of 
AHSV-5 VP7 quasi-crystals. It was also suspected that greater amounts of AHSV-5 
VP7 quasi-crystals may reside in the resuspended pellet as opposed to supernatant 
and the protocol was therefore adjusted as per 2.2.4.4. Briefly, this protocol included 
initial clarification of the crude extract by low-speed centrifugation at 
1200 x g/RCF (max). After a second low-speed spin at 3000 x g/RCF (max) the 
resultant pellet was then used for density gradient purification and spun at a low speed 
spin of 17 500 x g/RCF (max). In addition, sodium chloride was included in the buffer 
i.e. 0.2 M Tris-0.15 M NaCl, to mimic physiological conditions and increase its ionic 
strength. A sucrose gradient was used for further optimisation in order to reduce costs 
as iodixanol is an expensive medium.  
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After agroinfiltration with AHSV-5 VP7 alone as per 2.2.4.4, N. benthamiana plants 
showed no signs of necrosis five days after vacuum-infiltration and were therefore 
harvested at 6 dpi to increase maturation time and potentially promote further crystal 
formation (Figure 2.15).   
6 dpi 6 dpi 
  
Figure 2.15: N. benthamiana leaf physiology at 6 dpi after vacuum-infiltration. The 
images above show the variability in physiology of different leaves from the same plant at 
6 dpi. Plants infiltrated with recombinant pRIC3.0-AHSV5- VP7 alone at an OD600 of 0.5 
showed no signs of necrosis on 5 dpi and were therefore harvested on 6 dpi. 
As shown in Figure 2.16, the gradient layers separated well, and the 40% and 50% 
sucrose layers in combination seemed sufficient to trap the majority of thick plant 
crude extract from the resuspended pellet. This resulted in a clean 68% layer. 
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Figure 2.16: Optimising AHSV-5 VP7 quasi-crystal purification using 
0.2 M Tris-0.15 M NaCl, pH 8, buffer and low speed density sucrose gradient 
ultracentrifugation. Image displaying the 40, 50 and 68% sucrose step gradient after 
ultracentrifugation, using resuspended crude pellet. Crude extract was prepared from 
N. benthamiana plants expressing AHSV-5 VP7 alone. The inoculum culture OD600 for 
vacuum-infiltration was 0.5 and leaves were harvested at 6 dpi. White lines denote the change 
in sucrose percentage and corresponding fractions.    
In Figure 2.17.a, a qualitative western immunoblot analysis of the gradient displayed 
in Figure 2.16 revealed strong AHSV-5 VP7 monomer and trimer bands in all the 
crude samples and gradient fractions, with marginally stronger bands in fractions 1 
and 2. A quantitative analysis via Coomassie staining in Figure 2.17.b, agreed with 
these findings and revealed relatively clean and strong AHSV-5 VP7 monomer bands 
in fractions 1, 2 and 3. 
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Figure 2.17: Analysis of AHSV-5 VP7 expression after sucrose gradient purification. 
(a) Western immunoblot analysis and (b) Coomassie stained SDS-PAGE gels of crude extract 
and 40, 50 and 68% sucrose density gradient fractions (1-5). Equal sample volumes of 22 µl 
were added to each lane. N. benthamiana plants infiltrated with AHSV-5 VP7 alone. Arrows 
indicate the positions of AHSV-5 VP7 monomer (37 kDa) and VP7 trimer (135 kDa). Mw: NEB 
molecular weight marker (sizes displayed in kDa), (-): Negative control - pRIC3.0 empty vector 
crude leaf extract, Cr1: Crude plant extract before 1200 x g/RCF (max) centrifugation, Cr2: 
Crude plant extract after 1200 x g/RCF (max) centrifugation, P: Resuspended pellet, S: 
Supernatant, R: Remaining sample above the cushion after ultracentrifugation, 1-5: Fractions 
1-5. 
Samples resulting from the gradient shown in Figure 2.16 were analysed via TEM. 
Figure 2.18.a and b show clear well-structured AHSV-5 VP7 crystal formations of 
approximately 200 nm in fraction 1 after TEM observation. Figure 2.18.c and d show 
larger crystal conglomerates in fraction 2, however not as clean as in fraction 1. Fewer 
crystals and more plant extract was observed in fraction 3 (Figure 2.18.e).  
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Figure 2.18: TEM images indicating AHSV-5 VP7 crystal formations after density gradient 
ultracentrifugation, (a) and (b) in fraction 1/ 68% sucrose, (c) and (d) in fraction 2/ 50% sucrose 
and (e) in fraction 3/ 40-50% sucrose. N. benthamiana plants infiltrated with AHSV-5 VP7 
alone. Scale bar: 100 nm. 
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2.3.2.5 Sucrose- and iodixanol density gradient conversion 
The successful sucrose gradient needed to be converted to an iodixanol alternative. 
Iodixanol is safe to use in animals and when compared to sucrose is a preferable 
substitute for vaccine preparation. Sucrose is easily contaminated and needs to be 
extracted before the vaccine can be used. Agroinfiltration and density gradient 
purification was therefore carried out as per 2.2.4.5. N. benthamiana plants were 
infiltrated with AHSV-5 VP7 alone. Figure 2.19 shows that fraction 1 and 2 of the 
iodixanol gradient were clean and that the 30% iodixanol layer seemed sufficient to 
obstruct the crude plant extract from falling into lower iodixanol layers. A clear white 
band was observed between the 40% and 60% layers. 
 
Figure 2.19: Iodixanol density gradient conversion. Image displaying the 40, 50 and 68% 
iodixanol step gradient after ultracentrifugation, using resuspended crude pellet. Crude extract 
was prepared from N. benthamiana plants expressing AHSV-5 VP7 alone. The inoculum 
culture OD600 for vacuum-infiltration was 0.5 and leaves were harvested on 6 dpi. Black lines 
denote the change in iodixanol percentage and corresponding fractions and red arrows 
indicate the observed bands which were subsequently aspirated.  
Figure 2.20.a demonstrates a western immunoblot analysis of the fractions removed 
from the iodixanol gradient above (Figure 2.19). Strong monomer and trimer bands 
were observed in the lanes where the aspirated band (B) (40/60% interface) was 
loaded and fractions 2, 3 and 4. Lighter bands were observed in fractions 1, 5 and 6 
and very faint bands in the resuspended pellet (P). Coomassie staining revealed 
higher concentrations of AHSV-5 VP7 in the aspirated band and fractions 2, 3 and 4, 
however fraction 4 was heavily contaminated (Figure 2.20.b). Unfortunately, gel 
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quantification as per 2.2.5 revealed low concentrations of AHSV-5 VP7: 2.39 µg/ml in 
the aspirated band (B) and 12.70 µg/ml in fraction 2 and a total of 0.52 µg/g FW yield 







Figure 2.20: Analysis of AHSV-5 VP7 expression after iodixanol density gradient 
conversion. (a) Western immunoblot analysis and (b) Coomassie stained SDS-PAGE gels of 
crude extract and 30, 40 and 60% iodixanol density gradient fractions (1-6). Equal sample 
volumes of 22 µl were added to each lane. N. benthamiana plants were infiltrated with AHSV-5 
VP7 alone. Arrows indicate the positions of AHSV-5 VP7 monomer (37 kDa) and VP7 trimer 
(135 kDa). Mw: NEB molecular weight marker (sizes displayed in kDa), Cr: Crude plant extract 
before 1200 x g/RCF (max) centrifugation, P: Resuspended pellet, (-): Negative control - 
pRIC3.0 empty vector crude leaf extract, B: Aspirated band at 40/60% interface, 1-6: Fractions 
1-6. 
In Figure 2.21, TEM was used to observe crystals in the fractions removed from the 
iodixanol gradient in Figure 2.19. Well-structured large crystal formations ranging 
from 600 nm to 800 nm were seen in the aspirated band (Figure 2.21.a) and fraction 3 
(Figure 2.21.b). The conversion from sucrose to an iodixanol gradient alternative was 
____________________________________________________________________________________________________
Shelley Helen Fearon Student No: SMTSHE005 Page 80 
therefore successful, however AHSV-5 VP7 quasi-crystals resided in higher fractions 









Figure 2.21: TEM images of AHSV-5 VP7 quasi-crystals after density gradient 
ultracentrifugation. (a) Crystals in aspirated band at 40/60% interface. (b) Crystals in fraction 
3/ 30-40% layer. N. benthamiana plants infiltrated with AHSV-5 VP7 alone. Scale bar: 100 nm 
(a) and 200 nm (b). 
2.3.2.6 Increasing AHSV-5 VP7 quasi-crystal yields for immunogenicity 
studies 
Although large VP7 crystals were viewed in the previous experiment, gel densitometry 
revealed low protein concentrations of AHSV-5 VP7 – too low for use as doses for a 
vaccine. Attempts were therefore made to increase these yields by increasing 
biomass, adjusting gradient layers and increasing ultracentrifugation time in order to 
increase the probability of particles reaching their isopycnic point.  
Agroinfiltration and purification was carried out as per 2.2.4.6. N. benthamiana plants 
were infiltrated with AHSV-5 VP7 alone. Figure 2.22 shows that the 30% and 36% 
iodixanol layers in combination seemed sufficient to obstruct the crude extract from 
falling into lower layers allowing fractions 1 and 2 to remain clean. 
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Figure 2.22: Iodixanol density gradient purification of AHSV-5 VP7 quasi-crystals. 
Image displaying the 30-50% iodixanol step gradient after ultracentrifugation, using 
resuspended crude pellet. Crude extract was prepared from N. benthamiana plants 
expressing AHSV-5 VP7 alone. The inoculum culture OD600 for vacuum-infiltration was 0.5 
and leaves were harvested on 5 dpi. Black lines denote the change in iodixanol percentage 
and corresponding fractions and the red arrow indicates observed bands.  
Coomassie staining, in Figure 2.23, revealed high concentrations of AHSV-5 VP7 
protein with very little plant contaminants observed. Gel densitometry showed 
concentrations of 213.16 µg/ml in fraction 2 and 2.66 µg/g FW yield (FW yield 
calculated as per 2.2.5). Unfortunately, fraction 1 showed signs of bacterial 
contamination and was therefore not analysed further and not used for vaccine 
purposes. 
 
Figure 2.23: Analysis of AHSV-5 VP7 expression after iodixanol density gradient 
purification. Coomassie stained SDS-PAGE gels of fraction 1 (40/50% iodixanol) and 2 (40% 
iodixanol). Equal sample volumes of 22 µl were added to each lane. Arrow indicates the 
positions of AHSV-5 VP7 monomer (37 kDa). Mw: NEB molecular weight marker (sizes 
displayed in kDa), 1: Fraction 1, 2: Fraction 2. 
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TEM of fraction 2, showed many well-structured large AHSV-5 VP7 quasi-crystal 
formations ranging from 500 nm to 1 µm (Figure 2.24). 
   
  
Figure 2.24: TEM images of AHSV-5 VP7 quasi-crystals after iodixanol density gradient 
purification. 500 µl fractions stored at -20C. Crystals observed in fraction 2/ 40% iodixanol. 
N. benthamiana plants infiltrated with AHSV-5 VP7 alone. Scale bar: 100 nm. 
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 In Situ TEM of Recombinant pRIC-AHSV5-VP7 Agroinfiltrated 
N. benthamiana Leaves 
In situ TEM was performed in an attempt to confirm that AHSV-5 VP7 quasi-crystals 
were forming inside N. benthamiana leaves and not as a result of favourable 
physiological conditions which may arise during the purification process. 
N. benthamiana plants were agroinfiltrated with recombinant pRIC3.0-AHSV5-VP7 
alone, harvested on 5 dpi, fixed, embedded and sectioned for in situ TEM as per 2.2.7. 
Whilst fixation of cellular structures seemed to be satisfactory and A. tumefaciens was 
observed (Figure 2.25), no AHSV-5 VP7 quasi-crystals were observed in situ.  
  
Figure 2.25: In situ TEM images of A. tumefaciens in N. benthamiana leaves. Left: 
Unstained grids, Right: Grids prepared with 2% uranyl acetate and lead citrate. Scale bars: 
1 µm (left) and 0.5 µm (right). 
2.4 Discussion 
To test the immunogenicity of AHSV-5 VP7 quasi-crystals an optimised purification 
protocol was required to produce sufficient antigen yields and purity for animal studies. 
Many researchers have expressed and purified AHSV VP7 using the conventional 
mammalian and insect expression systems (Basak et al. 1996; Bekker et al. 2014; 
Burroughs et al. 1994; Chuma et al. 1992; Maree and Paweska 2005; Martinez-
Torrecuadrada et al. 1996; Rutkowska et al. 2011; Wade-Evans et al. 1997; Wall et 
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al. 2017). In contrast, this study aimed to express and purify AHSV-5 VP7 quasi-
crystals from N. benthamiana, as the literature suggests that plant expression systems 
may hold various advantages over the more conventional expression platforms (Chen 
et al. 2013; Mir-Artigues et al. 2019; Rybicki 2019; Schillberg et al. 2019). 
The successful expression of AHSV-5 VP7 in N. benthamiana using the pRIC3.0 and 
pEAQ-HT vectors was confirmed by western immunoblot using a polyclonal anti-
AHSV5-VLP guinea-pig antiserum. To optimise the expression conditions of VP7, 
recombinant protein yields resulting from pRIC3.0 and pEAQ-HT were compared. 
AHSV-5 VP7 was expressed on its own and co-expressed with AHSV-5 VP2, VP3 and 
VP5 in order to ascertain whether other AHSV capsid proteins may affect the 
expression levels of AHSV VP7. Interestingly, after qualitative assessment via SDS 
PAGE and western immunoblotting, higher levels of AHSV VP7 trimers were noted 
when N. benthamiana leaves were co-infiltrated with AHSV-5 VP2, VP3, VP5 and VP7 
using the pRIC3.0 vector. The co-expressed capsid proteins may have a positive effect 
on VP7 trimer formation. Studies focusing on the closely related BTV, have found that 
BTV VP3 affects the intracellular distribution of VP7 and trimer lattice formation 
(Bekker et al. 2014; French and Roy 1990; Kar et al. 2007). Furthermore, the increase 
in expression levels suggested by the strong trimer bands observed in Figure 2.3 
lane 2 (pRIC3.0 - Co), when utilising the self-replicating plant expression vector 
pRIC3.0, may result from an increase in gene expression by rolling circle replication 
mentioned in 2.1 (Regnard et al. 2010). However, the difference in expression levels 
may also result from leaf variability.  
The vector comparison was therefore repeated and included comparisons on optical 
densities and harvest days. Overall when considering the expression and protein 
production of AHSV-5 VP7, this experiment revealed relatively similar expression 
levels when using both expression vectors, OD600 readings and harvest days. A slight 
difference of higher expression levels was noted when using the pRIC3.0 vector and 
harvesting at 5 dpi. Based on the increase in AHSV-5 VP7 protein expression using 
the pRIC3.0 vector and co-infiltration (AHSV-5 VP2, VP3, VP5 and VP7) observed in 
Figure 2.3, the pRIC3.0 vector and co-expression tactic were selected for the 
purification experiments to follow. Furthermore, an OD600 of 0.5 and harvest day at 
3 dpi were selected as the optimal parameters for purification experiments. Three dpi 
was selected as the optimal harvest day despite observing higher yields at 5 dpi as 
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plants were shown to have deteriorated rapidly after syringe-infiltration by this day. 
Additionally, an OD600 of 0.5 was used since higher yields of VP7 were observed at 
3 dpi when using the pRIC3.0 vector (Figure 2.5.b). It is important to note that the 
analysis by western immunoblotting was a qualitative assessment, as a quantitative 
assessment via Coomassie staining and gel densitometry was difficult to perform on 
crude extracts. 
The first protocol used to purify out AHSV-5 VP7 quasi-crystals was a relatively 
standard procedure used by members of the BRU for purifying AHSV VLPs. PBS, 
pH 7.4, was used as the buffer of choice and high-speed differential centrifugation 
(23 300 x g/RCF (max)) was used to extract contaminants. The subsequent crude 
supernatant was used for density gradient purification and high-speed density gradient 
ultracentrifugation (174 900 x g/RCF (max)) performed. Unfortunately, after TEM 
analysis of gradient fractions, no evidence of AHSV-5 VP7 quasi-crystals was 
apparent in any of the fractions. CLPs alone were observed as seen in Figure 2.6.c, 
and western immunoblot analysis revealed VP7 monomer and trimer bands (37 kDa 
and 135 kDa respectively) in the higher fractions (5-12) (Figure 2.6.b). Suggesting 
that after ultracentrifugation the majority of available AHSV-5 VP7 was in soluble form. 
Hence, it was suspected that due to its insolubility VP7 quasi-crystals were being lost 
in the pellet during high-speed differential spins and clarification. 
Considering these findings, the differential centrifugation speeds were reduced to 
1200 x g/RCF (max) and an iodixanol cushion was used to concentrate AHSV-5 VP7 
at the 25/60% iodixanol interface. Additionally, the harvest day was increased to 5 dpi 
allowing an increase in potential crystal maturation time, as vacuum-infiltrated plants 
seemed relatively healthy by 5 dpi. Due to the aforementioned protocol adjustments a 
few small crystals were observed by TEM in the aspirated gradient band (40% 
iodixanol layer) which originated from the 25/60% layer of the iodixanol cushion. 
Additionally, many CLPs were seen in the 30/40% gradient layer originating from the 
25/60% layer of the iodixanol cushion. Once again most of the available AHSV-5 VP7 
was observed in the higher fractions suggesting that mostly the soluble form was 
present.  
In light of the previous findings, it was suspected that PBS (pH 7.4) was not a suitable 
buffer for enhancing VP7 trimer-trimer interactions. Assembly of BTV-10 VP7 crystals 
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and rotavirus nucleocapsid protein, VP6, hexagonal lattices are pH dependent 
(Monastyrskaya et al. 1997; Sabara et al. 1987). And Bekker et al (2017) reported that 
hydrophobic and electrostatic interactions are likely to influence trimer-trimer 
interactions which can be affected by ionic strength and pH. 0.2 M Tris-HCl (pH 8) was 
therefore selected which has been utilized by various researchers when attempting to 
isolate and purify AHSV-5 VP7 crystals from insect cells (Bailey 2016; Burroughs et 
al. 1994; Maree et al. 2016). In addition, a single-infiltration with AHSV-5 VP7 alone 
was used for further experiments. For subsequent experiments the initial low-speed 
differential centrifugation step was retained, a second differential spin was included 
(23 300 x g/RCF (max)), and both the supernatant and pellet resulting from the 
23 300 x g/RCF (max) spin were used for purification using a 50% iodixanol cushion 
After western immunoblot analysis of fractions from the 50% iodixanol cushion little 
loss of VP7 protein was observed after the low-speed spin (1200 x g/RCF (max)) when 
using both buffers. However, when using 0.2 M Tris-HCl, there seemed to be an 
increase in protein loss after the second spin (23 300 x g/RCF (max)). Additionally, 
when using 0.2 M Tris-HCl, the majority of AHSV-5 VP7 was observed in the higher 
fractions when using the supernatant for purification, and in the pellet when using the 
pellet for purification. In contrast, when using PBS, VP7 was only observed in the 
higher fractions of both the pellet- and supernatant-cushion. These results suggest 
that higher quantities of insoluble AHSV-5 VP7 are present when using 
0.2 M Tris-HCl, pH 8. However, VP7 quasi-crystals were not observed in any of the 
fractions after ultracentrifugation. Crystal formations were observed in the crude 
extract before and after the 23 300 x g/RCF (max) spin and the latter showed signs of 
degradation suggesting that high-speed spins may damage the crystalline-structure. 
A finding that was also reported by Maree and Paweska (2005). 
Based on the previous findings, 0.2 M Tris, pH 8, seemed to increase trimer-trimer 
interactions and was therefore used for further optimisation experiments. However, 
150 mM sodium chloride was included to mimic physiological conditions and increase 
ionic strength. In addition, low-speed differential centrifugation (1200 x g/RCF (max)) 
was retained, the resuspended-pellet after 3000 x g/RCF (max) spin was used for 
density gradient purification, and the ultracentrifugation speed was reduced to 
17 500 x g/RCF (max). Furthermore, sucrose gradients were used for further 
optimisation to reduce costs, and maturation time was increased as limited necrosis 
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and chlorosis was observed on plant leaves 5 dpi so harvest day could be extended 
to 6 dpi. After western immunoblot analysis, AHSV-5 VP7 was observed in all gradient 
fractions and Coomassie staining showed higher concentrations in the lower fractions 
(Figure 2.17) displaying an increase in the insolubility of AHSV-5 VP7. This was 
confirmed by the observation of many well-formed quasi-crystals in fraction 1 (68%) 
and fraction 2 (50%) during TEM (Figure 2.18). However, while these crystals retained 
the crystal lattice they did not resemble the flat hexagonal formations reported by 
others (Basak et al. 1996; Chuma et al. 1992; Maree et al. 2016; Rutkowska et al. 
2011). In addition, they were relatively small when compared to previous research 
(Burroughs et al. 1994; Chuma et al. 1992; Maree and Paweska 2005; Wall et al. 2017; 
Bailey 2016) ranging in size from 200-700 nm and forming conglomerates of various 
shapes. This may be a consequence of using plant expression systems. Interestingly, 
similar structural changes were observed by Rutkowska et al. (2011) when using a 
mutated version of AHSV VP7 which included an epitope of the foot-and-mouth 
disease virus (FMDV). However, despite the differences in crystal shape, the protocol 
adjustments seemed favourable for crystal-formation. These findings in conjunction 
with previous observations gave support to the hypothesis that high-speed spins may 
damage quasi-crystals, 0.2 M Tris-0.15 M NaCl, pH 8, strengthens VP7 trimer-trimer 
interactions, and a low-speed spin of 3000 x g/RCF (max) seems sufficient to isolate 
VP7 crystals in the pellet for further purification steps. 
The penultimate step was to convert the successful sucrose step gradient into an 
iodixanol alternative. OptiprepTM iodixanol is a preferable gradient medium for vaccine 
preparation as it is sterile, while sucrose is notoriously easy to contaminate. After 
conversion to iodixanol, analysis by western immunoblot and Coomassie staining 
demonstrated higher concentrations of AHSV-5 VP7 in the lower fractions, except for 
fraction 1, and observation by TEM revealed VP7 quasi-crystals in fraction 3 of the 
iodixanol gradient (Figure 2.21). Unfortunately, quantification by gel densitometry 
revealed low protein concentrations (2.39 µg/ml in the aspirated band (B) and 
12.70 µg/ml in fraction 2 and a total of 0.52 µg/g FW yield).  
In order to increase AHSV-5 VP7 crystal concentrations, the biomass was increased, 
and ultracentrifugation time was increased to 3.5 hours to allow more crystals to reach 
their isopycnic point. In addition, the gradient layers were adjusted to shift the crystals 
to a lower fraction. As a result, many well-formed quasi-crystals were observed in 
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fraction 1 (40/50%) and 2 (40%) and after gel densitometry, concentrations of 
213.16 µg/ml and 2.66 µg/g FW yield were achieved in fraction 2. 10-50 µg in 400 µl 
(max) was needed for guinea-pig immunogenicity experiments, hence the 
concentrations were adequate to commence with these studies.  
To confirm that AHSV-5 VP7 quasi-crystals were assembling in N. benthamiana 
leaves and not in vitro as a result of an ideal physiological environment created during 
the extraction process, leaves were agroinfiltrated with recombinant pRIC3.0-AHSV5-
VP7, fixed on 5 dpi, embedded, leaf-ultra-sections prepared and in situ TEM 
performed. However, while A. tumefaciens was observed, no evidence of AHSV-5 VP7 
quasi-crystals was seen. The typical pH for tobacco plant cell cytoplasm is between 
7.5 and 7.8 which may decrease in response to abiotic stress such as agroinfiltration 
(Martiniere et al. 2013; Urbanowski 2012; Grosse-Holz et al. 2018). Interestingly, when 
using PBS, pH 7.4, in the purification process mostly the soluble version of AHSV-5 
VP7 was present, therefore low pH cytosolic conditions may impede trimer-trimer 
formations. Future studies should include immunogold labelling for TEM to aid in 
AHSV VP7 quasi-crystal observation. 
In conclusion, AHSV-5 VP7 was successfully expressed and VP7 quasi-crystals 
produced in N. benthamiana. The expression vectors pEAQ-HT and pRIC3.0 were 
compared and since pRIC3.0 resulted in higher yields of AHSV-5 VP7 it was selected 
as the optimal expression vector. Additionally, 6 dpi was established as the optimal 
harvest day to increase quasi-crystal maturation time. High amounts of VP7 quasi-
crystals were present in the pellet after low-speed differential centrifugation and the 
resuspended pellet was suitable for density gradient purification. 0.2 M Tris-
0.15 M NaCl, pH 8, increased trimer-trimer interactions and high-speed 
ultracentrifugation was found to destroy quasi-crystals. An FW yield of approximately 
2.66 µg/g of plant-produced AHSV-5 VP7 quasi-crystals was achieved and this was 
considered satisfactory as previous researchers have reported yields of approximately 
0.0025 ng/cell (Burroughs et al. 1994), 0.03 ng/cell (Chuma et al. 1992) and 0.5 ng/cell 
(Maree and Paweska 2005) when using recombinant baculovirus-infected Sf9 insect 
cells.  
For the purposes of this study, density gradient ultracentrifugation was considered a 
successful method for AHSV VP7 quasi-crystal purification, however, future work 
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should seek a more scalable alternative such as depth filtration and tangential flow 
cytometry, as density gradient ultracentrifugation can be tedious particularly when 
upscaling and requires expensive equipment (Dennis 2019). To our knowledge this is 
the first time that AHSV VP7 quasi-crystals have been expressed using a plant 
expression platform. 
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CHAPTER 3: TESTING THE IMMUNOGENICITY OF AHSV-5 VP7 QUASI-CRYSTALS AS 
A CANDIDATE VACCINE 
3.1 Introduction 
AHSV VP7 is a highly immunogenic protein and its immunodominance has been 
widely utilised in serological assays to identify infections and distinguish between 
Orbivirus serogroups (Maree and Paweska 2005; Martinez-Torrecuadrada et al. 
1996). AHSV VP7 is highly conserved within its serogroup with greater than 98% 
amino acid identity between the nine serotypes, and has been established as the 
group-specific antigen (Chuma et al. 1992; Williams et al. 1998). In vaccine design, 
this similarity between serotypes is a favourable characteristic as it negates the need 
for a multivalent vaccine.  
As mentioned previously, another advantageous characteristic of AHSV VP7 quasi-
crystals is the highly ordered repetitive conformation which results in the repetition of 
immunologically important epitopes thereby potentially enhancing humoral and cell-
mediated immune responses (Bailey 2016; Friede and Aguado 2005; Rutkowska et 
al. 2011; St Clair et al. 1999; Storni et al. 2005). A study by St Clair et al. (1999) 
demonstrated that cross-linking human serum albumin crystals for vaccine delivery 
resulted in a 6 to 10-fold increase in antibody titres raised in Sprague–Dawley rats. 
AHSV VP7’s intrinsic ability to aggregate and self-form crystalline structures can 
therefore be utilised to produce large quantities of cross-linked quasi-crystals to meet 
the demand for vaccine production (Maree and Paweska 2005; St Clair et al. 1999).  
Furthermore, particulates are more efficiently processed by antigen presenting cells 
(APC) than soluble antigens (Snapper 2018; Vidard et al. 1996). Antigens larger than 
200-500 nm need to be transported from peripheral tissues to lymphoid organs by 
APCs resulting in T-cell activation. Smaller antigens, 20-200 nm, freely enter the 
lymphatic system and activate B-cell responses (Bachmann and Jennings 2010; 
Manolova et al. 2008; Snapper 2018; Vidard et al. 1996). Particulates have been 
utilised in many antigen delivery systems and various studies have shown that 
dendritic cell uptake of particles enhances the production of interleukins stimulating 
innate and cellular immune responses. More specifically, some of these antigen 
delivery systems have been shown to induce T-helper (Th)1 and cytotoxic T-
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lymphocyte (CTL) responses (Friede and Aguado 2005; Sharp et al. 2009; Storni et 
al. 2005). Dendritic cells and macrophages are the most important APCs for activation 
of T-cell responses (Bachmann and Jennings 2010). Dendritic cells efficiently 
phagocytose particulates of less than 0.5 µm, whilst macrophages process particles 
less than ±5 µm (Foged et al. 2005; Hirota and Ter 2012; Yue et al. 2010). In a recent 
study by Bailey et al. (2016) VP7 crystals did not yield a favourable humoral response 
and this was speculated to be due to large antigen sizes often exceeding 5 µm. In 
contrast, plant-derived quasi-crystals produced in this study (Chapter 2) tend to range 
from 50 nm to 1000 nm which we hypothesise to be satisfactory to yield both humoral 
and cell-mediated responses.  
The role of humoral immunity to AHSV infection has been relatively well studied. 
However, cell-mediated immunity has been overlooked. The survival of vaccinated 
animals after a lethal viral challenge but void of sufficient humoral responses and 
neutralising antibodies for protection suggest that cell-mediated responses are 
paramount in AHSV immunity (Guthrie et al. 2009; Martinez-Torrecuadrada et al. 
1996; Wade-Evans et al. 1997). The importance of cell-mediated immunity against the 
closely related Bluetongue virus (BTV) has been established and BTV NS1, NS3, VP2, 
VP5 and VP7 CTL epitopes have been described (Andrew et al. 1995; Jeggo et al. 
1984; Wade-Evans et al. 1997). AHSV VP7 has been hypothesised to have T-cell 
epitopes similar to that of BTV VP7 (Martinez-Torrecuadrada et al. 1996). And 
research by Pretorius et al (2016) has demonstrated that innate, humoral and cell-
mediated immune responses were induced in horses after AHSV infection (Pretorius 
et al. 2016). Furthermore, another study detected proliferating CD8 T-cells in 
peripheral blood mononuclear cells (PBMC) obtained from horses after infection by 
attenuated AHSV-4. The cytotoxicity of these CD8 T-cells was tested using the 
fluorescent antigen-transfected target cells-cytotoxic T lymphocytes (FATT-CTL) 
assay. VP1, VP2, VP4, VP7 and NS3 antigen-specific CD8 T-cells resulted in cell lysis 
which suggested that CTL immune responses are important in protection against 
AHSV (Faber et al. 2016). 
Cell-mediated immune responses are activated by the fast-acting innate immune 
system. Pattern recognition receptors (PRR) such as the membrane bound: Toll-like 
receptors and C-type lectin receptors, and the cytoplasmic: NOD-like receptors and 
RIG-I-like receptors, recognise pathogen-associated molecular patterns (PAMPs). 
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This initiates signalling cascades leading to the production of cytokines by infected 
cells and PBMCs (Cui et al. 2014; Takeuchi and Akira 2009, 2010). Cytokines include 
interferons (IFNs), chemokines, tumour necrosis factors and interleukins (IL) that 
regulate and mediate inflammatory and immune responses to pathogens (Justiz 
Vaillant and Qurie 2019). Activation of B-cell receptor pathways cause B-cell 
proliferation and differentiation into antibody secreting plasma cells or memory B-cells 
(Janeway et al. 2001; Savignac et al. 2010; Dorner and Radbruch 2007). The antibody 
isotypes IgM, IgG and IgA are important for controlling viral infection and either 
opsonise or neutralise the virus or activate the complement system (Figure 3.1). 
B-cells can also act as APCs to naive T-cells (Dorner and Radbruch 2007). After 
antigens have been processed and presented by APCs they are presented on MHC-I 
or MHC-II which stimulate CD8 and CD4 T-cells respectively (Figure 3.1). The former 
activates CTLs mediating cell lysis by cytotoxic granules and the latter activates Th1, 
Th2 and Th17 cells which further regulate B-cell production, upregulate macrophages 
and further activate CTLs (Alberts et al. 2002; Dorner and Radbruch 2007; Janeway 
et al. 2001). 
Interferons are an important part of the antiviral immune response, they stimulate 
macrophages and natural killer (NK) cells, induce apoptosis in infected cells and 
increase the production of major histocompatibility complexes, MHC-I and MHC-II 
(Morris 1988; Samuel 2001). In particular, type-I interferons play a pivotal role in 
antiviral studies and IFN1-alpha and -beta have been shown to be important for 
immunity against BTV and AHSV (Castillo-Olivares et al. 2011; Pretorius et al. 2016; 
Schroder et al. 2004). Chemokines are attractants of T-cells, monocytes and 
granulocytes. The chemokine CX3CL1, activated by interferon-gamma and tumour 
necrosis factor-alpha, is an important chemoattractant to cytotoxic effector 
lymphocytes as its receptor CX3CR1 is expressed on NK cells and CTLs (Pretorius et 
al. 2016; Umehara et al. 2004; Wojdasiewicz et al. 2014). Interleukins are a large 
group of proteins which are involved in regulating both the innate and adaptive immune 
responses (Figure 3.1). Interleukins involved in adaptive immunity include, IL-1 which 
activates macrophages, B-cells, T-cells and stimulates T-cell IL-2 production. IL-2 
induces proliferation and differentiation of T-cells, B-cells, NK cells and CTL activation. 
Furthermore, IL-21 is produced by CD4 T-cells and various interleukins are produced 
by Th2 cells (IL-4, IL-5, IL-10, IL-13, IL-19 and IL-31), Th17 cells (IL-9, IL-17 and 
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IL-26), NKT-cells (IL-9 and IL-13) and NK cells (IL-21). The interleukins, IL-10, IL-12 
and IL-18 are responsible for the induction of Th1 cells. IL-28 stimulates cell 
presentation of viral antigens to CD8 T-cells and IL-5 activates CD8 T-cell proliferation 
(Justiz Vaillant and Qurie 2019).  
 
Figure 3.1: Simplified representation of cell-mediated and humoral responses, and 
associated interleukins.  The presentation of epitopes via MHC-I and -II to CD8+ and CD4+ 
T-cells is represented. Additionally, differentiation into CTLs and Th1, Th2 and Th17 cells are 
depicted as well as their associated interleukins. Yellow dots represent cytokines. Black 
arrows signify proliferation and differentiation, and red arrows depict activation. DC: Dendritic 
cells; M: Macrophages; NK: Natural Killer; APC: Antigen presentation cell; MHC: Major 
histocompatibility complex; CTL: Cytotoxic T-cells; Th: T-helper; IL: Interleukin; IFN: 
Interferons; Ig: Immunoglobulin. 
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In order to investigate the cell-mediated immune response to AHSV VP7 quasi-
crystals, RNA sequencing (RNA-seq) of spleen-derived mRNA was used to assess 
the guinea-pig transcriptome post-vaccination with AHSV-5 VP7 quasi-crystals. RNA-
seq is a powerful technique used to perform genome-wide transcriptome profiling. It is 
a highly sensitive tool and is preferred over array-based technologies to capture global 
expression profiles and provide more precise results. RNA-seq has been widely used 
in differential gene expression analyses and is therefore considered a good tool for 
studying the immune transcriptome profile (Anamika et al. 2016).  
We therefore tested the humoral and cell-mediated immune response to AHSV-5 VP7 
quasi-crystals using western immunoblotting and RNA-seq transcriptome profiling. 
Furthermore, we assessed the stability of AHSV VP7 quasi-crystals to examine the 
viability of the candidate vaccine. 
3.2 Materials & Methods 
 Assessing AHSV-5 VP7 Quasi-Crystal Stability 
AHSV-5 VP7 crystals were purified as per 2.2.4.6 respectively. A 1100 µl volume 
(58 µg/ml) of purified AHSV-5 VP7 quasi-crystals was removed and aliquoted into 
21 x 50 µl (2.9 µg per 50 µl) samples. Seven aliquots were stored at 4C, -20C 
and -80C (Figure 3.2). AHSV-5 VP7 quasi-crystals were then examined one day 
post-purification (pp) and 2-, 4-, 8-, 12-, 16-, 20- and 28-weeks pp. Of the 50 µl volume 
stored, 15 µl was removed and assessed using a Tecnai 20 transmission electron 
microscope (TEM) as per 2.2.6 and 35 ul was removed for western immunoblot and 
Coomassie staining analysis as per 2.2.5. 
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Figure 3.2: AHSV-5 VP7 quasi-crystal stability assessment timeline. Samples were 
analysed at 2-, 4-, 8-, 12-, 16-, 20- and 28-weeks post-purification (pp) via TEM, western 
immunoblot and Coomassie staining analysis. 
 AHSV-5 VP7 Quasi-Crystal Vaccine Preparation for Immunogenicity Studies 
In order to prepare the primary AHSV VP7 inoculum and booster for guinea-pig 
immunogenicity studies, AHSV-5 VP7 was expressed and quasi-crystals purified 
under sterile conditions using the methods described in 2.2.4.6. The control inoculum 
was produced in the exact same manner as the AHSV VP7 inoculum, however an 
empty pRIC3.0 expression vector was used for infiltration. Quantification was carried 
out as per 2.2.5. To examine the ASHV VP7 and control inocula preparations for 
contamination, samples were streaked onto lysogeny broth (LB) agar plates [1.0% 
tryptone, 0.5% yeast extract, 0.5% NaCl, 1.5% agar, pH 7.0] and incubated O/N at 
27C. Additionally, endotoxin levels were quantified by means of the 
ToxinSensorChromogenic LAL Endotoxin Assay Kit (Genscript Biotech Corporation, 
Piscataway, USA). The primary AHSV VP7, booster and control inocula were all stored 
at -20C until required and 25 µl samples were removed on the day of vaccination to 
re-assess sterility and concentration levels as per 2.2.5. Directly preceding 
vaccination, 5% Montanide PET Gel A adjuvant (Seppic, Paris, France) was added 
to the inocula under sterile conditions.  
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 Guinea-Pig Immunogenicity Study 
In the absence of the ideal animal model i.e. horses, guinea-pigs were selected as a 
suitable substitute as they have previously demonstrated a favourable humoral 
response to AHSV, similar to that of horses (Lelli et al. 2013b). The guinea-pig 
immunogenicity study took place in the Research Animal Facility (RAF) at the 
University of Cape Town (UCT) and was approved by the Faculty of Health Sciences 
(FHS) Animal Ethics Committee (AEC), UCT (FHS AEC ref no.: 016/019). All 
procedures were carried out by a trained animal technologist, Mr Rodney Lucas 
(Registration no: SAVC L03/5973), who also performed the daily welfare monitoring 
of all animals. Ten female guinea-pigs (Cavia porcellus) of the Hartley strain and 
approximately 12-weeks-old (480-590 g) were acquired for this study. Five guinea-
pigs per group were considered a suitable number of biological replicates for RNA-
sequencing experiments as per the ‘ENCODE Guidelines and Best Practices for RNA-
Seq’ and  (https://genohub.com/next-generation-sequencing-guide/#replication). 
Guinea-pigs were randomly assigned into control (C1-5) and experimental (X1-5) 
groups and housed together in large pens including the appropriate materials for 
bedding and enrichment. Following transport to RAF UCT, guinea-pigs were given 
time to acclimatise to their new environment for at least ten days before the experiment 
commenced.  
On day 0 and prior to primary inoculation, 100 µl pre-bleeds were drawn from each of 
the ten guinea-pigs (Figure 3.3). Five guinea-pigs (X1-5) were then subcutaneously 
injected with the primary inoculum using a 23 G needle and a further five injected with 
the control (C1-5) described in 3.2.2. Each guinea-pig received a total volume of 400 µl 
dispensed as 100 µl injections at four sites. Each 400 µl experimental sample 
contained 35.13 µg of purified AHSV-5 VP7 quasi-crystals (3.2.2). On day 13 the 
experimental guinea-pigs (n=5) were subcutaneously injected with a 400 µl booster 
which contained 26.87 µg of purified AHSV-5 VP7 quasi-crystals, prepared as 
described in 3.2.2 (Figure 3.3). Control guinea-pigs (n=5) were also injected with a 
400 µl preparation prepared in the same way as the booster but void of AHSV-5 VP7 
as per 3.2.2. The subcutaneous route of injection was selected as it is considered the 
preferred route of administration due to slow rates of absorption and reduced distress 
to the animal. Following subcutaneous injection, dendritic cells have been found to be 
the primary APCs recruited and the C-type lectin, FC receptor and Toll-like receptor 
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pathways are more likely to be activated mediating T-cell responses (Fathallah et al. 
2013). No signs of severe inflammation or infection were detected after the primary 
inoculation or booster at the injection sites. Animals were weighed on a weekly basis 
and both experimental and control guinea-pigs gained weight well throughout the 
experiment. On day 41 all guinea-pigs were exsanguinated whilst under a deep 
terminal anaesthesia using ketamine/xylazine, after which they were euthanised by a 
1ml Potassium Chloride (1-2 mM/kg) cardiac puncture (Figure 3.3). Serum was 
separated from whole blood via centrifugation at 2000 xg/RCF (max) for 20 min by 
Mr Rodney Lucas. Randomisation was implemented when selecting guinea-pigs for 
the above procedures. 
Spleens were extracted directly after euthanasia on day 41 by Mr Rodney Lucas and 
immediately cut into thin sections to produce a single dimension of less than 0.5 cm. 
Each spleen weighed ≤1 g and analogous sections were therefore placed in 5 ml 
RNAlater stabilisation solution (Thermo Fisher Scientific, Massachusetts, USA) 
immediately to stabilise and preserve RNA. These samples were stored O/N at 4C to 
allow the solution to thoroughly penetrate the tissue. After which the supernatant was 




Figure 3.3: Guinea-pig immunogenicity study timeline. 100 µl pre-bleeds were removed 
on day 0, and primary and booster inoculations were performed on day 0 and day 13, 
respectively. Exsanguination and spleen removal were carried out on day 41. 
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 Testing Neutralisation Capability of AHSV-5 VP7 Quasi-Crystals 
Serum neutralisation tests (SNT) were performed by Ms Carina Lourens, Technologist 
at the Equine Research Centre, Department of Veterinary Tropical Diseases, 
University of Pretoria. Guinea-pig anti-AHSV-5 VP7 sera were assayed against AHSV 
serotype 4, 5 and 8, and the Onderstepoort Biological Product (OBP) vaccine was 
used as the positive control.  
 Analysis of Humoral Immune Response to AHSV-5 VP7 Quasi-
Crystals 
3.2.5.1 SDS PAGE and western immunoblot analysis of guinea-pig pre-
bleeds and final-bleeds 
Guinea-pig pre-bleed and final-bleed, control and experimental sera were used to 
detect purified AHSV-5 VP7 antigen (0.77 µg loaded per well). Purified AHSV-5 VP7 
was prepared using the methods described in 2.2.4.6 and SDS PAGE carried out as 
per 2.2.5. Western immunoblotting was performed as per 2.2.5 with a few alterations: 
After transfer and blocking of HyBondTM C Extra nitrocellulose membranes (AEC-
Amersham, Gauteng, South Africa) each lane was labelled, excised and placed into 
one of the allocated polyclonal anti-AHSV-5 VP7 guinea-pig sera (X1-5 or C1-5). The 
antigen detection capability of polyclonal anti-AHSV-5 VP7 guinea-pig sera were 
assessed at dilutions of 1:50 000 and 1:100 000.  
As a positive control, polyclonal anti-AHSV-5 VLP guinea-pig serum previously used 
as the primary antibody for detection of AHSV-5 VP7 (2.2.5) at a 1:5000 dilution was 
used to detect AHSV-5 VP7 antigen. Additionally, various negative controls were used: 
(1) In order to assess secondary antibody contamination, no primary antibody was 
used and goat anti-guinea-pig IgG alkaline phosphatase-conjugated secondary 
antibody (Sigma-Aldrich, St Louis, Missouri) was used to detect AHSV-5 VP7 antigen 
at a dilution of 1:5000, (2) Final-bleed mouse sera (1:20 000) obtained from mice 
injected with a plant-produced vaccine control, prepared using the empty pRIC3.0 
expression vector, were used to detect AHSV-5 VP7 antigen, (3) Plant-produced 
Shuni virus (SHUV) protein, kindly provided by Mr Matt Verbeek (BRU, MCB, UCT), 
was loaded as the antigen and probed with anti-AHSV-5 VP7 guinea-pig pre-bleed 
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(C2) and final-bleed (C2, X1 and X2) sera to assess non-specific binding, (4) The 
vaccine-control, prepared in the same way as the vaccine but void of AHSV-5 VP7, 
was loaded and probed with anti-AHSV-5 VP7 final-bleed (C2 and X1) guinea-pig sera 
to assess non-specific binding, (5) Polyclonal anti-foot and mouth disease virus 
(FMDV) guinea-pig serum, kindly provided by Mr Scott De Beer (BRU, MCB, UCT), 
was used as the primary antibody (1:2000) to detect AHSV-5 VP7 antigen, (6) A 
semi-crude preparation of AHSV-5 VP7 was used as the antigen and probed by anti-
AHSV-5 VP7 final-bleed control guinea-pig (C2) serum to assess non-specific binding. 
Furthermore, blocking buffer containing 3% bovine serum albumin (BSA) (Sigma-
Aldrich, St Louis, Missouri) as opposed to 5% fat-free milk and the pre-absorption 
technique (3.2.5.2) was tested to increase specificity of the anti-AHSV-5 VP7 guinea-
pig sera. 
3.2.5.2 Pre-absorption with host cell proteins to increase binding 
specificity of anti-AHSV-5 VP7 guinea-pig sera 
Six grams of leaf biomass was removed from healthy four-week-old N. benthamiana 
plants and combined with 20 ml 0.2 M Tris-0.15 M NaCl, pH 8. The mixture was 
thoroughly homogenised using the T25 digital Ultra-Turrax blender (IKA, Staufen, 
Germany) and placed at 4C with gentle shaking for 30 min. The homogenate was 
then filtered through one layer of MiraclothTM (Merck, Darmstadt, Germany) and 
centrifuged at 1200 xg/RCF (max) for 10 min at 4C using the Beckman Avanti J-25 
High Speed Centrifuge (Beckman Coulter, Brea, CA). To allow binding of plant 
proteins to the nitrocellulose, the supernatant was then transferred to a container 
possessing 5 x 5 cm pre-wet (dH2O) HyBondTM C Extra nitrocellulose and incubated 
for 2 hrs at room temperature with gentle agitation. The plant extract was then removed 
and replaced with 15 ml anti-AHSV-5 VP7 guinea-pig serum diluted to 1:50 000, which 
allowed binding of non-specific anti-plant antibodies. This was incubated for 2 hrs at 
room temperature with gentle shaking and then stored O/N at -20C until utilised in 
subsequent western immunoblots. The pre-absorption technique was repeated for all 
final-bleed experimental and control guinea-pig sera.  
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 Transcriptome Profiling: Analysing the Cell-mediated Immune 
Response to AHSV-5 VP7 Quasi-crystals  
3.2.6.1 RNA extraction & integrity analysis 
15-20 mg of RNAlaterTM stabilised spleen tissue was placed in a 2 ml Eppendorf tube 
containing 600 µl of the RNeasy Mini Kit lysis buffer (Qiagen GmbH, Hilden, 
Germany). The lysis buffer included 1% β-Mercaptoethanol. A TissueLyser LT 
(Qiagen, Hilden, Germany) and stainless-steel beads were used to disrupt and 
homogenise the lysate. Total RNA was extracted from guinea-pig spleens (C1-5 and 
X1-5) using the RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany) according to the 
manufacturer’s instructions, and an on-column DNase digestion (Qiagen GmbH, 
Hilden, Germany) was used to remove genomic DNA contaminants. The resultant 
RNA was eluted in 60 µl RNase free water and 30 µl removed to assess RNA 
concentration and quality. The remaining 30 µl of eluted RNA, ranging from between 
348.1-672.2 ng/µl, was combined with 90 µl E.Z.N.A. RNA Transport buffer (Omega 
Bio-tek, Georgia, USA) and couriered to Omega Bio-tek (Georgia, USA) at room 
temperature for RNA integrity analysis, library preparation, transcriptome sequencing 
and bioinformatics analyses. 
RNA concentration was assessed using a NanoDrop 1000 Spectrophotometer 
(Thermo Fisher Scientific, Massachusetts, USA) at 260 nm and RNA quality quantified 
at the absorbance ratio 260/280 nm and 260/230 nm. A further assessment of RNA 
quality was performed by agarose gel electrophoresis. Samples were diluted in RNAse 
free H2O to yield ±2 µg of RNA, combined with 6x DNA loading dye (Thermo Fisher 
Scientific, Massachusetts, USA), heat-denatured for 5 min at 65C and subsequently 
snap cooled on ice until loading. 2 µl of O’GeneRuler™1 kb DNA ladder (Thermo 
Fisher Scientific, Massachusetts, USA) was used as a molecular weight marker, in the 
absence of the more appropriate RNA molecular weight marker. Sample volumes of 
10 µl were loaded onto a 1% agarose gel including 3 µl ethidium bromide (EtBr) and 
electrophoresed at 60 volts for approximately 1.5 h. The 28S (5 kb) and 18S (1.9 kb) 
ribosomal subunit RNA bands were assessed as a proxy to ascertain the total RNA 
quality. 
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Furthermore, the RNA quantity, purity and integrity of all ten samples was assessed 
by Omega Bio-tek (Georgia, USA) using the bioanalyser, Agilent 2200 TapeStation 
System (Agilent, California, USA) and RNA ScreenTape (Agilent, California, USA). 
RNA samples with RIN (RNA integrity number) scores greater than 7.2 were selected 
for subsequent mRNA library preparation and RNA sequencing. 
3.2.6.2 Transcriptome sequencing & bioinformatics analyses 
RNA library preparation and sequencing were performed by Omega Bio-tek (Georgia, 
USA). At least 0.5 µg of starting total RNA was needed for library preparation and the 
Agilent 2100 TapeStation System (Agilent, California, USA) revealed between 5.91 µg 
to 21.68 µg of total RNA in our samples. The TruSeq Stranded mRNA Library Prep Kit 
(Illumina, California, United States) was used for mRNA library preparation as per 
manufacturer’s instructions. RNA sequencing (RNA-seq) was performed using an 
Illumina HiSeq X high-throughput platform, sequencing ±40 million reads in 150 bp 
paired-end format per sample. Five guinea-pigs per group was considered a suitable 
number of biological replicates for RNA-seq experiments as per the ‘ENCODE 
Guidelines and Best Practices for RNA-Seq’ and  (https://genohub.com/next-
generation-sequencing-guide/#replication). 
Bioinformatics analyses were performed by Omega Bio-tek (Georgia, USA) using the 
Illumina Basespace platform (https://basespace.illumina.com) and DESeq2 tool for 
mapping and differential gene expression analysis. Approximately 20.21-53.54 million 
150 bp paired-end raw reads for each sample were imported, filtered and trimmed by 
removing adapter sequences and low-quality base reads using the BowTie short read 
aligner. The resultant high-quality reads were mapped to a reference genome (Cavia 
porcellus) using STAR in the Illumina RNA alignment App. Unfortunately, the Cavia 
porcellus genome was not available as a standard reference genome at the time of 
this study as the Mammalian Genome Project had only sequenced the guinea-pig 
genome to 2x coverage and was therefore only assembled to scaffold level. The 
existing scaffold genome was therefore used as a reference in combination with de 
novo transcriptome assembly by using the Illumina Basespace Custom Genome 
Builder App. Genes were annotated using GENCODE and DESeq2 results revealed 
an annotated gene count of 26 855. The total number of mapped reads for each 
transcript were determined and these were normalised to FPKM (fragments per 
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kilobase of exon model per million mapped reads). These normalised gene counts 
were then log2 transformed to observe proportional changes in the data. As 
mentioned, differential gene expression analysis was then performed on the 
experimental (n=5) and control (n=5) datasets by Omega Bio-tek (Georgia, USA) in 
Illumina Basespace (https://basespace.illumina.com) using the DESeq2 analysis tool 
(Love et al. 2014).  
The DESeq2 model uses a generalized linear model (GLM) for differential expression 
analysis (Love et al. 2014) where: 
𝐾𝑖𝑗 ∼ NB(µ𝑖𝑗 , 𝑎𝑖) 
µ𝑖𝑗 = 𝑠𝑗𝑞𝑖𝑗 
log2(𝑞𝑖𝑗) = 𝑋𝑗 . 𝛽𝑖 
where: 
− Counts 𝑲𝒊𝒋 for gene 𝒊 sample 𝒋 are modeled using a negative binomial 
distribution with fitted mean 𝛍𝐢𝐣 and a gene-specific dispersion parameter 
𝒂𝒊. 
− The fitted mean is composed of a sample-specific size factor 𝒔𝒋 and a 
parameter 𝒒𝒊𝒋 proportional to the expected true concentration of 
fragments for sample 𝒋.   
− The dispersion parameter 𝒂𝒊 defines the relationship between the 
variance of the observed count and its mean value, which depends both 
on the size factor 𝒔𝒋  and the covariate-dependent part 𝒒𝒊𝒋 (defined 
above). 
− The coefficients 𝜷𝒊 give the log2 fold changes for gene 𝒊 for each column 
of the model matrix 𝑿 (Love et al. 2014). 
 
After normalisation and transformation, an annotated gene count of 7213 was tested 
for statistical significance by the DESeq2 model. The DESeq2 model uses the Wald 
test to test the statistical significance of  differential expression, where the estimated 
____________________________________________________________________________________________________
Shelley Helen Fearon Student No: SMTSHE005 Page 103 
standard error of the log2 fold change (between the control and experimental group) is 
tested to see if it differs significantly from zero (Love et al. 2014). The DESeq2 model 
adjusts the Wald test p-values for multiple testing, taking into account the false 
discovery rate (FDR), using the procedure of Benjamini and Hochberg (Benjamini and 
Hochberg 1995) to calculate q-values (corrected p-values). Experimental and control 
‘regularised transformed gene counts/ expressed transcripts’ were found to be 
significantly differentially expressed if the q-value (corrected p-value) ≤ 0.05. Three 
hundred and fifty genes were found to be significantly differentially expressed (DE) 
when compared to the control gene counts. 
3.2.6.3 Global and cell-mediated immune response analyses 
R (R Core Team 2018) was used to analyse the global immune response from the  
DESeq2 results, with the main focus being the cell-mediated immune response. 
Twenty two immune pathways and their related genes were accessed using the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) (https://www.genome.jp/kegg/pathw 
ay.html) and Reactome pathway databases (https://reactome.org/PathwayBrowser/) 
(Table 3.1). Unfortunately, Cavia Porcellus was not one of the listed KEGG or 
Reactome organisms. The National Center for Biotechnology Information (NCBI) 
Taxonomy browser (https://www.ncbi.nlm.nih.gov/taxonomy) and Lifemap NCBI 
(http://lifemap-ncbi.univ-lyon1.fr/) were used to ascertain the closest living relative to 
Cavia porcellus. As a result, the Heterocephalus glaber and Mus musculus immune 
pathways from the KEGG and Reactome pathway databases respectively were used 
for further analyses. 
Table 3.1: Innate and adaptive immune pathways and the respective categories and pathway 
databases used. 
Analysed Immune Related Pathways Database Categories Pathway Database 
Chemokine signalling pathway 





Natural killer cell mediated cytotoxicity 
Leukocyte transendothelial migration 
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Fc gamma R-mediated phagocytosis Organism: 
Heterocephalus glaber 
 
NOD-like receptor signalling pathway 
Complement and coagulation 
cascades 
Platelet activation 
T cell receptor signalling pathway 
Th1 and Th2 cell differentiation 
Th17 cell differentiation 
IL-17 signalling pathway 
Antigen processing and presentation 
C-type lectin receptor signalling 
pathway 
Toll-like receptor signalling pathway 
RIG-I-like receptor signalling pathway 
Cytosolic DNA-sensing pathway 






Signal transduction Ras signalling pathway 
Rap1 signalling pathway 
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Ensembl and NCBI Entrez gene IDs were converted to gene symbol/name using the 
biomaRt package (Steffen Durinck 2009) in R (R Core Team 2018). Commonalities 
between gene symbols/name from the selected KEGG and Reactome immune 
pathways and the 350 significantly differentially expressed genes were examined 
using R (R Core Team 2018). 30 of the Cavia Porcellus innate and adaptive immune 
response pathway genes were found to be significantly differentially expressed, 8.6% 
of the 350 significantly differentially expressed genes. Additionally, commonalities 
between the larger ‘annotated gene count’ dataset (including all expression data not 
only significantly differentially expressed genes) and gene symbols from the selected 
KEGG and Reactome immune pathways were examined using R (R Core Team 
2018). Heatmaps were constructed using the plotly package (Sievert 2018) in R (R 
Core Team 2018). Heatmaps were not scaled and were therefore a direct 
representation of the regularised and log2transformed gene transcript count. 
Significantly differentially expressed genes and related biological processes, 
molecular function and immune pathways were analysed and visualised using the 
gene ontology (GO) resource (http://geneontology.org/), biomaRt package (Steffen 




 Assessing Stability of AHSV-5 VP7 Quasi-Crystals 
Vaccines often require storage over long periods of time at varying temperatures. The 
stability or thermolability of a vaccine is therefore an important consideration when 
determining its vaccine potential. We therefore sought to establish the stability of 
AHSV-5 VP7 quasi-crystals at 4C, -20C and -80C over 28 weeks.  
Figure 3.4 shows the western immunoblot and Coomassie staining analysis of 
AHSV-5 VP7 over a 28-week period at 4C, -20C and -80C. Overall the AHSV-5 
VP7 protein bands seemed qualitatively similar in density with no sign of degradation 
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indicating that the protein is stable over varying temperatures and over the 
assessment period of 28-weeks. 
 
Figure 3.4: Stability assessment of AHSV-5 VP7. Western immunoblots (top) and 
Coomassie stained SDS-PAGE gels (bottom) of purified AHSV-5 VP7 samples stored at 4C, 
-20C and -80C. 15 µl volumes of stored samples were added to each lane. Arrows indicate 
the positions of AHSV-5 VP7 monomer (37 kDa). Mw: NEB molecular weight marker (sizes 
displayed in kDa), 1: 1-day post purification (pp), 2, 4, 8, 12, 16, 20, 28: no. of weeks pp. 
Table 3.2 shows TEM images of purified AHSV-5 VP7 samples over a 28-week period 
at 4C, -20C and -80C. Only one image per sample, of the largest crystal observed, 
is displayed in Table 3.2. The rate of crystal observation was much higher when 
analysing the -20C and -80C stored samples compared to samples stored at 4C. 
By the 4th week pp samples stored at 4C displayed very few AHSV-5 VP7 quasi-
crystals and only one very large crystal of ±900 nm was observed by the 8th week pp. 
No crystals were observed after 8 weeks when storing samples at 4C. More crystals 
of a greater size were observed in samples stored at -80C when compared to -20C. 
However, the largest crystals observed over the 28-week assessment period were 
found in the -20C sample on 28-weeks pp (±819 nm) and the 4C sample on 8-weeks 
pp (±900 nm). 
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Table 3.2: Stability assessment of AHSV-5 VP7 quasi-crystals.  Quasi-crystals observed 
via TEM analysis. Purified AHSV-5 VP7 samples stored at 4C, -20C and -80C. Days or 
weeks pp indicated in the left column. Only one image per sample of largest crystal seen 






4C -20C -80C 
1 Day pp  
 
 
2 Weeks pp 
   
4 Weeks pp 
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8 Weeks pp 
   
12 Weeks pp  
  
16 Weeks pp  
  
20 Weeks pp  
  
28 Weeks pp  
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 Guinea-Pig Immunogenicity Study 
In order to assess the vaccine potential of plant-produced AHSV-5 VP7 quasi-crystals, 
immunogenicity studies were performed on five experimental (X1-5) and five control 
(C1-5) female Hartley strain guinea-pigs. AHSV-5 VP7 quasi-crystals were purified 
from N. benthamiana plants using density gradient ultracentrifugation (2.2.4.6) and the 
presence of quasi-crystals confirmed by TEM (2.2.6). Concentrations of AHSV-5 VP7 
quasi-crystals in the primary inoculum was estimated to be 87.83 µg/ml and the 
booster 67.18 µg/ml (quantified by gel densitometry as per 2.2.5). These 
concentrations were considered acceptable for inoculation as 10-50 µg in ≤400 µl was 
previously determined as sufficient to yield an adequate immune response in guinea-
pigs. AHSV-5 VP7 inocula were assessed for contamination as per 3.2.2. No growth 
was observed on LB agar plates subjected to the AHSV-5 VP7 quasi-crystal 
preparation and endotoxin tests demonstrated very low results of between 0.64 EU/ml 
and 0.84 EU/ml (EU= endotoxin unit).  
Directly preceding guinea-pig inoculation, 5% Montanide PET Gel A adjuvant was 
added (3.2.2). PET Gel A is a polymeric adjuvant and an immunostimulant which 
stimulates the innate immune system by a pro-inflammatory response. Additionally, 
the polyacrylates in PET Gel A adsorb the antigen particles, enhancing phagocytosis 
and therefore the activity of antigen presenting cells (APC). In this study, PET Gel A 
was selected as an adjuvant to stimulate the innate immune response which would 
subsequently enhance adaptive immunity to build a specific immune response to 
AHSV-5 VP7 quasi-crystals (Deville et al. 2011; Parker et al. 2009; Vialle et al. 2010).  
After subcutaneous primary inoculation on day 0 and a booster on day 13 (Figure 3.3) 
a slight raised bump appeared at the injection site in both control and experimental 
animals. However, no severe signs of inflammation were observed at any time during 
the study. Guinea-pigs seemed healthy and continued to gain weight well throughout 
the experiment. On day 41 guinea-pigs were anaesthetised, exsanguinated, 
euthanised and their spleens removed. The sera were extracted from whole blood 
(3.2.3) and used to examine the humoral immune response to AHSV-5 VP7 quasi-
crystals (3.3.3). Additionally, spleens were extracted, incubated in RNAlaterTM and 
used to isolate mRNA for transcriptome sequencing to analyse the cell-mediated 
immune response (3.3.4). 
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 Analysis of Humoral Immune Response to AHSV-5 VP7 Quasi-
Crystal  
Guinea-pig anti-AHSV-5 VP7 serum was analysed via SNTs (3.2.4) and western 
immunoblotting (3.2.5) to assess serum neutralisation capability and the humoral 
response to AHSV-5 VP7 quasi-crystals respectively. As expected, the SNT results 
revealed that guinea-pig anti-AHSV-5 VP7 serum had no neutralisation capability. 
Whilst western immunoblot analysis of anti-AHSV-5 VP7 guinea-pig sera showed very 
high levels of antigen binding capacity.  
3.3.3.1 Western immunoblot analysis of pre-bleed and final-bleed guinea-
pig sera (1:50 000 dilution) 
Figure 3.5 displays western immunoblot analysis of anti-AHSV-5 VP7 guinea-pig sera 
derived from one of the experimental guinea-pigs denoted X2 and one of the control 
guinea-pigs denoted C2. X2 serum demonstrated high levels of AHSV-5 VP7 
immunogenicity. At a 1:50 000 dilution anti-AHSV-5 VP7 final-bleed X2 detected 
0.77 µg AHSV-5 VP7 (lane 4). Detection was at a similar level to that of the positive 
control, anti-AHSV-5 VLP serum, however the positive control had a 10-fold lower 
dilution of 1:5000. Interestingly, although the pre-bleeds C2 and X2 (1:50 000) (lanes 
1 and 2 respectively) did not detect AHSV-5 VP7 as expected, the final-bleed taken 
from control animal C2 (1:50 000 dilution) (lane 3) demonstrated detection of AHSV-5 
VP7, albeit at a much lower level (Figure 3.5). Furthermore, anti-AHSV-5 VP7 pre-
bleed C2 (1:50 000) and final-bleed C2 (1:50 000) did not detect Shuni viral protein 
(lane 8 and 9 respectively) as expected. However, the anti-AHSV-5 VP7 final-bleed 
X2 (1:50 000) did detect 0.77 µg Shuni viral protein (lane 10) to a similar level as that 
of the control (lane 3), suggesting non-specificity. The secondary antibody (goat anti-
guinea-pig) alone (lane 5) did not detect AHSV-5 VP7, ruling out the possibility of 
secondary antibody contamination Figure 3.5.  
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Figure 3.5: Western immunoblot analysis of anti-AHSV-5 VP7 guinea-pig pre-bleed and 
final-bleed sera (X2 and C2). Lanes 1-7: Purified AHSV-5 VP7 antigen (0.77 µg) probed with 
pre-bleed C2, pre-bleed X2, final-bleed C2, final-bleed X2, goat anti-guinea-pig secondary Ab 
only at 1:5000 dilution (2), mouse final-bleed control serum at 1:20 000 dilution (M) and 
positive control anti-AHSV-5 VLP guinea-pig serum at 1:5000 dilution (+). Lanes 8-10: SHUV 
antigen (0.77 µg) probed with pre-bleed C2, final-bleed C2 and final-bleed X2. Lane 11: Empty 
vector (EV) control probed with final-bleed C2. Pre-bleed and final-bleed, C2 and X2 guinea-
pig sera used at 1:50 000 dilution. Mw: NEB molecular weight marker (sizes displayed in kDa); 
Final-B: Final-Bleed: Pre-B: Pre-Bleed. Arrows indicate the positions of AHSV-5 VP7 
monomer (37kDa), AHSV-5 VP7 trimer (135 kDa) and SHUV dimer (50 kDa). Lane numbers 
(1-11) displayed below the image. 
3.3.3.2 Pre-absorption technique to increase binding specificity of 
guinea-pig sera (1:50 000 dilution) 
In an attempt to increase antibody-antigen binding specificity of anti-AHSV-5 VP7 
guinea-pig sera (C2 and X2), two methods were used. Namely, the pre-absorption 
technique (3.2.5.2) or the addition of 3% BSA in blocking buffer as an alternative to 
5% non-fat dairy milk (3.2.5.1).  
Western immunoblot analysis of the impact of these two methods on binding specificity 
of anti-AHSV-5 VP7 guinea-pig sera (C2 and X2) is represented in Figure 3.6. Pre-
absorbed final-bleed X2 serum at 1:50 000 dilution (lane 2) detected purified AHSV-5 
VP7 (0.63 µg) whilst the pre-absorbed final-bleed C2 (1:50 000) (lane 1) was unable 
to detect 0.63 µg AHSV-5 VP7. Additionally, when using 3% BSA blocking buffer, a 
very light band was observed when using the final-bleed C2 serum (1:50 000) to probe 
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for AHSV-5 VP7 (lane 5) and a strong band was observed when probed with final-
bleed X2 (1:50 000) (lane 6). SHUV antigen (0.63 µg) was not detected using the pre-
absorbed anti-AHSV-5 VP7 final-bleed X2 serum (1:50 000) (lane 3). Anti-FMDV 
guinea-pig serum (not pre-absorbed) detected AHSV-5 VP7 (lane 7), however this 
was at a serum dilution of 1:2000 and may therefore be as a result of non-specificity 
at such low dilutions. Alternatively, this may be due to plant-specific antibodies binding 
residual host plant proteins in the AHSV-5 VP7 sample as the anti-FMDV guinea-pig 
serum was not pre-absorbed. No plant protein was detected in lane 4 where the semi-
crude empty vector control was used and probed with the pre-absorbed final-bleed C2 
at a 1:50 000 dilution. 
 
Figure 3.6: Western immunoblot analysis of pre-absorbed anti-AHSV-5 VP7 guinea-pig 
#2 final-bleed sera. Lanes 1 and 2: Purified AHSV-5 VP7 antigen (0.63 µg) probed with 
preabsorbed final-bleed C2, and preabsorbed final-bleed X2. Lane 3: SHUV antigen (0.63 µg) 
probed with preabsorbed final-bleed X2. Lane 4: Semi-crude empty vector control probed with 
preabsorbed final-bleed C2. Lanes 5, 6 and 7: Purified AHSV-5 VP7 antigen (0.63 µg) probed 
with final-bleed C2 diluted in 3% BSA, final-bleed X2 diluted in 3% BSA, and anti-FMDV 
guinea-pig serum at 1:2000 dilution. Final-bleed C2 and X2 guinea-pig sera used at 1:50 000 
dilution. Mw: NEB molecular weight marker (sizes displayed in kDa). Arrows indicate the 
positions of AHSV-5 VP7 monomer (37 kDa), VP7 trimer (135 kDa) and SHUV dimer (50 kDa). 
Lane numbers (1-7) displayed below the image. 
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3.3.3.3 Western immunoblot analysis of pre-bleed and final-bleed guinea-
pig sera (1:100 000 dilution) 
Figure 3.7 shows a western immunoblot analysis of anti-AHSV-5 VP7 guinea-pig 
pre-bleed (Figure 3.7.a) and pre-absorbed final-bleed (Figure 3.7.b) sera (C1-5, 
X1-5) at a 1:100 000 dilution. As expected, pre-bleeds C1-5 and X1-5 (a) were unable 
to detect 0.53 µg AHSV-5 VP7 antigen. At a 1:100 000 dilution guinea-pig final-bleed 
sera X1, X2 and X4 were capable of detecting 0.53 µg AHSV-5 VP7, whilst X3 showed 
very faint bands similar to that of the final-bleed control sera C1, C3 and C4 suggesting 
non-specificity still present although at low levels. This suggests that the pre-
absorption technique was not completely successful in increasing the specificity of all 
samples. No bands were present in lanes where 0.53 µg AHSV-5 VP7 was loaded 
and detected by C2, C5 and X5 final-bleed sera (Figure 3.7. b). No band was 
observed when using 0.53 µg Shuni viral protein and probing with final-bleed X1 
guinea-pig serum at a 1:100 000 dilution (lane 12).  
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Figure 3.7: Western immunoblot analysis of anti-AHSV-5 VP7 guinea-pig pre-bleed and 
final-bleed sera (C1-5 and X1-5).  Analysis of (a) pre-bleed and (b) pre-absorbed final-bleed 
sera. (a) and (b) Lanes 1-10: Purified AHSV-5 VP7 antigen (0.53 µg) probed with control sera 
(C1-5) and experimental guinea-pig sera (X1-5). (+): Purified AHSV-5 VP7 antigen (0.53 µg) 
probed with anti-AHSV-5 VLP guinea-pig serum at 1:5000 dilution. (b) Lane 12: SHUV protein 
(0.53 µg) probed with final-bleed X1 serum. Lane 13: Empty vector (EV) crude control probed 
with final-bleed X1 serum. All pre-bleed and final-bleed guinea-pig sera (C1-5 and X1-5) used 
at 1:100 000 dilution. Arrows indicate the positions of AHSV-5 VP7 monomer (37 kDa), AHSV-
5 VP7 trimer (135 kDa) and SHUV dimer (50 kDa). Mw: NEB molecular weight marker (sizes 
displayed in kDa). Lane numbers displayed below the image. 
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 RNA-seq Transcriptome Profiling 
3.3.4.1 RNA extraction & integrity analysis 
28 days after the booster inoculation, guinea-pigs were exsanguinated, and spleens 
removed. Whole RNA was isolated from stabilised spleen tissue as per (3.2.6.1). 
Resultant RNA concentrations as determined by NanoDrop (3.2.6.1) ranged from 
348.1-672.2 ng/µl before transportation to Omega Bio-tek (Georgia, USA) (Table 3.3). 
260/280 ratios ranged from 2.09 to 2.13 indicated high levels of RNA purity and very 
low levels of protein and phenol contamination. However, 260/230 ratios ranged from 
1.24 to 2.08 (Table 3.3), these low values are likely to indicate the presence of 
guanidine salt which absorbs at 230 nm and is included in the RNeasy Mini Kit lysis 
buffer.  
Table 3.3: RNA concentration and purity for spleen derived guinea-pig samples as 
determined by NanoDrop. Control (C1-5) and experimental (X1-5) samples indicated. RNA 
purity assessed by 260/280 and 260/230 ratios which indicate protein and guanidine 
contamination respectively if ≤ 2.0. 
RNA Sample Concentration (ng/µl) 260/280 260/230 
C1 672.2 2.11 2.08 
C2 616.1 2.13 2.07 
C3 354.4 2.12 1.68 
C4 348.1 2.11 1.74 
C5 437.8 2.09 1.74 
X1 369.3 2.10 1.48 
X2 585.7 2.12 1.24 
X3 437.4 2.09 1.92 
X4 634.2 2.12 2.02 
X5 466.8 2.08 2.01 
 
Figure 3.8 shows the RNA quality of samples as assessed by 1% agarose gel 
electrophoresis, performed as per 3.2.6.1. Levels of ribosomal RNA 28S and 18S were 
used as a proxy to determine the quality of total RNA extracted. 28S and 18S bands 
seemed strong however the levels of 28S were similar to that of the 18S band. 28S 
levels should be twice as high as 18S and therefore a high 28S/18S ratio indicates 
that purified RNA is intact. However, this observation may be as a result of using a 
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simple 1% agarose gel as opposed to the inclusion of formaldehyde. A denaturing 
agent such as formaldehyde ensures that RNA remains single-stranded and separates 
accurately during gel electrophoresis. Additionally, RNA does not incorporate EtBr as 
well as DNA and this may skew observations. 
 
Figure 3.8: Agarose gel electrophoresis to assess RNA quality. 1% agarose gel including 
3 µl EtBr electrophoresed at 60 volts for approximately 1.5 h. 2 µg of whole RNA loaded in 
lanes 1-10. C1-5: Spleen derived RNA from control guinea-pigs, X1-5: Spleen derived RNA 
from experimental guinea-pigs, Mw:  O’GeneRuler™1 kb DNA ladder. Arrows indicate 28S 
(5 kb) and 18S (1.9 kb) ribosomal RNA (rRNA) bands. 
Once received by Omega Bio-tek (Georgia, USA), a further assessment of RNA quality 
was performed using an Agilent 2200 TapeStation Bioanalyser. Figure 3.9 displays 
RNA integrity as assessed by the Agilent Bioanalyser. The overall quality of RNA 
seemed high with RINe values greater than 7.2. The RIN algorithm takes into account 
various electrophoretic RNA measurements as recorded by a bioanalyzer to compute 
RIN scores. The most significant of these being the 28S/18S ratio and analysis of the 
‘fast region’ (area between 18S and 5S rRNA) which signifies RNA degradation 
(Schroeder et al. 2006). Due to high RINe results, samples were considered ready for 
mRNA library preparation and RNA sequencing. Additionally, the Agilent 2200 
TapeStation System (Agilent, California, USA) revealed between 5.91 µg to 21.68 µg 
of total RNA in our samples. 
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Figure 3.9: RNA quality as assessed by the Agilent 2200 TapeStation and RNA Screen 
Tape. C1-5: Spleen derived RNA from control guinea-pigs, X1-5: Spleen derived RNA from 
experimental guinea-pigs, Mw: RNA molecular weight marker. Arrows indicate 28S (5 kb) and 
18S (1.9 kb) ribosomal RNA (rRNA) bands. RINe values indicate the integrity of RNA. 
3.3.4.2 RNA sequencing & bioinformatics 
The mRNA library was prepared from spleen-derived total RNA by Omega Bio-tek 
(Georgia, USA) as per (3.2.6.2). Ten RNA-seq transcriptome datasets, five 
experimental (X1-5) and five control (C1-5), were produced from the mRNA library. 
These datasets consisted of between 20.21 to 53.54 million 150 bp paired-end reads 
(Table 3.4) after low quality bases and reads had been removed.  
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Table 3.4: Total number of reads/transcripts and % of total reads which aligned to the 
reference genome. Control (C1-5) and experimental (X1-5) samples indicated. 
Samples 
Total number of reads 
(after trimming) 




C1 35.74 x 106 78.50% 
C2 34.31 x 106 77.39% 
C3 40.00 x 106 83.68% 
C4 20.21 x 106 80.70% 
C5 49.36 x 106 73.52% 
Experimental 
Guinea-Pigs 
X1 40.89 x 106 82.15% 
X2 37.27 x 106 84.00% 
X3 52.15 x 106 82.45% 
X4 53.54 x 106 82.56% 
X5 43.84 x 106 80.02% 
 
DESeq2 results revealed an annotated gene count of 26 855 prior to normalisation 
and transformation (Table 3.5). Gene annotation was performed by GENCODE. 
Sequencing depth normalisation and log2 transformation was performed on all 
datasets, resulting in an assessed gene count of 7213. The assessed gene count 
(7213) was tested for statistical significance and of these 350 genes were found to be 
significantly differentially expressed (DE) when compared to the control (FDR 
corrected p-value (q-value) ≤0.05) (Table 3.5). Explanation of q-value in 3.2.6.2. 
Table 3.5: Gene count assessment. Annotation gene count = no. of genes annotated, 
Assessed gene count = no. of genes tested for statistical significance, Differentially expressed 
(DE) gene count = no. of significantly DE genes (q≤0.05), DE immune response gene count = 





DE Gene Count 
(q≤0.05) 
DE Immune Response 
Gene Count 
26 855 7 213 350 30 
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3.3.4.3 Analysis of global immune response to AHSV-5 quasi-crystals 
Of the 350 significantly DE genes (q≤0.05) only 30 of these correlated with genes from 
18 of the 22 KEGG and Reactome immune pathways as shown by Table 3.6. and the 
heatmap in Figure 3.10. 
Table 3.6: Significantly (q≤0.05) DE immune response genes and related pathways and 
molecular function.  Immune pathways accessed via KEGG and Reactome Pathway 
databases. And molecular function accessed via KEGG and String database. Gene 




Molecular Function from KEGG 
(https://www.genome.jp/kegg/pathway.html) & 
String (https://string-db.org) 
Innate Immune Response Pathways 
Chemokine 
Signalling Pathway 
Prkcz Protein kinase C, zeta 
Stat2 Signal transducer and activator of transcription 2 
Grk2 G protein-coupled receptor kinase 2 
Cx3cr1 
Chemokine (C-X3-C motif) receptor 1; Belongs to 
the G-protein coupled receptor 1 family 
Natural Killer Cell –
Mediated Cytotoxicity 
Fcer1g  
Fc fragment of IgE receptor Ig; High affinity 
immunoglobulin epsilon receptor subunit gamma; 
Associates with a variety of FcR alpha chains to 
form a functional signalling complex. Regulates 
several aspects of the immune response. The 
gamma subunit has a critical role in allowing the 




Stat2 Signal transducer and activator of transcription 2 
Bcl3 B-cell CLL/lymphoma 3, transcription coactivator 
Fcer1g  
Fc fragment of IgE receptor 1g; High affinity 
immunoglobulin epsilon receptor subunit gamma; 
Associates with a variety of FcR alpha chains to 
form a functional signalling complex. Regulates 
several aspects of the immune response. The 
gamma subunit has a critical role in allowing the 





Matrix metallopeptidase 2; Belongs to the 
peptidase M10A family 
Limk1 LIM domain kinase 1 
____________________________________________________________________________________________________




Wasf2 WAS protein family, member 2 




Heat shock protein 90kDa alpha (cytosolic), class 
A member 1 
Nampt Nicotinamide phosphoribosyltransferase 
Stat2 Signal transducer and activator of transcription 2 
Vdac1 Voltage dependent anion channel 1 
Complement and 
Coagulation Cascade 
C1s Complement component 1, s subcomponent 
C1qa Complement C1q subcomponent subunit A 
Platelet Activation 
Vamp8 Vesicle associated membrane protein 8 
Col3a1 Collagen type III alpha 1 chain 
Prkcz Protein kinase C zeta 
Fcer1g 
Fc fragment of IgE receptor Ig; High affinity 
immunoglobulin epsilon receptor subunit gamma; 
Associates with a variety of FcR alpha chains to 
form a functional signalling complex. Regulates 
several aspects of the immune response. The 
gamma subunit has a critical role in allowing the 
IgE Fc receptor to reach the cell surface. Also 
involved in collagen-mediated platelet activation 
and in neutrophil activation mediated by integrin 
Adaptive (Cell-Mediated) Immune Response Pathways 
T-Cell Receptor 
Signalling Pathway 
Nck2  NCK adaptor protein 2 gene 
TH1 & 2 Cell 
Differentiation 
Notch2  Neurogenic locus notch homolog protein 2 




Scavenger receptor class B, member 1; Belongs 




Heat shock protein 90kDa alpha (cytosolic), class 
A member 1 
Smad4  
Mothers against decapentaplegic homolog; SMAD 
family member 4 




Heat shock protein 90kDa alpha (cytosolic), class 
A member 1 
Usp25 
Ubiquitin specific peptidase 25; Belongs to the 
peptidase C19 family 
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Il17ra Interleukin 17 receptor A 
Antigen Processing & 
Presentation 
Hsp90aa1 
Heat shock protein 90kDa alpha (cytosolic), class 
A member 1 
Pathways involved in both Innate and Adaptive Immune Responses 
Cytokine-Cytokine 
Receptor Interaction 
Il17ra Interleukin 17 receptor A 
Cx3cr1 
Chemokine (C-X3-C motif) receptor 1; Belongs to 
the G-protein coupled receptor 1 family 
Ifnlr1 Interferon, lambda receptor 1 
Tnfsf14 





REL proto-oncogene, NF-kB subunit; V-rel avian 




Protein kinase D3; Belongs to the protein kinase 
superfamily. CAMK Ser/Thr protein kinase family 
Arap3 
Arf-GAP with Rho-GAP domain, ankyrin repeat 
and PH domain-containing protein 3  
Prkcz Protein kinase C zeta 
Jak-Stat Pathway 
Stat2 Signal transducer and activator of transcription 2 
Pim1 Pim-1 proto-oncogene, serine/threonine kinase 
Ifnlr1 Interferon, lambda receptor 1 
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Figure 3.10: Heatmap displaying 30 significantly DE genes involved in immune 
pathways. Gene pathways accessed via KEGG and Reactome pathway databases. Gene 
names/ symbols displayed on the y axis. Colour bar signifies the regularised and 
log2transformed gene transcript count. Guinea pig control (C1-5) and experimental (X1-5) 
samples displayed below the x axis. Significant DE determined by q-value ≤ 0.05.  
The 30 significantly DE genes (q≤0.05) were found to be involved in 18 global immune 
response pathways shown in Table 3.6. With respect to genes involved in innate 
immunity, 17 genes were found to be significantly differentially expressed in these 
pathways. 8 genes were found to be involved in adaptive, cell-mediated responses, 
and 10 of the 30 significantly DE genes were found to play a role in pathways relating 
to both innate and adaptive immunity (Table 3.6).  
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Interestingly, no significantly DE genes were highlighted in the B-cell receptor 
signalling pathway and in the innate pattern recognition receptor pathways: Toll-like 
receptor signalling, RIG-I-like receptor signalling and Cytosolic DNA-sensing pathway. 
3.3.4.4 Analysis of innate immune pathways which trigger adaptive 
responses 
Chemokines play a pivotal role in cell trafficking and aid in inflammatory immune 
responses. They are part of innate immunity and assist in triggering adaptive immune 
responses. The heatmap represented in Figure 3.11 demonstrates the expression of 
genes involved in the chemokine signalling pathway across all control and 
experimental samples. A significant increase (q≤0.05) in expression of Grk2 (G 
protein-coupled receptor (GPCR) kinase 2), Cx3cr1 (C-X3-C motif chemokine receptor 
1), Stat2 (Signal transducer and activator of transcription 2) and Prkcz (Protein kinase 
C zeta) was observed. Additionally, an increase in expression of Grk5 (GPCR kinase 
5), Cx3cl1 (C-X3-C motif chemokine), Ccr9 (C-C motif chemokine receptor 9), Pik3R5 
(phosphoinositide-3-kinase regulatory subunit 5) and Raf1 (B-Raf proto-oncogene 
serine/threonine-protein kinase) in at least four of the experimental samples was 
noted, however this was not found to be significant. 
Chemokines regulate many biological processes such as cell growth, differentiation 
and apoptosis. After chemokine receptor (Cx3cr1 and Ccr9) activation, the signal is 
transduced by GPCRs (Grk2 and Grk5) expressed on immune cells, and the G protein 
subunits dissociate to activate various downstream pathways. The GPCR beta subunit 
then activates various protein kinases (Pik3R5, Prkcz and Raf1) which consequently 
activate MapK1/3 (mitogen-activated protein kinase 1/3) triggering cytokine 
production, cell growth, differentiation, migration and apoptosis (Kanehisa and Goto 
2000). 
Additionally, chemokine receptor (Cx3cr1 and Ccr9) stimulation activates the Jak-
STAT signalling pathway (Stat2) which results in the same cellular processes and 
cytokine production as mentioned above ((Kanehisa and Goto 2000). 
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Figure 3.11: Heatmap displaying gene expression in the chemokine signalling pathway. 
Gene pathway accessed via KEGG pathway database. Red asterisks indicate significantly DE 
genes, q-value ≤ 0.05. Green asterisks indicate differential expression observed but not 
significant. Gene names/ symbols displayed on the y axis. Colour bar signifies the regularised 
and log2transformed gene transcript count. Guinea pig control (C1-5) and experimental (X1-
5) sample ID displayed below the x axis.  
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Natural killer (NK) cells are involved in early innate defence responses to pathogens, 
however under many circumstances T helper cells further stimulate the production of 
NK cells. The heatmap in Figure 3.12 shows expression levels of genes involved in 
NK cell-mediated cytotoxicity. A significant (q≤0.05) increase was found in the 
expression of Fcer1g (Fc fragment of IgE receptor Ig). Additionally, an increase in 
expression of Lck (lymphocyte cell-specific protein tyrosine kinase), Raf1 (B-Raf proto-
oncogene serine/threonine-protein kinase), Itgal (integrin subunit alpha L), Rac2 (Ras-
related C3 botulinum toxin substrate 2 - small GTP binding protein) and Ifngr1 
(interferon gamma receptor 1) was observed in at least four of the experimental 
samples when compared to the controls. However, this observation was not found to 
be significant (q≥0.05). 
Various NK cell surface receptors exist and bind ligands on the target cell’s surface 
triggering NK cell-mediated cytotoxicity. NKP46 is one of these receptors which after 
activation triggers the adapter protein FCER1g. This adapter protein then transduces 
the signal and results in signalling cascades which include the activation of protein 
kinases, Raf1 and Rac2. This leads to the release of cytokines, in particular Ifgn 
(Interferon gamma), which then binds to its receptor (Ifngr1) on the target cell and 
activates Fas (Cell surface death receptor) initiating apoptosis (Kanehisa and Goto 
2000).  
Additionally, Itgal and Itgb2 (integrin subunit beta 2) form the integrin, lymphocyte 
function-associated antigen-1, expressed on NK cells. After infection, this integrin 
interacts with the target cell surface ligand, Icam1/2, indirectly activating Rac2. And as 
mentioned in the previous pathway, this also leads to apoptosis of the target cell via 
the interferon gamma receptor 1 and Fas activation (Kanehisa and Goto 2000). 
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Figure 3.12: Heatmap displaying gene expression in the natural killer cell-mediated 
cytotoxicity pathway. Gene pathway accessed via KEGG pathway database. Red asterisk 
indicates significantly DE genes, q-value ≤ 0.05. Green asterisk indicates differential 
expression observed but not significant. Gene names/ symbols displayed on the y axis. Colour 
bar signifies the regularised and log2transformed gene transcript count. Guinea pig control 
(C1-5) and experimental (X1-5) sample ID displayed below the x axis. 
C-type lectin receptors (CLRs) are a large superfamily of proteins. They are pattern-
recognition receptors on macrophages, neutrophils and dendric cells which recognise 
ligands originating from pathogens. The binding of a ligand to CLR stimulates a 
signalling cascade which ultimately results in the production of inflammatory cytokines 
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and chemokines which trigger innate and adaptive immune responses (Kanehisa and 
Goto 2000). Figure 3.13 shows a heatmap demonstrating expression of genes 
relating to the CLR signalling pathway. A significant (q≤0.05) decrease in Bcl3 (B-cell 
CLL/lymphoma 3) and an increase in Fcer1g and Stat2 (Signal transducer and 
activator of transcription 2) were observed. Furthermore, an increase in Rela (RELA 
proto-oncogene, NF-kB subunit), Calm3 (calmodulin 3), Prkcd (protein kinase C delta), 
Nfkb2 (nuclear factor kappa B subunit 2) and Ikbke (inhibitor of nuclear factor kappa 
B kinase subunit epsilon) expression was observed in at least four of the experimental 
samples. 
By different signalling cascades, the Ig receptor FCER1G, the calcium-binding 
messenger protein CALM3, the protein kinase encoded by Prkcd, and the transcription 
factors Nfkb2 and Rela are involved in activating transcription of various interleukins 
(IL-1b, IL-6, IL-10, IL-12b and IL-23a) which participate in Th1 (cell-mediated) and 
Th17 cell differentiation. Additionally, the protein kinase and transcription activator 
encoded by Ikbke and Stat2 respectively are involved in T follicular helper (Tfh) cell 
differentiation. In the nucleus Bcl3 is a transcription activator and is a co-regulator of 
cell proliferation (Massoumi et al. 2006). In the CLR signalling pathway, Bcl3 is part of 
Th2 cell differentiation (humoral response) and therefore downregulation of Bcl3 could 
indicate a decrease in Th2 cell differentiation (Kanehisa and Goto 2000). 
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Figure 3.13: Heatmap displaying gene expression in C-type lectin receptor signalling 
pathway. Gene pathway accessed via KEGG pathway database. Red asterisk indicates 
significantly DE genes, q-value ≤ 0.05. Green asterisk indicates differential expression 
observed but not significant. Gene names/ symbols displayed on the y axis. Colour bar 
signifies the regularised and log2transformed gene transcript count. Guinea pig control (C1-
5) and experimental (X1-5) sample ID displayed below the x axis. 
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3.3.4.5 Analysis of cell-mediated immune response to AHSV-5 VP7 quasi-
crystals 
When T-cell receptors encounter foreign antigens associated with major 
histocompatibility complexes (MHCs) and costimulatory molecules such as CD28, a 
series of signalling cascades occur leading to proliferation of T-cells, production of 
cytokines and cell-differentiation in effector T-helper (Th) or cytotoxic T-cells (CTLs). 
Figure 3.14 displays a heatmap representing the expression of genes involved in the 
T-cell receptor signalling pathway. A significant increase (q≤0.05) in Nck2 (NCK 
adaptor protein 2 gene) expression was observed and a notable difference in Nck1 
(NCK adaptor protein 1 gene) expression in four of the experimental samples. Nck2 
and Nck1 are involved in the positive regulation of T-cell proliferation. And by 
associating with Lcp2 (lymphocyte cytosolic protein 2) and activating the protein 
kinase, PAK (p21 (RAC1) activated kinase) these adaptor proteins play an important 
role in actin filament reorganisation (Kanehisa and Goto 2000). 
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Figure 3.14: Heatmap displaying gene expression in the T-cell receptor signalling 
pathway. Gene pathway accessed via KEGG pathway database. Red asterisk indicates 
significantly DE genes, q-value ≤ 0.05. Green asterisk indicates differential expression 
observed but not significant. Gene names/ symbols displayed on the y axis. Colour bar 
signifies the regularised and log2transformed gene transcript count. Guinea pig control (C1-
5) and experimental (X1-5) sample ID displayed below the x axis. 
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Effector T helper (Th) cells (Th1, Th2 and Th17) originate from naive CD4 T-cells in 
response to antigen presenting cell (APC) signals from MHCII. The heatmap 
represented in Figure 3.15 shows the regularised and log transformed mRNA 
transcript counts/ expression levels of genes involved in Th1 and Th2 cell 
differentiation. A significant (q≤0.05) increase in the expression of Notch2 (Neurogenic 
locus notch homolog protein 2) was observed, Additionally, an increase in expression 
of the interleukin and interferon receptors genes, Il2rb (interleukin 2 receptor subunit 
beta) and Ifngr1 (interferon gamma receptor 1), was evident in four of the experimental 
guinea-pigs when compared to the controls. In response to foreign antigens, both the 
notch 2 protein and the interleukin 2 receptor lead to the production of interleukins 
such as IL-2, IL-4, IL-5 and IL-13 driving Th2 cell differentiation and therefore humoral 
immunity. Whilst, the interferon gamma receptor activates the Jak(1/2)-STAT1 
pathway which drives the production of IFN-gamma and cell differentiation into Th1 
cells, stimulating strong cell-mediated immune responses (Kanehisa and Goto 2000).  
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Figure 3.15: Heatmap displaying gene expression in the Th1 and Th2 cell differentiation 
pathway. Gene pathway accessed via KEGG pathway database. Red asterisk indicates 
significantly DE genes, q-value ≤ 0.05. Green asterisk indicates differential expression 
observed but not significant. Gene names/ symbols displayed on the y axis. Colour bar 
signifies the regularised and log2transformed gene transcript count. Guinea pig control (C1-
5) and experimental (X1-5) sample ID displayed below the x axis. 
Th17 cells originate from CD4 T cells and are involved in innate and cell-mediated 
immune responses. Previous studies have suggested a Th17 role in immunity to 
AHSV (Pretorius, 2016). The heatmap represented in Figure 3.16 shows the 
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expression levels of genes involved in Th17 cell differentiation. A significant (q≤0.05) 
decrease in Smad4 (SMAD family member 4) expression was found, and a significant 
increase in expression was evident for Hsp90aa1 (Heat shock protein 90 alpha family 
class A member 1) and Rara (Retinoic acid receptor alpha).  
Activation of the SMAD4 transcription factor is dependent on concentrations of TGF-β, 
high concentration of TGF-β have been shown to inhibit IL-17 production while low 
concentrations stimulate IL-17 production (Hahn et al. 2011; Kanehisa and Goto 
2000). Therefore, low expression levels of SMAD4 are likely to stimulate cell 
differentiation into Th17 cells. Furthermore, the aryl hydrocarbon receptor (Ahr) 
associates with the molecular chaperone HSP90 (Hsp90aa1) and has been shown to 
induce the production of cytokines IL-17, IL-21 and IL-22 (Ehrlich et al. 2018; Tsuji et 
al. 2014).  Therefore, upregulation of Hsp90aa1 also suggests cell differentiation into 
Th17 cells.  
In contrast, an increase in retinoid acid, as suggested by upregulation of Rara, in 
combination with the cytokines interleukin-2 and TGF-β upregulates Foxp3 which 
inhibits Th17 cell differentiation (Kanehisa and Goto 2000).  
____________________________________________________________________________________________________
Shelley Helen Fearon Student No: SMTSHE005 Page 134 
 
Figure 3.16: Heatmap displaying gene expression in Th17 cell differentiation. Gene 
pathway accessed via KEGG pathway database. Red asterisk indicates significantly DE 
genes, q-value ≤ 0.05. Green asterisk indicates differential expression observed but not 
significant. Gene names/ symbols displayed on the y axis. Colour bar signifies the regularised 
and log2transformed gene transcript count. Guinea pig control (C1-5) and experimental (X1-
5) sample ID displayed below the x axis. 
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When considering the IL-17 signalling pathway in Figure 3.17, a significant increase 
in Hsp90aa1, Il17ra (Interleukin 17 receptor A) and Usp25 (Ubiquitin specific peptidase 
25) were observed. The IL-17A cytokine is produced by CD4-, CD8- and NK T cells 
and plays an important role in proinflammatory responses, recruitment of B cells and 
NK cells. After IL-17A receptor activation results in the association of the adaptor 
molecule Act1 and HSP90 and interaction is critical for IL-17-mediated activation of 
pro-inflammatory cytokines, chemokines and antimicrobial peptides. Therefore, 
upregulation of Il17ra and Hsp90aa1 suggests IL-17 signal activation. However, the 
deubiquitinase USP25 has been shown to supress IL-17A signalling and 
downregulation of Usp25 therefore suggests the converse to be true (Kanehisa and 
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Figure 3.17: Heatmap displaying gene expression in IL-17 signalling pathway. Gene 
pathway accessed via KEGG pathway database. Red asterisk indicates significantly DE 
genes, q-value ≤ 0.05. Green asterisk indicates differential expression observed but not 
significant. Gene names/ symbols displayed on the y axis. Colour bar signifies the regularised 
and log2transformed gene transcript count. Guinea pig control (C1-5) and experimental (X1-
5) sample ID displayed below the x axis. 
Figure 3.18 and Figure 3.19 show a significant increase (q≤0.05) in Scarb1 
(Scavenger receptor class B member 1) and Hsp90aa1 gene expression respectively. 
The pattern recognition receptor SCARB1 and molecular chaperone HSP90 are both 
involved in MHC-1 antigen processing and presentation. SCARB1 mediates binding 
and uptake of peptides into macrophages, and HSP90 chaperones cytosolic peptides 
for MHC-I antigen presentation to CD8 T cells thereby playing an important role in cell-
mediated immunity (Binder et al. 2001; Fabregat et al. 2018; Kanehisa and Goto 
2000).  
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Figure 3.18: Heatmap displaying gene expression in the Class 1 MHC Antigen 
Processing and Presentation. Gene pathway accessed via Reactome pathway database. 
Red asterisk indicates significantly DE genes, q-value ≤ 0.05. Green asterisk indicates 
differential expression observed but not significant. Gene names/ symbols displayed on the y 
axis. Colour bar signifies the regularised and log2transformed gene transcript count. Guinea 
pig control (C1-5) and experimental (X1-5) sample ID displayed below the x axis. 
 
Figure 3.19: Heatmap displaying gene expression in antigen processing and 
presentation. Gene pathway accessed via KEGG pathway database. Red asterisk indicates 
significantly DE genes, q-value ≤ 0.05. Green asterisk indicates differential expression 
observed but not significant. Gene names/ symbols displayed on the y axis. Colour bar 
signifies the regularised and log2transformed gene transcript count. Guinea pig control (C1-
5) and experimental (X1-5) sample ID displayed below the x axis. 
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Cytokines are signalling molecules which regulate cells involved in innate and adaptive 
immune responses. After activation, cytokines are released from various cells and 
induce responses by binding specific cell surface receptors. The heatmap presented 
in Figure 3.20 demonstrates gene expression levels of cytokines and their specific 
receptors. Three cytokine receptor genes were found to be significantly (q≤0.05) 
upregulated, Ifnlr1 (Interferon, lambda receptor 1), Cx3cr1 and Il17ra, and the ligand 
Tnfsf14 (Tumour necrosis factor (ligand) superfamily, member 14). As mentioned 
before, the transmembrane receptor protein encoded by Il17ra, is part of the IL-17 
signalling pathway and is activated by the IL-17A cytokine produced by CD4-, CD8- 
and NK T cells. The chemoattractant encoded by Cx3cr1 was highlighted in the 
chemokine signalling pathway and has been shown to have a role in activating CTLs 
and NK cells (Pretorius, 2016). The interferon lambda receptor encoded by Ifnlr1 has 
been shown to play an important role in antiviral defences (Pott et al. 2011). The 
tumour necrosis factor ligand, TNFSF14, has been shown to stimulate T cell 
proliferation and interferon gamma (IFNG) production after binding to receptor 
TNFRSF14 (Tamada et al. 2000).  
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Figure 3.20: Heatmap displaying gene expression in cytokine-cytokine receptor 
interactions. Gene pathway accessed via KEGG pathway database. Red asterisk indicates 
significantly DE genes, q-value ≤ 0.05. Green asterisk indicates differential expression 
observed but not significant. Gene names/ symbols displayed on the y axis. Colour bar 
signifies the regularised and log2transformed gene transcript count. Guinea pig control (C1-
5) and experimental (X1-5) sample ID displayed below the x axis. 
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3.4 Discussion 
In order to test the viability of an AHSV-5 VP7 quasi-crystal vaccine we examined its 
stability over a 28-week period at 4C, -20C and -80C. Western immunoblots and 
Coomassie staining revealed that AHSV-5 VP7 is a highly stable protein at 4C, -20C 
and -80C (Figure 3.4). Quasi-crystals on the other hand were more stable at -20C 
and -80C over the 28-week period (Table 3.2). No crystals were observed in samples 
stored at 4C after 8 weeks. Quasi-crystals seemed to increase in size over time at 
both -20C and -80C. This is an important consideration as vaccines are often stored 
over long periods of time and changes in particulate size may impact their efficacy. 
Particularly, since efficient APC processing and presentation depends on the size of 
the particulate (Bachmann and Jennings 2010; Manolova et al. 2008; Snapper 2018; 
Vidard et al. 1996). However, the largest plant-produced crystal sizes observed in this 
study were below 1 µm and therefore well below the maximum of 5 µm for efficient 
macrophage phagocytosis and display (Foged et al. 2005; Hirota and Ter 2012; Yue 
et al. 2010). 
To thoroughly test the immunogenicity of an AHSV candidate vaccine the global 
immune response of the vaccine in relation to natural infection needs to be considered. 
Whilst the humoral response to AHSV has been well studied very little investigation 
has gone into cellular immunity. However, cell-mediated responses have been shown 
to play an important role in response to AHSV infection (Guthrie et al. 2009; Martinez-
Torrecuadrada et al. 1996; Pretorius et al. 2016; Wade-Evans et al. 1997). In order to 
investigate the immunogenicity of plant-produced AHSV VP7 quasi-crystals we tested 
both the humoral and cell-mediated response by western immunoblotting and 
transcriptome analyses.  
Guinea-pig immunogenicity studies of AHSV-5 VP7 were carried out over a 41-day 
period. Guinea-pigs were injected with experimental (X1-5) or control (C1-5) inocula 
on day 0 and the booster was received on day 13 (3.2.3). Experimental inocula 
concentrations were 35.13 µg and 26.87 µg for the primary and booster respectively. 
After performing SNTs using the extracted anti-AHSV-5 VP7 guinea-pig sera, sera 
demonstrated no neutralising capability (3.3.3). This was not surprising as various 
studies have shown that VP7 does not possess antigenic sites which induce 
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neutralising antibodies. AHSV VP2 is the major target for neutralising antibodies 
(Alberca et al. 2014; Bailey 2016; Kanai et al. 2014). 
Western immunoblotting revealed that AHSV-5 VP7 quasi-crystals were highly 
immunogenic and stimulated a strong humoral response. At a dilution of 1:50 000, the 
anti-AHSV-5 VP7 final-bleed (X2) serum detected 0.77 µg AHSV VP7 protein. This 
detected VP7 at the same level as the positive control (anti-AHSV-5 VLPs) which was 
used at a 10-fold lower dilution of 1:5000 (Figure 3.5). Non-specific binding was still 
detected at 1:50 000 dilution. This premise was based on the fact that the control final-
bleed (C2) serum still detected AHSV-5 VP7 and moreover, the anti-AHSV-5 VP7 
final-bleed (X2) serum detected 0.77 µg SHUV protein (Figure 3.5). The pre-
absorption technique (Figure 3.6) was then used in an attempt to extract 
N. benthamiana host-specific antibodies and increase specificity of the sera. However, 
even at 1:100 000 dilution the final-bleed control (C1, C3 and C4) sera still lightly 
detected AHSV-5 VP7 at a similar level to the final-bleed experimental sera X3 
(Figure 3.7). This indicates that AHSV-5 VP7 quasi-crystals did not stimulate an 
AHSV-5 VP7 specific humoral response in guinea-pigs X3 and X5. However, a very 
strong humoral response is indicated in guinea-pigs X1, X2 and X4 shown by the 
strong bands observed when using the sera to probe for 0.53 µg AHSV-5 VP7 at a 
1:100 000 dilution. 
To assess the cell-mediated immune response, spleen-derived guinea-pig mRNA was 
isolated and deep RNA sequencing performed to assess the transcriptome of guinea-
pigs vaccinated with AHSV-5 VP7 quasi-crystals. After whole RNA extraction, 
concentrations and integrity were considered satisfactory to continue with library 
construction and sequencing after NanoDrop assessment (Table 3.3), agarose gel 
electrophoresis (Figure 3.8) and analysis via the Agilent Bioanalyser with RIN ͤ scores 
of between 7.2 to 8.4 (Figure 3.9). After RNA sequencing, ten datasets were 
assembled (five per group) and analysed by Omega Bio-Tek using Illumina Basespace 
and the Deseq2 analysis tool (3.2.6.2). Between 37.27 and 53.54 million reads were 
obtained for the experimental sample datasets and between 20.21 and 49.36 million 
reads for the control group after trimming off low quality reads. Coverage of the 
reference genome was relatively high ranging from between 73.52 to 84.00%. DEseq2 
results revealed 350 significantly differentially expressed genes (q≤0.05) and 
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unfortunately only 8.6% (30 genes) of these correlated with the global immune 
response involving eighteen immune related pathways (Figure 3.10 and Table 3.6).  
Significantly differentially expressed genes were identified in both innate and adaptive 
immune response pathways. Of these, seventeen were involved in innate immunity 
(Table 3.6). These pathways included those relating to the inflammatory immune 
response such as chemokine signalling and leukocyte transendothelial migration. And 
pathways connected to recognition and destruction of pathogens, such as the NOD-
like receptor signalling pathway, FC gamma R-mediated phagocytosis, C-type lectin 
receptor signalling pathway, natural killer cell-mediated cytotoxicity and the 
complement and coagulation cascade. When focusing on the adaptive immune 
pathways, eight genes were found to be involved in cell-mediated responses (Table 
3.6). Namely T-cell receptor signalling, Th1, Th2 and Th17 cell differentiation, IL-17 
signalling and pathways relating to antigen processing and presentation. Additionally, 
ten of the 30 significantly DE genes were found to play a role in pathways related to 
both innate and adaptive immunity (Table 3.6). Namely cytokine-cytokine receptor 
interactions and signal transduction pathways: Ras, JAK-STAT and Rap1.  
Several important cytokines and associated receptors were found to be upregulated 
in experimental samples. The chemokine CX3CL1 was upregulated in three of the 
experimental samples and its receptor CX3CR1 was significantly upregulated 
(Figure 3.11). CX3CL1 is a strong chemoattractant to effector lymphocytes and its 
receptor CX3CR1 is expressed on CTLs and NK cells (Pretorius et al. 2016; Umehara 
et al. 2004). Pretorius et al. showed a decrease in chemokines such as CX3CL1 48 h 
after inoculation with AHSV-4, in contrast even 28 days after the AHSV-5 VP7 booster 
inoculation, CX3CR1 was still significantly upregulated. Additionally upregulation of 
the chemokine receptor CCR9, G protein-coupled receptor kinases GRK2 and GRK5, 
protein kinases PIK3R5, PRKCZ and RAF1, and the transcription activator STAT2, 
suggest activation of the chemokine signalling pathway and consequently cytokine 
production, cell differentiation, migration and apoptosis (Figure 3.11) (Kanehisa and 
Goto 2000).   
The interferon gamma receptor IFNGR1 was upregulated in four of the experimental 
samples (Figure 3.12 and Figure 3.15). IFNGR1 activates the Jak (1/2)-STAT1 
pathway and drives IFN-gamma production and cell differentiation into Th1 cells 
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inducing strong-cell mediated responses. IFNG is secreted by T-cells and NK cells 
and has been shown to have antiviral activity (Pretorius et al. 2016; Schroder et al. 
2004; Kanehisa and Goto 2000). The cytokine TNFSF14 (Tumour necrosis factor 
(ligand)) was also found to be significantly upregulated. TNFSF14 plays a role in 
activating T-cell proliferation and the production of IFNG after binding to is receptor 
TNFRSF14 (Figure 3.20) (Tamada et al. 2000). Furthermore, the interferon lambda 
receptor IFNLR1 was significantly upregulated in experimental samples. IFNLR1 and 
its cytokine IFNL1 have been shown to play an important role in antiviral defences 
(Figure 3.20) (Pott et al. 2011).  
Along with IFNGR1, various components regulating NK cell-mediated cytotoxicity 
were found to be upregulated including the adapter protein FCER1G, protein kinases 
LCK, RAF1 and RAC2 and the integrin ITGAL (Figure 3.12). Activation of NK 
cytotoxicity activates the cell surface death receptor FAS which binds to ligands on the 
target cell’s surface and leads to target cell apoptosis. Additionally, NK cells regulate 
the differentiation of CD4 T-cells (Kanehisa and Goto 2000; Pallmer and Oxenius 
2016).  
Evidence of Th1 and Th17 immune responses was observed. Various genes involved 
in activating Th1 and Th17 cell differentiation via the C-type lectin receptor (CLRs) 
signalling pathway were found to be upregulated including FCER1G, the calcium-
binding messenger protein CALM3, the protein kinase PRKCD and the transcription 
factors NFKB2 and RELA (Figure 3.13) (Kanehisa and Goto 2000). Furthermore a 
significant decrease in expression of the transcription factor BCL3, a co-regulator of 
T-cell proliferation and Th2 cell differentiation, suggests downregulation of Th2 cell 
differentiation and therefore humoral immunity (Figure 3.13) (Kanehisa and Goto 
2000; Massoumi et al. 2006). In contrast, upregulation of NOTCH2 and the interleukin 
receptor IL-2RB suggest activation of Th2 cell differentiation. The interleukin IL-2 
induces proliferation and differentiation of T-cells, B-cells, NK cells and CTL activation 
(Justiz Vaillant and Qurie 2019) (Figure 3.15). Furthermore, upregulation of the 
adaptor protein genes Nck2 and Nck1 in the T-cell receptor signalling pathway suggest 
the activation of T-cell proliferation (Figure 3.14) (Kanehisa and Goto 2000).  
A significant increase in the interleukin receptor IL-17RA suggests previous 
upregulation of the interleukin IL-17 produced by Th17 cells (Figure 3.17). Previous 
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studies have suggested that Th17 plays an important role in immunity to AHSV and a 
subgroup of CD8 T-cells have also been shown to produce IL-17 (Hamada et al. 2013; 
Pretorius et al. 2016). In addition, further studies have shown IL-17 to be crucial for 
recruiting B-cells, NK cells, macrophages and neutrophils to the site of infection and 
for viral clearance after RNA virus infection (Ryzhakov et al. 2011; Hamada et al. 
2013). A significant downregulation of the transcription factor SMAD4 further suggests 
that IL-17 production was stimulated (Figure 3.16). SMAD4 is dependent on 
concentrations of TGF-β, high concentration of TGF-β have been shown to inhibit 
IL-17 production while low concentrations TGF-β and therefore SMAD4 stimulate 
IL-17 production and cell differentiation into Th17 cells (Hahn et al. 2011; Kanehisa 
and Goto 2000). Significant upregulation of the molecular chaperone HSP90AA1 
concurs with an increase in Th17 cell differentiation (Figure 3.16). HSP90AA1 
associates with the aryl hydrocarbon receptor AHR and induces the production of 
cytokines IL-17 and IL-21 in the Th17 cell differentiation pathway (Ehrlich et al. 2018; 
Tsuji et al. 2014).  Furthermore, in the IL-17 signalling pathway, activation of the IL-17A 
receptor results in the association of the adaptor molecule Act1 and HSP90 
(Figure 3.17). This association is important for the IL-17-mediated activation of pro-
inflammatory cytokines, chemokines and antimicrobial peptides. Therefore, 
upregulation of Il17ra and Hsp90aa1 suggests IL-17 signal activation and reconfirms 
the Th17 response. However, in contrast, downregulation of the deubiquitinase USP25 
inhibits IL-17A signalling and therefore suggests downregulation of  the IL-17-
mediated activation of pro-inflammatory cytokines, chemokines and antimicrobial 
peptides (Figure 3.17) (Kanehisa and Goto 2000; Monin and Gaffen 2018; Song et al. 
2016). 
Furthermore, upregulation of the pattern recognition receptor SCARB1 and HSP90 
indicates an increase in MHC-1 antigen processing and presentation to CD8 T-cells 
(Figure 3.18 and Figure 3.19). SCARB1 plays a critical role in mediating binding and 
uptake of peptides into macrophages, and HSP90 is responsible for chaperoning 
cytosolic peptides for MHC-I antigen presentation to CD8 T cells thereby playing an 
important role in cell-mediated immunity (Binder et al. 2001; Fabregat et al. 2018; 
Kanehisa and Goto 2000).  
Moreover, whilst the experimental guinea-pigs X3 and X5 showed no evidence of a 
humoral response they did show differential expression (similar to that of X1, X2 and 
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X4) with regard to genes involved in cell-mediated responses. In fact, the chemokine 
gene Cx3cl1 and its receptor gene Cx3cr1 were highly upregulated in X3 and X5. And 
as mentioned before, this receptor and its chemokine play an important role in CTL 
and NK cell activation. 
Interestingly, no significantly differentially expressed genes were observed in the 
B-cell receptor signalling pathway, but this may be because the spleens were removed 
28 days post the booster inoculation. This may not be the most favourable time for 
observing upregulation of the B-cell receptor signalling pathway. Future experiments 
should therefore include an AHSV VP7 booster at least one week prior to guinea-pig 
euthanasia this is likely to enhance the immune transcriptome including humoral and 
cellular responses. 
In conclusion, western immunoblotting revealed a favourable humoral response to 
AHSV-5 VP7 quasi-crystals. Transcriptome analysis of the cell-mediated immune 
response demonstrated upregulation of some key cytokines and associated receptors 
involved in CTL responses such as CX3CL1 and CX3CR1 and Th1, Th2 and Th17 
immune responses. This was a preliminary study and was therefore beyond its scope 
to perform qPCR experiments to validate the RNA-seq results. Future studies should 
include qPCR validation and the booster inoculation should be adjusted to at least one 
week prior to exsanguination and spleen removal to enhance the immune 
transcriptome. Additionally, at the time of this study the Cavia porcellus genome was 
not available as a standard reference genome.  Because of this differentially 
expressed genes involved in the humoral and cellular immune response to AHSV-5 
VP7 may have been missed. Another animal model whose standard reference 
genome is available should therefore be considered for future studies, unless the 
Cavia porcellus reference genome is available. It would also be interesting to 
investigate the immune response to AHSV-5 VP7 crystals over various timepoints by 
transcriptome profiling of PBMCs. 
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CHAPTER 4: CONCLUSIONS 
Reoccurring international AHS outbreaks and the recent outbreaks in South Africa 
occurring in 2016 and 2019 emphasise the need for a safer, affordable and more 
reliable vaccine alternative for the prevention of AHS. The literature suggests that a 
particulate subunit vaccine (SUV) combined with a plant expression system provides 
an economically viable, safer, easily scalable and DIVA compliant alternative (Chen 
et al. 2013; Mir-Artigues et al. 2019; Rybicki 2019; Schillberg et al. 2019). AHSV-5 
VP7 is highly immunogenic, serogroup-specific and its quasi-crystal configuration aids 
in the repetition of immunologically important epitopes making it a good monovalent 
vaccine alternative to the commercially available polyvalent live-attenuated vaccine 
(Maree and Paweska 2005; Martinez-Torrecuadrada et al. 1996; Bailey 2016; Zientara 
et al. 2015. 
The main aim of this study was to develop plant-produced AHSV-5 VP7 quasi-crystals, 
and to test their immunogenicity. The objectives included: (1) Optimising the 
expression conditions for production of AHSV-5 VP7 in N. benthamiana; (2) 
Characterising and optimising the purification protocol for AHSV VP7 quasi-crystal 
production; and (3) Testing the specific humoral and cell-mediated immune response 
in guinea-pigs induced by immunisation of the VP7 quasi-crystals. Furthermore, the 
thermostability of AHSV VP7 quasi-crystals and in-situ crystal formation in 
N. benthamiana leaves was assessed. 
In order to produce adequate AHSV VP7 yields in N. benthamiana of high enough 
purity for guinea-pig immunogenicity studies, optimal conditions for its expression and 
an optimised purification protocol was needed. AHSV-5 VP7 was successfully 
expressed in N. benthamiana and quasi-crystals purified using a discontinuous density 
gradient. Yields of approximately 213.16 µg/ml and 2.66 µg/g FW yield were achieved 
and the purity of these samples was found to be qualitatively good as very few 
contaminants were observed. While VP7 trimers (135 kDa) were observed in western 
immunoblots they were not observed in Coomassie stained gels. In an immunoassay 
such as western blotting, particularly when using a polyclonal primary antibody, more 
antibodies could potentially bind the trimer structure as opposed to the linear monomer 
resulting in a strong trimer band. This therefore is not quantitative as it does not equate 
to higher levels of trimers but rather higher levels of antibody-protein binding. 
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Coomassie stained gels and quantification using gel densitometry are therefore 
considered more quantitative. However, the lack of trimer observation in Coomassie 
stained gels could also be as a result of reduced staining of trimers by Coomassie 
Brilliant Blue G-250 stain. If the latter is true, the reported yields may have been 
underestimated in this study.  
Western blot and Coomassie staining analyses revealed pRIC3.0 as the optimal 
expression vector, as use of this vector resulted in higher yields of AHSV VP7 protein 
when compared to pEAQ-HT. Furthermore, the optimal harvest day of 6 dpi increased 
maturation time resulting in an increase in AHSV-5 VP7 quasi-crystal formation. The 
buffer 0.2 M Tris-0.15 M NaCl, pH 8, proved to be a favourable buffer for promoting 
trimer-trimer interactions. And after low-speed differential centrifugation large amounts 
of AHSV-5 VP7 quasi-crystals seemed to reside preferentially in the pellet. This pellet 
was adequate for use in low-speed density gradient ultracentrifugation as a means of 
purifying AHSV-VP7 quasi-crystals. Moreover, the results demonstrated that high-
speed ultracentrifugation is likely to destroy AHSV VP7 quasi-crystals. The size 
distribution of AHSV-5 VP7 quasi-crystals produced in N. benthamiana seemed 
smaller (200-700 nm) than those reported in the literature (Burroughs et al. 1994; 
Chuma et al. 1992; Maree and Paweska 2005; Wall et al. 2017; Bailey 2016. And 
whilst they maintained the crystal lattice they formed uncharacteristic shapes in 
contrast to the commonly reported hexagonal crystals. This may be as a result of 
utilising plant expression systems. For the purposes of this study, this size range of 
crystals was satisfactory for APC presentation to the adaptive arm of the immune 
response as discussed in Chapter 3.  
Future studies should investigate more scalable alternatives to density gradient 
centrifugation for large-scale purification of AHSV VP7 quasi-crystals such as depth 
filtration and tangential flow cytometry (Dennis 2019). Furthermore, the purity of  these 
plant-produced quasi-crystals should be more quantitatively assessed by means of 
chromatography methods (i.e. affinity, gel permeation or reverse phase 
chromatography) or mass spectrometry (Rhodes and Laue 2009). 
In situ TEM was performed in order to affirm that AHSV-5 VP7 quasi-crystal assembly 
occurs within N. benthamiana leaf cells as opposed to during the extraction process. 
Unfortunately, no AHSV-5 VP7 quasi-crystals were observed in-situ. This experiment 
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would need to be repeated to confirm whether this is due to pH changes in the plant 
cell (Chapter 2), a technical error or whether quasi-crystals are in fact forming during 
the purification process due to an ideal physiological environment being created during 
the extraction process. The latter seems unlikely since large VP7 crystals were 
observed in plant crude extract approximately two hours after harvesting and before 
density gradient purification.  
To assess the validity of an AHSV VP7 candidate vaccine, the stability of VP7 quasi-
crystals was assessed over a 28-week period across a range of temperatures 
(4C, -20C and -80C). VP7 protein was found to be highly stable when assessed by 
western immunoblots and Coomassie staining. While quasi-crystals were more stable 
at -20C and -80C over the 28-week period. Crystals stored at 4C were not 
preserved after 8 weeks. In contrast, crystals stored at -20C and -80C increased in 
size over the 28-week period. This is a crucial consideration when considering protein 
crystals as candidate vaccines. As APC presentation is dramatically affected by 
particle size and changes in particulate size can therefore alter the efficacy of a 
vaccine (Bachmann and Jennings 2010; Manolova et al. 2008; Snapper 2018; Vidard 
et al. 1996). 
A vaccine stimulating both humoral and cell-mediated responses is likely to be 
preferential to one which solely induces neutralising antibodies (Guthrie et al. 2009; 
Martinez-Torrecuadrada et al. 1996; Wade-Evans et al. 1997; Pretorius et al. 2016). 
In order to test the immunogenicity of AHSV-5 VP7 quasi-crystals as a candidate 
vaccine, guinea-pig immunogenicity studies were successfully carried out over a 
41-day period and the humoral and cell-mediated immune responses to AHSV-5 VP7 
quasi-crystals were investigated. Western immunoblotting revealed that plant-
produced AHSV-5 crystals are highly immunogenic and stimulate a strong humoral 
response as a 1:100 000 dilution of anti-AHSV-5 VP7 serum in three of the 
experimental guinea-pigs detected 0.53 µg AHSV-5 VP7. These are encouraging 
results for a candidate vaccine and suggest that plant-produced AHSV VP7 quasi-
crystals may also be a good diagnostic reagent for ELISAs. Presently, VP7 based 
diagnostic tests are the OIE accepted method for AHSV diagnosis (Bekker et al. 2017; 
Zientara et al. 2015). A plant-production platform may therefore be a more economical 
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alternative compared to other eukaryotic cell culture production systems (Chen et al. 
2013; Rybicki 2009; Lomonossoff and D’Aoust 2016).  
With regard to the cell-mediated immune response to AHSV-5 VP7 quasi-crystals, 
transcriptome analysis of spleen-derived mRNA via RNA-seq revealed 350 
significantly differentially expressed genes (q≤0.05). Unfortunately, only 8.6% of these 
genes were associated with the global immune system making it difficult to highlight 
the exact immune pathways at play. However, it was noted that these genes were part 
of eighteen different innate and adaptive immune related pathways. Differential 
expression of genes involved in the T-cell receptor signalling pathway, T-helper (Th)1, 
Th2 and Th17 cell differentiation and IL17 signalling pathway suggest a cell-mediated 
immune response to AHSV-5 VP7 quasi-crystals. The upregulation of several key 
cytokines and associated receptors were evident in response to AHSV VP7 crystals 
i.e. TNFSF14, CX3CR1, IL17RA and IFNLR1, some of which play an important role in 
cytotoxic T-cell responses e.g. CX3CL1 and CX3CR1 (Burroughs et al. 1994; Chuma 
et al. 1992; Maree and Paweska 2005; Wall et al. 2017; Bailey 2016. Additionally, 
TNFSF14 activates T-cell proliferation, and IFNLR1 and its cytokine IFNL1 have been 
shown as key interferons in antiviral defences (Pott et al. 2011). IL-17RA suggests 
previous upregulation of the interleukin IL-17 produced by Th17 cells and Th17 cells 
are hypothesised to play an important part in AHSV immunity (Hamada et al. 2013; 
Pretorius et al. 2016).  
With regard to AHSV VP7 quasi-crystal production, future research should look to 
further assess buffer pH and the extent to which buffer pH affects crystal formation. 
Immunogold labelling for in situ TEM should be considered to aid in AHSV VP7 quasi-
crystal visualisation. And with regard to transcriptome analyses, studies to follow 
should consider adjusting the booster inoculation to at least one week prior to 
termination of immunogenicity studies in order to enhance the humoral and cell-
mediated immune response. Furthermore, the expression levels of a subset of 
immune response genes should be quantified by qPCR in order to validate the RNA-
seq results. And since the Cavia porcellus reference genome was not available at the 
time of this study, further studies should seek to utilise another animal model whose 
reference genome is available for RNA-seq alignment. Most importantly, there are 
limitations in assessing the immune response in an animal model that is not the natural 
host. Pretorius et al. (2016) assessed the immune transcriptome using PBMCs from 
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horses vaccinated with attenuated AHSV-4. PBMCs may therefore be a suitable option 
for investigating the immune response to AHSV VP7 quasi-crystals.   
To the best of our knowledge this is the first report of plant-produced AHSV VP7 quasi-
crystals and, furthermore, the first time that the specific cell-mediated immune 
response to VP7 quasi-crystals has been assessed. Further investigation needs to be 
done to investigate the validity of AHSV VP7 quasi-crystals as an effective vaccine. A 
techno-economic analysis was beyond the scope of this study but needs to be 
addressed in order to thoroughly assess the vaccine production cost. Additionally, 
future immunogenicity studies need to be performed and if AHSV VP7 crystals 
demonstrate higher levels of immunogenicity when compared to commercially used 
LAVs this may highlight a safer, easy to produce, more cost-effective vaccine 
alternative. Furthermore, this plant-production platform could also be utilised to 
produce AHSV VP7 quasi-crystals for diagnostic reagents in ELISAs. 
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